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ABSTRACT
Malaria in Kenya continues to pose a great threat to health. Trials with 
sulfadoxine/pyrimethamine (SP), currently recommended to replace chloroquine 
(CQ) in drug-resistant areas, were carried out between 1997 and 1999 in 
Plasmodium falciparum endemic and epidemic sites. In vitro assays showed that 
over 50% of isolates were resistant to CQ and SP and sensitive to both quinine and 
mefloquine. In Busia, an endemic site, efficacy o f combination treatment with CQ 
and SP was compared with SP alone. The combination was more effective in fever 
resolution. SP and co-trimoxazole (sulfamethoxazole/trimethoprim) were 
compared in the Oyugis and Tiwi endemic sites and all outcomes were found to be 
equivalent. Codon changes in dhps and dhfr genes (on chromosomes 8 and 4) 
conferring in vitro resistance to sulfadoxine and pyrimethamine, predicted SP 
treatment failures in Mosoriot, an epidemic site, but age-related recovery seen in 
the endemic site Tiwi masked the influence o f mutations in dhps. Resistance- 
related mutations in dhfr and dhps were mutually associated in both sites, which 
probably indicates drug selection acting on both gene-products. Mutations in 
pfmdr! and pfert genes (chromosomes 7 and 5) associated with in vitro CQ 
resistance, were examined in the Mwea endemic site. The pfcrtlhrlb  mutation was 
found on presentation in all CQ-susceptible and resistant cases. The pfmdrI 
mutations, Tyr86 and Tyrl246, were similarly present in most of the pre-treatment 
infections, but an increase in prevalence was seen in samples from recrudescent 
infections. Genotyping of parasite strains revealed that parasites from both 
endemic and epidemic areas were genetically diverse suggesting that the source o f  
epidemic outbreaks was endemic sites of high transmission. Quantitation o f  
parasite-specific RNA by nucleic acid sequence-based amplification (QT-NASBA) 
was evaluated for the detection of low malaria parasitacmias. The test maybe 
useful in monitoring therapeutic response to drugs.
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1.1 Global malaria situation
A recent review has concluded that every year about 1 million deaths 
(range 744,000-1,300,000) from the direct effects of malaria occur in Africa with 
more than 75% of them in children (Snow et al., 1999). The impact of malarial 
disease on human suffering and economic loss remains unacceptably high with the 
direct economic costs o f malaria weighing particularly heavily on poor countries 
with few resources. Recent research has shown a close correlation at the country 
level between the rate of economic development and the burden of malaria, 
indicating malaria is an important constraint on economic progress. The annual 
economic burden o f malaria infection in 1995 was estimated at US$ 0.8 billion, for 
Africa alone (Foster and Phillips, 1998). This heavy toll can hinder economic and 
community development activities throughout the region, (see Figure 1.1.).
1.2 Plasmodium species
The protozoan genus Plasmodium belongs to the phylum Apicomplexa; 
class Sporozoa; subclass Coccidia; family: Plasmodiidae; order Eucoccidiorida; 
sub-order Haemosporina), (Levine et al., 1980). There are more than 100 species 
of the genus found in the blood of infected birds, reptiles and mammals (Gilles, 
1993). Of the 4 species of plasmodia affecting humans (Gamham, 1966) 
Plasmodium falciparum, is the most virulent. P. vivax. P. ovale and P. malariae 
are less virulent and related mortality is very low (Bruce-Chwatt and Peters, 
1979). P. falciparum is prevalent in sub-saharan Africa, parts of India, Central 
and South America, South East Asia and the Pacific. P. malariae has a similar 
global distribution. P. ovale is mainly restricted to West Africa and the Western 
Pacific. P. vivax affects the tropical and temperate regions of S. America and Asia 
and parts of Eastern and Northern Africa
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Figure 1.1 World Malaria distribution and problem areas (boxed). Shading indicates main 
malaria transmission areas (from WHO/Control of Tropical Diseases/ Health Map, 1997,
In Trigg and Kondrachine, 1998).
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Figure 1.2 Malaria parasite life cycle showing stages where
antimalarial drugs act, [slightly modified from Gilles 
and Warrell, 1993],
1.3 Malaria Life Cycle
The plasmodia of mammals are transmitted in nature by their appropriate 
species of mosquito belonging to the genus Anopheles. The life cycle of the four 
human malaria parasites are essentially similar. In the cycle the mammalian host 
(man) is considered as the intermediate host while the definitive host is the 
invertebrate (mosquito). The life cycle of Plasmodium (Gilles and Warrell, 1993) 
[Figure 1.2] begins with the inoculation of sporozoites with mosquito saliva into the 
subcutaneous tissue, bloodstream and lymph vessels o f man by the bite of the female 
infected mosquito during its night-time blood meal. The sporozoites then invade the 
liver cells where they undergo the first stage of asexual development (liver 
schizogony: 6-20 days) producing merozoites which are infective to red blood cells. 
In the red blood cells (erythrocytes), the merozoite develops into a trophozoite stage 
which later divides to form the erythrocytic schizont. The schizonts burst open to 
release more merozoites which can again infect other erythrocytes to perpetuate the 
erythrocytic cycle. This growth cycle, in the case of P. falciparum takes 48 hours. 
Some merozoites entering erythrocytes will differentiate into the sexual male and 
female gametocytes. Transmission from the human host to the anopheline vector 
requires the production of these transmission stages. Developing gametocyte- 
infected RBCs sequester from the peripheral circulation to the blood spaces o f the 
bone marrow and the spleen (Smalley et al„ 1980). This takes 8-10 days, after which 
“mature” gametocytes are released into the circulation and become infectious to the 
mosquito vector after a further 2-3 days. Anopheline mosquitoes can pick up 
infection when they feed on the blood of infected humans. Sexual fusion takes place 
within the stomach. Multiplication then takes place in oocysts on the mosquito 
stomach and eventually the invasive sporozoites escape, migrate and finally enter the 
salivary gland of the insect. (10-30 days). When the infected mosquito takes a blood- 
meal from human, it injects a dose of sporozoites marking the beginning of another 
cycle. P. vivax and P. ovale can form dormant stages from a proportion of the 
inoculated sporozoites which do not immediately develop into pre-erythrocytic 
schizonts. The dormant stages known as hypnozoites, (Krotoski et al., 1982), may 
persist in the liver for several months, from 3 to 9 months or even 5 years before
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1.4 Clinical manifestations and pathogenesis
Clinically malaria begins as a flu-like illness 10 to 16 days after the infected 
mosquito bite. Typical cycles of fever, as a result of synchronous rupture of blood 
stage schizonts, are seen in untreated individuals every 48 to 72 hours depending on 
the Plasmodium species. Shaking chills and drenching sweats may then develop 
(Miller el al., 1994). The frequency depends on the malaria species, coinciding with 
cycles o f parasite multiplication and erythrocyte destruction leading to anaemia. 
Falciparum malaria may not always show this cyclic pattern but may have a daily 
fever and can be fatal if untreated or if treated with less effective drugs. In a 
proportion of cases, P. falciparum infection progresses from mild illness to severe or 
complicated disease. Some of the manifestations of severe and complicated 
falciparum malaria include, cerebral malaria, repeated generalized convulsions, 
hyperpyrexia, hypoglycaemia, pulmonary oedema, metabolic acidosis and renal 
failure, (Warrell, 1992). In areas o f moderate to high malaria endemicity severe and 
complicated forms of malaria are mainly seen in children, while in low endemic 
areas, adults are also affected. Severe malarial anaemia is seen most frequently in 
areas of very intense transmission and mostly in young children, whereas cerebral 
malaria predominates in areas of moderate transmission affecting older children 
(Greenwood, 1997). The epidemics of clinical malaria usually develop in situations 
where many non-immune individuals have moved to malaria endemic areas or when 
malaria transmission suddenly emerges in a region with mostly non-immune 
individuals. Many aspects of P. falciparum pathology associated with organ failure, 
and which may lead to death, are apparently due to cytoadherence of late-stage 
parasitized erythrocytes to the endothelium of micro-vessels supplying the brain 
(cerebral malaria), kidney or other vital organs (Warrell, 1992). Malarial anaemia is 
the consequence of acute haemolysis, whose severity seems to correlate with 
parasitaemia, and dyserythropoietic changes in the bone marrow impairing proper 
red cell production (Harinasuta and Bunnag, 1988). Renal failure can be the
undergoing schizogony and giving rise to blood stages and symptomatic malaria,
(Warhurst, 2001a).
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1.5 The malaria vector
Although there are about 400 species o f Anopheles, the vector that 
transmits malaria parasites, only 60 of them transmit malaria under natural 
conditions, and only 30 are of major importance, (Bruce-Chwatt, 1985). Of these 
the Anopheles gambiae complex and Anopheles funestus are the most efficient 
vectors for P. falciparum transmission. Of all factors related to malaria 
transmission, apart from host immunity, the number (density), human biting habits, 
and longevity of anopheline mosquito vectors are the most important, (Breman, 
2001). Mosquito longevity is particularly important, because the portion of the 
parasite’s life cycle that takes place within the mosquito, that is from gametocyte 
ingestion to subsequent inoculation, can take from 8-30 days, depending on the 
ambient temperature. In general, sporogony within the mosquito is not completed 
at temperatures below 16-18°C, and transmission does not occur, (Breman, 2001). 
The entomologic inoculation rate (EIR), defined as the number of sporozoite­
positive mosquito bites per person per year, is the most common measure of 
malarial transmission. This reflects the transmission pattern varies in different 
geographic areas. It can be as low as less than one (<1) infective bite per person 
per year as is seen in some parts of South East Asia and Latin America to >300 in 
parts of tropical Africa. A high EIR results in stable and intense transmission, with 
young children and pregnant women, being the most vulnerable for severe illness, 
(Beier et a!., 1999; McElroy et a/., 1997). The lower the EIR, the greater the 
number of susceptible individuals who, on infection, can develop severe illness 
(McElroy et al., 1997).
1.6 Malaria Endemicity
The pattern of transmission o f  malaria in a particular locality is graded as 
epidemic, hypoendemic, mesoendemic, hyperendemic or holoendemic (Marsh, 
1993). These definitions correspond with increasing prevalence, decreasing time 
periods between periods of local transmission and increasing levels of infection
consequence of severe haemolytic anaemia, haemoglobinuria and hypovolemia
(Miller, 1985).
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acquired immunity among the human host population (Mendis and Carter, 1993; 
Miller et al., 1994).
1.6.1 Classification of endemicity
1.6.1.1 Holoendemic malaria
This can be defined as a locality experiencing an annual transmission 
intensity of at least 10 infective bites per person per year and acquired immunity 
develops within the population (Miller et al., 1994; Sauerwein and Meuwissen, 
1995; Snow and Marsh, 1995). The spleen rate (% of enlarged spleens) in age group 
2-9 years is constantly over 75%, adult spleen rates are low, and the parasite 
prevalence rate in children 2-9 years is over 75%. Transmission is perennial with 
peak levels during the wet seasons. Age is an important factor, where the longer 
exposure of adults makes them less likely to develop malaria symptoms.
1.6.1.2 Hyperendemic malaria
Child spleen rate is constantly over 50% and adult spleen rate is high (over 
25%). The parasite prevalence rate in children (2-9 years age group) is over 50%. 
Although transmission is hardly ever perennial, and varies with intensity with the 
season, it continues for the greater part of the year. High degree of immunity is 
acquired by the permanent inhabitants due to re-infection many times in the year.
1.6.1.3 Mesoendemic malaria
Child spleen rate is 11-50%. Parasite prevalence rate in children (2-9 years) 
is 11-50%. Seasonal transmission may result in outbreaks. Permanent residents 
acquire a substantial degree of immunity to clinical disease.
1.6.1.4 Hypoendemic
Child spleen rate in hypoendemic malaria area is about 0-10% per cent. 
Parasite prevalence rate is 0-10%. The inhabitants never acquire effective immunity. 
Sporadic epidemic outbreaks may occur.
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1.7 Malaria Epidemicity
Malaria epidemics not only increase malaria-specific morbidity and 
mortality but also affect the general health of the population. Over the past 20 
years, efforts to control malaria have met with less and less success. Mosquito 
vectors have become increasingly resistant to insecticides, and malaria parasites 
are developing resistance to drugs that should prevent or control this deadly 
disease. Projections on global warming also predict that there will be significant 
increases in the territory where malaria can occur. In addition to this changing 
geographic diversity and expanded potential for transmission, the ecologic and 
social factors that are influencing the resurgence of newly emerging disease all 
influence the reemergence o f malaria as well (Najera et al, 1998).
1.8 Highland vectors
Although there is a great diversity of anopheline species in the highland 
areas of Africa, members o f the A. gambiae complex are the principal vectors of 
malaria, as is true for most of the continent. A. gambiae sensu stricto have been 
reported in the Kenyan Highlands (White, 1972) and implicated as upland vectors. 
In the Africa highlands, malaria transmission is probably much more focal in its 
distribution than in many lowland areas.
1.9 Spread from lowlands to highlands
Chloroquine-resistant parasite strains are likely to pose a greater threat in 
the highlands, where immunity to malaria is low or absent, than in the lowlands, 
where exposure to the disease is generally greater. It seems likely that chloroquine 
resistant strains of falciparum malaria found in the hills (Khan et al., 1992) may 
have spread there from the lowlands.
1.10 Kenya malaria situation
Projected population data for the year 2000 indicates that 41%
(13.5niillion) of Kenya’s population are aged between 5 and 20 years, with about 
53% of school population living in areas where malaria transmission is said to be 
unstable, (Brooker, el al 2000). Assuming children in stable areas experience age-
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specific risks, and those living in unstable areas experience attacks once every 3-4 
years, first approximation suggest that between 0.7 and 5.3 million clinical attacks 
of malaria occur in stable areas, and between 0.8 and 1.2 million in unstable areas 
in school children in Kenya, (Brooker et al., 2000).
Malaria attacks have an impact on school attendance and educational 
outcomes. Data suggest that malaria accounts for between 3% and 8% of all 
reasons for absenteeism (Brooker et al., 2000).
1.10.1 Disease Burden
In Kenya malaria is responsible for approximately 30% of the total 
outpatient clinic visits and estimates of infant and child mortality on the Kenyan 
Coast show that at least 58 infants per 1000 live births and 12 children per 1000 
children aged between 1 and 4 years die o f malaria each year (Snow et al. 1994).
Cost to malaria includes loss of 15 days/man/year that is equivalent to 375 
million working days. In addition, in rural areas agricultural output is reduced 
during epidemics with more than 55% of workers remaining absent. In tourism, 
200 per 100,000 visitors are affected. Cost of antimalarials constitutes over 
300,000 UK sterling pounds a year, (Ministry of Health [MOH] Report, 1996).
1.10.2 Epidemiological Stratification
Kenya has both seasonal and perennial malaria transmission, see Figure 2.1 
In endemic regions (below 1,300 meters)-stable malaria is found with transmission 
occurring for more than 6 months of the year. These areas e.g., western and coastal 
regions experience stable and hyper- to holo-endemic malaria. Transmission 
becomes less stable and more seasonal (3-months), following the rainfall pattern, 
between altitudes 1,300-1,700 meters in the central region or districts of Kenya.
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1.10.3 Epidemic malaria in Kenya
Malaria epidemics have been reported in the western highlands of Kenya 
since 1926, occurring once every two years in areas between the altitude 1,500- 
2,000 meters. In 1941, an outbreak was reported at an exceptionally high altitude 
(>2,250 meters). After several decades of quiescence, resurgence of malaria 
epidemics have occurred since 1980’s in the western highlands and in the unstable 
malaria areas of the semi-arid north east and the Lake Turkana region.
The highlands were considered free of malaria through the 1960s, but since 
the 1980s malaria has been increasing (Oloo et al., 1996). More than 90% of 
malaria in Kenya is caused by P. falciparum (Khaemba et al., 1994) and 
transmitted most often by A. gambiae, with A. funestus as a secondary vector. It is 
generally assumed that malaria in the highlands of western Kenya is not due to 
local transmission but is imported from the nearly holoendemic-disease areas 
around Lake Victoria by the frequent travel of the tea plantation workers and their 
families.
1.11 Malaria control
1.11.1 Control strategies and constraints
The four basic elements of the global strategy for malaria control (WHO, 1993) 
are as follows:
1) To provide early diagnosis and prompt treatment.
2) To implement selective and sustainable preventive measures, including vector 
control.
3) To detect, contain and prevent epidemics at an early stage.
4) To strengthen local capacities in basic and applied research to permit and 
promote the regular assessment of a country’s malaria situation, in particular 
the ecological, social and economic determinants of the disease.
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1.11.2 Early diagnosis and prompt treatment
Case-management remains the basis of malaria morbidity and mortality 
control (WHO, 1996). Timely treatment for every clinical episode (especially in 
young children) with the correct dosage of an effective drug in order to avoid 
severe disease and mortality. Antimalarial drugs can be used to treat malaria 
infections and to prevent malaria infections when used prophylactically. Drugs could 
be used to kill gametocytes in attempts to prevent transmission. The primary aims of 
treatment in any situation are to prevent death from the disease and to reduce 
suffering.
1.11.3 Prevention and control o f epidemics
Factors associated with epidemics in Africa have been broadly mentioned 
(see above). However, to control epidemics it is essential to establish a monitoring 
system that can detect early any undesirable trends in malaria morbidity and 
mortality, and environmental changes usually associated with epidemics. A 
number of factors appear to be contributing to the resurgence and epidemics of 
malaria. One of these may be due to the rapid spread of resistance to antimalarial 
drugs.
1.11.4 Chemotherapy
The role of chemotherapy in malaria control is to deal with malaria as a 
disease. Eradication is no longer considered an achievable aim by any means 
except the hoped for vaccine.
1.11.4.1 Blood schizontocides
Examples of this group of drugs include chloroquine, amodiaquine, 
mefloquine and quinine. They are characterized by their rapid action on the 
erythrocytic stages of malaria parasites and can be divided into 2 groups depending 
on their effect on morphology of malaria parasites, (Gilles and Warrell, 1993) 
[Figure 1.2]. In the first group, e.g., chloroquine (CQ), amodiaquine (AQ) and
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quinacrine, these have 2 highly electronegative (easily protonatable) nitrogen 
atoms. These drugs act on the growing intraerythrocytic stages actively digesting 
haemoglobin. They have a rapid effect on the haemoglobin-containing digestive 
vesicles (pigment clumping) o f the intraerythrocytic parasites causing fusion of 
adjacent vesicles followed by the sequestration of the fused vesicles into large 
autophagic vacuole, (Warhurst, 1986).
Type II blood schizontocides are typified by quinine-like compounds such 
as mefloquine, halofantrine and benflumetol (lumefantrine). Pigment clumping 
does not occur in this group and they have one highly electronegative nitrogen 
atom. Cross-resistance develops more or less readily among type I blood 
schizontocides, but infections moderately resistant are treatable using type II blood 
schizontocides. The selective toxicity of antimalarial blood schizontocides is based 
on the selective uptake by infected erythrocytes. Uptake is glucose dependent in 
sensitive strains of P. falciparum. CQ accumulation in resistant strains is glucose 
insensitive (Fitch et al., 1974). The mechanism involved in the concentrative 
uptake of blood schizontocides is through sequestration of the base in the acid 
digestive vesicles and complexing with haemin ferriprotoporphyrin IX (FPIX) 
(Chou et al., 1980). Artemisinin derivatives are also blood schizontocides which 
complex with haem released from haemoglobin in the digestive vesicles 
(lysosomes) of parasite and produce toxic free radicals.
1.11.4.1.1 Quinine
Quinine (QN) is used as a third-line drug in the treatment of uncomplicated 
malaria and as first-line in severe malaria. Resistance although rare, has been 
reported (Reacher et al., 1981; Brandicourt et al., 1986; Pukrittayakamee et al., 
1994; Adagu et al., 1995). Oral quinine may also be combined with an antibiotic to 
treat uncomplicated malaria in areas of multi-drug resistance (Watt et al., 1992). 
However, there is poor compliance with oral quinine because of its bitter taste and 
consistent adverse effects (cinchonism), comprising nausea, dysphoria, tinnitus, 
and high-tone deafness. The main dangerous adverse effect of quinine is 
hypoglycemia, especially in children and pregnant women.
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1.11.4.1.2 Mefloquine
Mefloquine is structurally related to quinine and is used both in prophylaxis 
and oral treatment of uncomplicated malaria. Its long terminal half-life of 14-21 
days probably contributed to the rapid evolution and spread o f  mefloquine 
resistance in Southeast Asia, (White, 1999). However, the combination of 
artesunate and mefloquine in Thailand has slowed the further development of 
mefloquine resistance (Price et al., 1996). Mefloquine resistance is associated with 
amplification of the multi-drug resistance (mdr) genes that encode Plasmodium P- 
glycoprotein pumps, which reduce drug concentrations within parasites (Wilson et 
al., 1993; Price et al., 1997).
There has been considerable controversy over the true incidence of 
neuropsychiatrie side effects of mefloquine used for both treatment and 
prophylaxis (see 1.11.4.6). Extensive therapeutic use of MQ has been implicated in 
rapid development of resistance. Some side effects have also been reported such as 
nausea, vomiting, dizziness, loss of balance, diarrhoea. More serious concerns 
have been identified after prophylactic and treatment use of MQ resulting in 
neuropsychiatrie disturbances (e.g. hallucinations, mood changes and anxiety), 
(Harinasuta el al., 1983).
1.11.4.1.3 Artemisinin and its derivatives
Artemisinin and its derivatives are sesquiterpene lactone peroxides derived 
from the leaves of sweet wormwood (Artemisia annua £.). Developed in China, 
they are used increasingly in Asia and Africa. They kill all growing blood stages of 
the malaria parasite, including “young rings” by interacting with heme to produce 
carbon-centered free radicals that alkylate protein and damage the parasites’ 
microorganelles and membranes (Meshnick el al., 1996).
Artesunate is water-soluble and is dispensed for intravenous, intramuscular, 
oral (tablets), or rectal administration. Artemether and arteether are oil-soluble and 
available in tablets, capsule, or intramuscular injection form (Meshnik et al., 
1996). The artemisinin derivatives presently show no clinical cross-resistance with
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1.11.4.1.4 Halofantrine
Halofantrine, a structural relative o f mefloquine, is better tolerated and also 
effective in the treatment of chloroquine-resistant falciparum malaria, (Cosgriff et 
al., 1982; Boudreau et al., 1988). However, the development of cross-resistance 
with mefloquine and the finding of an association with sudden death, probably 
linked to prolongation of the electrocardiograph Qtc. interval (Nosten et al., 1993), 
have raised doubts about the safety and utility of halofantrine.
1.11.4.1.5 Amodiaquine
Amodiaquine AQ has been used for initial treatment of malaria infections 
in CQ resistant areas and in cases of CQ failure (Childs et al., 1989). AQ is a more 
effective drug than CQ (Peters, 1987). However, reports o f AQ resistance (Hall et 
al., 1975; Childs et al., 1989) and cross-resistance with CQ (Young and Johnson, 
1972) have been made. Side effects of AQ include liver cell damage
(hepatotoxicity) and blood disorders.
1.11.4.2 Antimetabolites |antifolates|
Antimetabolites are generally classified as type I (sulfonamides and
sulfones) and type II antifolates (pyrimethamine, trimethoprim and cycloguanil, 
the active metabolite of proguanil). They mimic essential metabolites of the 
malaria parasite, and are active against all the growing stages in the liver (liver 
schizonts), erythrocytic stages in the blood (blood schizonts) and growing stages in 
the mosquito (sporogonic stages). These parasite stages are all affected to a greater 
or lesser extent by the antifolate drugs or their combinations. It has been 
demonstrated that P. falciparum can synthesize tetrahydrofolate cofactors from 
GTP, PABA, and L-glutamate, showing that the parasite possesses a de novo folate 
synthetic pathway (Krungkrai et al., 1989). Additionally, the enzymes in the folate 
synthetic pathway, GTP cyclohydrolase (Krungkrai et al., 1985), 6-hydroxymethy- 
7,8-dihydropterin pyrophosphokinasc (PPPK), dihydropteroate synthase (DHPS),
other known antimalarials and this makes them useful for treating severe malaria in
areas of multi-drug resistant malaria (White, 1994; Meshnick et al., 1996).
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and dihydrofolate reductase (DHFR), have been identified in different plasmodium 
species. (Ferone, 1977; Sherman, 1979). Recently, the gene encoding dihydrofolate 
synthase/folylpolyglutamatc synthase DHFS/FPGS was isolated and characterized 
(Lee et al., 2001). The enzymes DHFS and FPGS catalyse the synthesis and 
polyglutamation of folate derivatives, (Salcedo et al., 2001).
Inhibition of parasite dihydrofolate reductase results in a reduction in the 
intracellular pool of tetrahydrofolate cofactors which are used in most cells for the 
de novo synthesis o f purines, methionine and thymidylate and for the 
interconversion of glycine with serine. Serine is the only identified source of 
methyl groups of methionine and thymidylate. Serine hydroxymethyltransferase 
converts serine to glycine with the formation of N5-Nl0-methylene 
tetrahydrofolate, the cofactor used to provide the methyl group that converts 
deoxyuridine monophosphate to the deoxythymidine monophosphate required for 
DNA synthesis. This activity is conducted by the enzyme action of thymidylate 
synthase (TS) and results in regeneration o f dihydrofolate (DHF), (see Figure 1.3). 
The major enzyme targets of malaria chemotherapcutics in the folate biosynthetic 
pathway are DHPS and DF1FR. DHPS, not found in mammals is responsible for the 
synthesis of 7,8-dihydropteroate from 2-amino-4-hydroxy-6-hydroxymethyl-7,8- 
dihydropteridine pyrophosphate and PABA. The drugs of the sulfa group are analogs 
of PABA and have been shown to be competitive inhibitors of the DHPS enzyme 
from the murine malarias P. berghei (Ferone, 1973, 1977; McCullough and Maren, 
1974) and P. chabaudi (Feronc, 1977; Walter and Konigk, 1980), as well as in P. 
falciparum (Zhang and Meshnick, 1991; Triglia et al., 1997). DHFR is two steps 
further down the folate biosynthetic pathway from DHPS and is responsible for the 
reduction of 7,8-dihydrofolate to tetrahydrofolate. Pyrimethamine and cycloguanil 
(DHFR inhibitors) are potent inhibitors of this enzyme (Ferone et al., 1969; Ferone, 
1970; Sirawarapom and Yuthavong, 1984; 1987; Zolg et al., 1989; Sirawarapom et 
al., 1990, 1997). Pyrimethamine is generally used in combination with the 
sulfonamide compound, sulfadoxine, as they show a marked synergism (Chulay et 
al., 1984; Scott et al., 1987), most likely due to the fact that they act on two different 
enzymes in the same biosynthetic pathway.
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The selective action of the antimalarial type II antifolates (DHFR 
inhibitors) resides in the greater affinity of the drug for the parasite enzyme than 
the host enzyme. Pyrimethamine binds 102-103 times more tightly to the 
plasmodial enzyme than to the host enzyme, similarly for drugs like cycloguanil 
and trimethoprim (Gutteridge and Trigg, 1971).
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1.11.4.3 Antimalarial drug combination
The Fansimef® (sulfadoxine, pyrimethamine, mefloquine) triple 
combination was used because resistance to MQ was found to develop more 
slowly when it was used in such a combination in a P. berghei model of malaria 
(Peters and Robinson, 1984). However, due to severe gastro-intestinal and 
dermatological side effects associated with the combination coupled with the 
pharmacokinetic incompatibility of Fansidar* and MQ, Fansimef® was withdrawn.
To prevent the high recrudescence rates that result when artemisinin or one 
of its derivatives is used alone, and to combat the development of resistance, they 
should always be combined with another unrelated antimalarial, such as 
mefloquine or doxycycline (Hien et al., 1993; Meshnik et al., 1996).
Oral tetracycline and doxycycline probably act by damaging P. falciparum 
mitochondria (Kiatfuengfoo et al., 1989). They act slowly and should always be 
used in combination with another antimalarial, such as in a 7-day course to 
supplement the faster acting drugs quinine and artesunate (Watt et al., 1992). 
Tetracyclines should not be used in children or pregnant women because of its 
calcium chelation property, but clindamycin is safe (Kremsner et al., 1994). Oral 
fluoroquinolones though showing some activity in vitro, are not effective clinically 
(Watt et al., 1991). Co-trimoxazole is effective in areas where sensitivity to 
pyrimethamine-sulfadoxine is retained.
A new hydroxynaphthoquinone antimetabolite (atovaquone) has been 
developed, based on the traditional antimalarial Lapacho heartwood. Atovaquone 
is used with proguanil, [a pro-drug metabolized to the antimalarial DHFR inhibitor 
cycloguanil] because of rapid resistance development when used alone. This 
combination attacks all growing stages in the malaria cycle (de Alencar et al., 
1997). It is effective in uncomplicated malaria, resistant to CQ and the antifolates.
1.11.4.4 Hypnozoitocidal drugs
P. vivax and P. ovale, but not P. falciparum or P. malariae, 
characteristically leave dormant parasites within hepatocytes (hypnozoites), which 
give rise to future relapses. Primaquine, an 8-aminoquinoline, kills these 
hypnozoites, (Warhurst, 1984). It is also used as a single dose to eradicate P.
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falciparum gamétocytes and this was demonstrated in Nicaragua but with limited 
effects (Garfield and Vermund, 1983). The limited success was attributed to timing 
of mass drug administration at a high-transmission period of the year. Treatment 
with primaquine carries the potential risk of haemolysis in patients with glucose-6- 
phosphate dehydrogenase (G6PD) deficiency. Etaquine, a more active and slowly 
eliminated successor to primaquine, is currently undergoing clinical trials.
1.12 Drug resistance
Drug resistance is defined as the ability o f a parasite strain to multiply or to 
survive in the presence of concentrations of a drug that normally destroy parasites 
of the same species or prevent their multiplication (WHO, 1963). Such resistance 
may be relative, yielding to increased doses o f the drug that can be tolerated by the 
host or complete, when the parasite withstands maximum doses tolerated by the 
host.
1.12.1 Types of drug resistance
A number of different mechanisms can account for resistance or changes in 
sensitivity of organisms to drugs, some inherent and others acquired (see Peters, 
1987). There is a selection by drug treatment from a “wild” population where a 
mixture of sensitive and resistant parasite clones may already exist, and these may 
differ extensively in a variety o f genes. Alternatively, random mutations enhancing 
drug resistance may be selected by drug treatment of a population derived from a 
single clone.
Different levels of drug resistance are encountered in malaria chemotherapy 
and criteria employed have been defined by WHO (1996) [see section 2.2.2.5].
1.12.2 Emergence and spread o f  quinoline resistance
Although the 4-aminoquinolines are still effective and widely used for 
treatment and prophylaxis, resistance has severely impaired their use in many 
malarious countries (Wemsdorfer and Payne, 1991). Resistance to CQ is prevalent
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in most areas of the world where the drug has been used (Sansonetti et al., 1985; 
Delfini, 1989; Rapouda et al., 1997; Shretta et al., 2000).
1.12.2.1 Biochemical mechanisms of resistance to Chloroquine
The emergence of CQ resistance has stimulated intensive investigations in 
understanding its molecular and biochemical basis. Proposed mechanisms of 
resistance to CQ have been based on the observations that CQ resistant (CQR) 
parasites accumulate much less drug than CQ susceptible parasites (Fitch, 1969; 
Verdier et al., 1985; Krogstad et al., 1987; Bray et al., 1992b). This hypothesis 
was confirmed when isolated vacuoles from CQR parasites were observed to have 
reduced CQ accumulation compared to CQ sensitive CQS parasites (Saliba et al., 
1998). The conflicting hypotheses are discussed below.
1.12.2.1.1 CQ resistant parasites have increased vacuolar pH
One biochemical explanation for CQ resistance in P.falciparum is that the 
pH in the digestive vacuole is elevated in the CQ resistant parasites and because 
CQ is a weak base, an increase in the vacuolar pH would result in decreased levels 
of CQ in the parasite digestive vacuole. Decreased vacuolar acidification in 
resistant isolates has been linked to a weakened proton pump ATPase or a reduced 
activity of a vacuolar chloride channel (Ginsburg and Stein, 1991; Bray et al, 
1992a). These workers showed that the discrepancy between steady-state drug 
levels seen in CQR and CQS strains could be explained by a weakened proton 
pump in resistant strains. Further support was provided by Bray et al., 1992a, using 
the vacuolar ATPase inhibitor bafilomycin A l; and CQ in combination with 
bafilomycin Al produced an apparent reduction in sensitivity of CQS and CQR 
strains. Cloning and characterisation of vacuolar ATPase from P.falciparum have 
identified 2 subunits with sequence homology to the A and B subunits found in a 
variety of other organisms. However, no differences were observed between CQR 
and CQS parasites in their A and B subunits composition to help explain CQR 
phenotype (Karcz et al., 1993; Karcz et al., 1994).
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1.12.2.1.2 Enhanced drug efflux of chloroquine
Earlier Krogstad et al, (1987) found that resistant strains of P. falciparum 
released pre-accumulated [JH]-chloroquine 40 to 50 times faster than in sensitive 
strains. The magnitude of this difference was found to be consistent with the 
difference in the IC5 0  for both strain types. This led the authors to  conclude that the 
lower steady-state levels of CQ in resistant parasites could result from export as in 
resistant tumour cells. This proposal was supported by the demonstration that 
enhanced efflux of CQ was partially reversed by verapamil (Martin et al, 1987). 
Other studies illustrated that CQ resistance could also be reversed by tri-cyclic 
antihistamines such as cypro-heptadine (Peters et al, 1989). CQ-induced 
ultrastructural changes seen in CQ sensitive P. falciparum and P. chabaudi 
become evident in CQ resistant parasites only after the co-administration of 
verapamil (Jacobs et al, 1988; Ohsawa et al, 1991). The reversal mechanism is 
assumed to result from competition between verapamil and CQ for efflux protein 
drug translocation sites, thus causing an increase in steady-state accumulation of 
CQ and partial return to sensitivity. However. Bray et al., (1992b) demonstrated an 
apparent equivalent efflux capacity for both sensitive and resistant parasites. This 
led them to suggest that changes in CQ accumulation force rather than efflux rate 
are responsible for CQ resistance. The observations that differences in drug 
resistance correlated more favourably with rates of drug uptake rather than drug 
efflux have been confirmed in other studies (Bray et al., 1994; Martiney et al., 
1995; Bray et al., 1996).
1.12.2.1.3 The reduced drug binding hypothesis
It was suggested that CQR may be due to a reduced affinity of the intra- 
parasitic binding site for CQ in resistant strains (Fitch, 1973). The proposed 
receptor for the 4-aminoquinolines in P. falciparum  is haemin, 
ferriprotoporphyrin-IX [FPIX] (Chou et al., 1980). It has been suggested that 
resistant parasites may have a reduced amount of FPIX complex (Fitch, 1983). It
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has been suggested that both the activity and saturable uptake o f CQ is due to the 
binding o f drug to ferriprotoporphyrin-IX (Bray et al., 1999). CQ sensitivity could 
be determined by the amount of this free haemin available within the vacuole. A 
parasite could become CQR by reducing the amount of high-affinity drug binding 
sites (Fitch, 1983), or by reducing the accessibility of the drug to 
ferriprotoporphyrin IX (Bray et al., 1998).
1.12.2.1.4 Chloroquine resistance due to loss or relocation of CQ 
transporter
It w as postulated by Warhurst (1986) that CQ accumulation in malaria 
parasites could be in part due to the presence o f a specific drug importer or 
permease, with the permease situated on either the plasma membrane or, in 
resistance, on the food vacuole membrane. It was suggested that the permease 
could export drug from the vacuole, into the cytosol and thus out of the parasite in 
resistance, a viewpoint partially supported by the mathematical model of Ferrari 
and Cutler, (1991). The hypothesis that an outward drug export could be 
responsible for CQR is consistent with the observations of enhanced drug efflux 
from resistant strains presented by Krogstad et al., (1987). However, this argument 
goes against the idea that change in inward drug transport is responsible for CQ 
resistance. Recently Sanchez et al., (1997) demonstrated that CQ-uptake was 
temperature-dependent, saturable and could be inhibited by E1PA [5-A/-ethyl-A- 
isopropyl amiloride], a specific inhibitor of Na7H+ exchanger (NHE). 
Furthermore, they suggest differences in the kinetics of CQ uptake between CQS 
and CQR parasites is due to an import mechanism with reduced affinity for CQ. 
Wunsch et al., (1998) added further evidence demonstrating inhibition of CQ 
uptake by NHE inhibitors and suggested CQR parasites have an elevated 
cytoplasmic pH over CQS parasites due to a constitutively activated NHE. They 
suggested that CQ activates the NHE of CQS parasites, resulting in the CQ uptake 
during a NaVH* exchange. In CQR parasites, the NHE is incapable of being 
activated as it is already constitutively activated. This differential stimulation of 
the NHE would result in lower accumulation of CQ within the digestive vacuole. 
Bray et al., (1999) showed that CQ uptake into isolated parasites occurs at normal
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rates in the absence of sodium, and under these conditions the NHE should not 
function.
1.12.2.2 Molecular basis of chloroquine resistance
Drug resistance in cancer cells is characterized by amplification of multi­
drug resistance mdr gene (see below for details on mdr genes) and overexpression 
of its protein product (Endicott and Ling, 1989). It was therefore reasoned that if 
mdr phenotype of tumour cells and CQ resistance have common mechanism, then 
it is possible that amplification and overexpression of mdr homologues in P. 
falciparum may be involved in CQ resistance. Subsequent work identified two 
homologues designated pfmdrl and pfmdr2 located in chromosome 5 and 14 
respectively (Foote et al., 1989). The pfmdrl gene is amplified and its protein 
product over- expressed in some, but not all CQ-resistant isolates. The presence of 
pfmdrl gene in some CQ resistant isolates at a copy number equivalent to that of 
CQ sensitive parasites led Foote et al., (1989) to suggest that perhaps the pfmdrl 
gene o f CQ resistant parasites was mutated at one or more positions within the 
primary sequence. They suggested that mutation might lead to functional alteration 
manifested at the level of the gene product which might thus render a parasite 
competent for CQ resistance.
1.12.2.2.1 Plasmodium falciparum  multi drug resistance genes
The mdr genes are members of a superfamily of genes that are similar in 
sequence, predicted secondary structure and functions, referred to as the ATP 
binding cassette (ABC) proteins (Higgins et al, 1992). The mdr gene encoded 
proteins, P-glycoproteins (Pgps), were first identified in mammalian tumour cells 
as causing multidrug resistance against anticancer drugs by active drug export 
(Juliano and Ling, 1976). The Pgp in mammalian cells are located in the plasma 
membrane and consist of two similar halves each with six transmembrane domains 
and an intracellular ATP binding site (Endicott and Ling, 1989). The putative 
transmembrane regions may together form pores through which chemotherapeutic 
drugs as well as endogenous substrates can pass. Carbohydrate residues are 
attached to the extracellular portion of the protein. The ATP binding domains are
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necessary for energy dependent efflux. The internal portion also contains 
appropriate configuration for initial binding and subsequent transport of a variety 
of compounds of different structure. P. falciparum  contains two mdr homologs- 
pfmdrl and pfmdr2. The proteins encoded by these two genes are designated 
P.glycoprotein homologue-1 (Pgh-1) and P.glycoprotein homologue-2 (Pgh-2). 
Some studies have shown association between Tyr-86 allele o f the pfmdrl gene 
with CQR for both in vivo and in vitro drug tests (Foote et al., 1990b; Basco et al., 
1995b; Adagu et al., 1995; Adagu et al., 1996; von Seidlein et al., 1997; 
Duraisingh et al., 1997). However, others (Awad-el-Kariem et al., 1992; Wilson et 
al., 1993; Basco et al., 1998) failed to observe any association. Association 
between CQR and mutation on pfmdrl is not complete and this has raised the 
thought that CQR might involve a multi-genic mechanism. Although other genes 
might be involved, the CQR phenotype may still be affected by pfmdrl gene 
changes. The cg2 gene and/or a neighbouring gene on chromosome 7 (Su et al., 
1997) which had been linked to CQR in a laboratory genetic cross (Wellems et al., 
1991) are currently of most interest.
1.12.2.2.2 Cg2
Wellems et al., (1990, 1991) provided evidence that rapid efflux of 
chloroquine from the digestive vacuole o f  the malaria parasite is governed by a 
single locus on chromosome 7. Subsequently, Su et al., (1997) mapped the 
chloroquine resistance locus within a 36-kb region o f chromosome 7 and identified 
several open reading frames in this region. The author suggested that cg2, a gene 
encoding a highly polymorphic protein, could be the chloroquine resistance 
mediator. The CG2 protein of approximately 330kDa is expressed in erythrocytic 
asexuals and is localised to the parasitophorous vacuole (Wellems et al. 1998). 
Wellems et al., (1998) reported that CG2 protein is not an integral membrane 
protein although it is associated with the membrane. The CG2 protein was 
suggested to be a sodium/hydrogen ion exchanger (NHE) (Wunsch et al., 1998) as 
they claimed it had the common binding motifs common with other NHE proteins 
The polymorphisms in the cg2 gene included variations in three repetitive 
sequences (k, y, a>) changes in the length of a central poly-Asn tract, and 12
47
individual point mutations outside the repetitive sequences (Su et al., 1997). Cg2 
had complex polymorphisms which appeared to be associated with CQR in a series 
of laboratory isolates from Africa (Su et al., 1997; Basco and Ringwald, 1999; 
Adagu and Warhurst, 1999b) and S.E Asia (Su et al., 1997). Indeed from this 
selection it appears that this polymorphism is highly associated with CQR but not 
sufficient, as there is a single Sudanese isolate which has the complex cg2 
polymorphism associated with CQR but is CQ sensitive.
1.12.2.2.3 Plasmodium falciparum chloroquine resistance transporter
More recently, a sharper focus has been gained on the parasite’s means of 
subverting CQ chemotherapy. In vitro studies involving transfection analysis 
conducted by Fidock (Fidock et al., 2000a, 2000b) in P. falciparum have validated 
the candidate CQR gene, pfcrt (P. falciparum chloroquine-resistance transporter), 
whose locus was first identified in the 1990 genetic cross of CQR and CQS 
parasite clones. The pfcrt product is a predicted integral membrane protein with 10 
transmembrane segments (Fidock et al., 2000b) and CQR forms of this protein 
carry multiple mutations, at residues 74, 75, 220, 271, 326, 356 and 371 
supplementary to an essential 76 mutation from lysine to threonine. Patterns of 
mutations have been detected that are characteristic of laboratory lines of P. 
falciparum strains from Southeast Asian/African or South American origin. The 
Lys76Thr (K76T) mutation has been invariably found in all in vitro CQR strains 
and no sensitive strains, regardless of origin. This is in the first transmembrane 
segment of the predicted pfcrt product (Fidock et al., 2000b). Transfections by 
Reed et al., (2000) have also clarified the long-controversial role of 
polymorphisms in pfmdr! (Plasmodium falciparum multidrug resistance gene 1) in 
the parasite response to quinolines, including CQ. Alterations in the primary 
sequence of pfmdr 1 increased the levels of CQ resistance of a P. falciparum strain 
already slightly resistant (i.e., possessing mutant pfcrt), but not that of a strain with 
a sensitive allele. Taken together, these studies indicate the primacy o f pfcrt, and 
the accessory role of pfmdrl, as loci for genetic mutations conferring the 
chloroquine-resistant phenotype in P. falciparum malaria. The first prospective 
field study designed to directly evaluate the pfcrt in the field was conducted in
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Mali, West Africa in 1998 (Djimde et al., 2001), where CQR remains low (3% RII 
and R1II). The pfcrt K76T mutation, identified as a definitive marker for in vitro 
CQR by Fidock et al., (2000b) and the pfmdr! N86Y polymorphism were used by 
Djimde et al (2001) to evaluate the contributions of mutant pfcrt and pfmdr 1 to CQ 
failure. Consistent with the in vitro studies of established and transfected parasite 
strains, all blood isolates with P. falciparum persisting post-treatment harboured 
the K76T pfcrt mutation.
The function of the Pfcrt protein is still unknown, although it has been 
suggested that it normally operates in facilitated diffusion of positively charged 
amino acids (such as histidine) or similar peptides from the digestive vacuole into 
the cytoplasm. When mutated, the protein may enhance CQ export capability, 
(Warhurst, 2001b).
1.13 Resistance to antimetabolites
1.13.1 Resistance to type II antifolates
1.13.1.1 Biochemical mechanism
The evidence suggesting that the major mechanism of resistance to 
pyrimethamine in Plasmodium spp, was due to altered drug binding to DHFR is 
consistent with most of the work that has analyzed the enzyme kinetics of DHFR in 
the rodent malaria parasites, P. berghei. P. vinckei, and P. chabaudi, as well as 
studies in P. falciparum. The most striking feature of this work is the almost universal 
finding that the inhibition constant (K,) for pyrimethamine of the DHFR enzyme had 
increased in pyrimethamine-resistant strains and isolates (Ferone, 1970; McCutchan 
et al., 1984; Walter, 1986; Sirawarapom and Yuthavong, 1984; Chen et al., 1987; 
Zolg et al., 1989). One exception to this finding was the observation that the DHFR 
activity from a pyrimethamine-resistant P. falciparum isolates had the same K, as the 
DHFR from a sensitive isolate; however, it was suggested that the enzyme expression 
was increased 30-to 80-fold (Kan and Siddiqui, 1979). More recent analysis of 
equivalent field isolates has not shown any altered levels o f enzyme and confirms that 
the DHFR enzyme in field isolates is structurally altered in resistance (Cowman et al., 
1988; Peterson et al., 1988).
49
The cloning of the gene encoding the dhfr gene from P. falciparum (Bzik etal., 1987; 
Cowman et al., 1988) and P. chabaudi (Cowman and Lew, 1989) allowed a detailed 
analysis of alterations in this enzyme and their role in the mechanism of resistance. 
The dhfr enzyme had previously been shown to co-purify with thymidylate synthase 
(ts) in Crithidia fasciculata (Ferone and Roland, 1980), and the association of the 
dhfr and ts genes was confirmed for P. falciparum when it was shown that a single 
open reading frame (Bzik ct al., 1987; Cowman et al., 1988) encoded both activities 
(Sirawarapom et al., 1990), a property that is shared by most protozoan organisms 
(Garrett et al., 1984; Grumont et al., 1986).
Analysis of alterations in the dhfr gene of experimentally induced 
pyrimethamine-resistant P. chabaudi and P. falciparum strains has shown that both 
amplification and mutation o f the gene can occur (Inselburg et al., 1987; Cowman 
and Lew, 1989, 1990; Tanaka et al., 1990a, 1990b; Watanabe and Inselburg, 1994). 
Induction of pyrimethamine-resistant P. chabaudi (Cowman and Lew, 1989, 1990) 
and P. falciparum (Inselburg et al., 1987; Tanaka et a!., 1990a, 1990b), by slowly 
increasing the level of drug, resulted in increased expression of dhfr-ts. This was due 
to a duplication of part of the chromosome containing the gene, which resulted in an 
increase in karyotype from 14 chromosomes to 15 chromosomes. Increased selection 
for high levels of pyrimethamine resulted in a mutated dhfr gene from a serine to 
asparagine at position 108 (Cowman and Lew, 1990). This is the equivalent mutation 
that has been found to be important in resistance to pyrimethamine in field isolates of 
P. falciparum (see below).
1.13.1.2 Molecular mechanism
Analysis of a genetic cross between pyrimethamine-resistant and 
pyrimethamine-sensitive P. falciparum parents demonstrated that the DHFR 
containing the Asn-108 segregated with the resistance phenotype (Peterson et al., 
1988), proving that this alteration was the determinant of the drug-resistant 
phenotype. The availability of the dhfr-ts gene sequence allowed the comparison of 
the gene from a large number of pyrimethamine-resistant and -sensitive field isolates 
of P. falciparum and the identification of important amino acid changes that appeared 
to be involved in the mechanism of resistance (Cowman et al., 1988; Peterson et a!..
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1988; Zolg et al., 1989; Snewin et al., 1989; Tanaka et al., 1990a; Thaithong et al., 
1992). This analysis suggested that the amino acid at position 108 in dhfr was 
critically important in the development of resistance to pyrimethamine. 
Pyrimethamine-sensitive field isolates have Ser-108, while resistant isolates have 
Asn-108. The dhfr gene from isolates that were highly resistant to pyrimethamine had 
additional mutations which suggested that pyrimethamine resistance arose as a single 
point mutation and subsequent drug pressure selected for additional mutations that 
conferred higher levels of drug resistance (Sirawarpom et al., 1997). These studies 
provide strong suggestive evidence that the amino acid differences found between 
pyrimethamine-sensitive and pyrimethamine-resistant P. falciparum were responsible 
for the mechanism of resistance. A serine in position 108 of the dhfr gene is linked 
to in vitro sensitivity to both pyrimethamine and cycloguanil. A mutation to 
asparagine at position 108 seems to be the key mutation for conferring in vitro 
pyrimethamine resistance (de Pecoulas et al., 1996), although a genotype without 
this mutation has been recently described (Wang et al., 1997b). An asparagine to 
isoleucine change at position 51 and a cysteine to arginine at position 59 appear to 
modulate higher levels of in vitro pyrimethamine resistance when they occur with 
the asparagine 108 mutation, and an isoleucine to leucine mutation at position 164 
in combination with the asparagine-108 and arginine -59 mutations has been found 
in P. falciparum lines that are highly resistant to both pyrimethamine and 
cycloguanil (Basco et al. 1995a, Reeder et al., 1996). Ala-16 to Val and 108 Ser to 
Thr have also been found together giving resistance to cycloguanil. It is clear that 
cross-resistance to both pyrimethamine and cycloguanil does occur and has been well 
documented (Schapira., 1984; Watkins et al., 1984).
Combinations of type I and type 11 antifolates (like SP) have generally been 
effective in the presence of pyrimethamine or cycloguanil resistance. Medium level 
cross-resistance between these two drugs occurs when the DHFR gene has Asn-108, 
and much higher levels of cross-resistance are seen with accumulation of mutations 
(Foote et al., 1990a; Peterson et al., 1990; Sirawarapom et al., 1997). For example, 
in southeast Asia SP is no longer useful, (Peterson et al., 1990) and many isolates of 
P. falciparum have mutations in dhfr, Alal6Val with Serl08Thr and Ilel64Leu with 
Seri 08Asn are seen.
51
1.13.2 Mechanism of resistance to type 1 antifolates
1.13.2.1 Biochemical mechanism
The sulfa drugs are an important group of antimalarial compounds and 
have generally been used in combination with DHFR inhibitors such as 
pyrimethamine. Sulfadoxine, the most commonly used sulfa drug, has been used 
extensively in combination with pyrimethamine. A sulfa-based drug dapsone (a 
sulfone) is used in combination with chlorproguanil and registered as LapDap and 
is currently undergoing clinical trials, (Winstanley, 2001; Mutabingwa et al., 
2001). The sulfa drugs are known to inhibit the enzyme DHPS from murine 
malaria parasites P. berghei (Ferone, 1973), and the enzyme from P. falciparum 
(Zhang and Meshnick, 1991;Triglia et al., 1997). They are structural analogues of 
PABA and act as competitive inhibitors of DHPS (Triglia et al., 1997). 
Additionally, DHPS may convert the drug to its sulfa analogue, which would 
inhibit dihydrofolate synthase, the next enzyme in the folate biosynthetic pathway. 
The gene encoding the enzyme dhps has been cloned, and is on chromosome 8 and 
codes for a bifunctional enyzme with 6-hydroxymethyl-7, 8-dihydropterin 
pyrophosphokinase (PPPK) at the N terminus of the protein (Triglia and Cowman, 
1994; Brooks et al., 1994). This is consistent with previous data from mouse 
malaria species showing that both enzyme activities co-purify (Ferone, 1973, 
1977).
1.13.2.2 Genetic mechanism of drug resistance to sulfadoxine
Point mutations have also been described in dhps gene, but its contribution 
to sulfadoxine resistance by P. falciparum is less clear (Wang et al., 1997b). 
Polymorphisms at 5 highly conserved positions within the dhps gene (codons 436, 
437, 540, 581 and 613) have been found in sulfadoxine-resistant parasites (Triglia 
et al., 1994; Brooks et al., 1994; Wang et al., 1997a; Jelinek et al., 1998). The 
most sulfadoxine-resistant parasites reported to have been assayed in vitro carried 
the Phe-436, Gly-437 and Ser-613 alleles (Wang et al., 1997a). Using the recently 
developed transfection method in P. falciparum. Triglia et al., (1998) introduced 
specific mutations in the dhps gene that corresponded to the ones identified in
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sulfadoxine-resistant field isolates. They found that the change from Ala- to Gly- 
437 gave the parasite a 5-fold increase in sulfadoxine-resistance and accumulation 
of further mutations raised the level of resistance to 24-fold.
Different genotypes o f dhfr and dhps have been found in different 
geographical areas where malaria is endemic. Broadly, the prevalence of mutated 
genes seems to correlate with the amount of SP usage in a determined region 
(Wang et al., 1997a). From comparison of isolates taken before and after treatment 
with SP it was concluded that in vivo selection of both pyrimethamine and 
sulfadoxine-resistant parasites occurs, while the most common number of 
mutations in the dhps gene was two, while dhfr was often triply mutated (Wang el 
al., 1997a; Curtis el al., 1998).
1.14 Genetic diversity
The genetic diversity among P. falciparum from different malaria endemic 
regions may be the result o f differences in intensities of infection, transmission 
patterns, human/ vector distribution, and the population dynamics of the parasite 
(Creasey el al., 1990). In Kenya, the 5-8 yearly cycles o f malaria epidemics in the 
highlands, (Khan el al., 1992, MOH, 1994-2001), have become a yearly 
occurrence since 1992 (MOH 1994-2001). A recent report (Shanks el al., 2000) 
suggest that drug resistance may be contributing to malaria epidemics in Kenya. It 
is possible that drug resistant strains have gradually spread from nearby endemic 
regions to the epidemic areas. Population movement between epidemic and 
endemic areas is likely to be a major vehicle for the spread. The transfer of 
infective anopheline mosquitos, trapped in luggage, cars or lorries may possibly 
also take place. An epidemic in S. America has been reported to be due to clonal 
infection (Laserson el al., 1999) with individuals being infected with a single 
parasite clone. However, in areas where malaria transmission is stable, P. 
falciparum  parasite populations are genetically diverse (Babiker and Walliker, 
1997). Polyclonality and extensive diversity are thought to be more likely in 
endemic infections than in epidemic outbreaks.
Polyclonality in field isolates has been reported (Snewin et al., 1991; 
Ntoumi et al., 1995; Viriyakosol et al., 1995). Parasites examined in this thesis (for
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drug susceptibility/ and sequence variations in resistance associated genes) were 
typed to assess their clonality/ genetic diversity (see chapters 4 and 5, 
respectively). Analysis of genetic variants of P. falciparum is facilitated because 
the parasite is haploid except for the zygote stage occuring briefly in the mosquito. 
This avoids the use o f complex analyses to interpret diploid patterns of inheritance. 
The repetitive regions in 3 markers encoding merozoite surface proteins 1 and 2 
(mspl and msp2) and glutamate rich protein (glurp) are used to investigate genetic 
diversity/ clonality among isolates of P. falciparum. (Viryakosol et al., 1995).
1.15 Quantitative nucleic acid sequence-based amplification (QT-NASBA)
Rapid diagnosis and prompt treatment is a key step in the control of malaria 
infection; more so in the phase of continuous spread and persistence of antimalarial 
drug resistance. Traditionally, diagnosis of infection or treatment failures/ re­
infection is by microscopic examination of Giemsa stained thick and thin blood 
smears. Although it is cheap, it requires expert microscopists to detect low level 
parasitaemia. Microscopic diagnosis of malaria is time consuming when dealing 
with large number of samples and sensitivity is low with a limit of detection o f  
about 20 parasites/ pi (Bruce-Chwatt, 1984). Antigen detection methods such as 
Parasight-F®, ICT MalariaPf* are rapid manual tests incorporating a dual-antibody 
immunoassay against the histidine-rich protein II antigen (HRP-2) of P. falciparum 
(Pieroni et al., 1998). The OptiMAL® test detects a species-specific enzyme, parasite 
lactate dehydrogenase (pLDH), produced by live parasites (Palmer et al., 1998). The 
techniques are fast and simple to perform, but at low parasitaemias (of 
approximately 100 parasites/pl) the sensitivity decreases drastically (Makler et al., 
1998). Polymerase chain reaction (PCR) assays have been developed and evaluated 
(Barker et al., 1994; Smits et al., 1997), however these techniques have been shown 
to allow only for semi-quantification of parasites (Hommel et al., 1998). A 
quantitative method capable of detecting very low level parasitaemia (less than 20 
parasites/ pi) will be a useful tool in the control, treatment and prevention o f  
malaria infection.
In this thesis, a quantitative nucleic acid sequence-based amplification [QT- 
NASBA] (van Gemen, et al., 1995) was developed and evaluated as reported in
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chapter 6. The technique could utilize for example, a ribonucleic acid (RNA) as 
target in the amplification and detection of malaria parasite which would be more 
likely to distinguish between live and dead parasites. It is envisaged that this 
method could detect the low parasitaemias present in early recrudescences after 
treatment. This would enhance the in vivo drug evaluation schemes used to follow 
the spread of resistance. Although the technique is still under development the 
results of the initial evaluation described in chapter 6 suggest that it is a promising 
method. Further optimization and evaluation will be needed to meet the much 
needed sensitivity, specificity, cost-effectiveness and speed that are characteristics 
o f an effective diagnostic procedure.
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1.16 Objectives of the study
Documented reports o f malaria control in Kenya consisted of anti-larval 
activities such as oiling water pools and surface drainage. Due to the abundance of 
breeding sites this approach was not effective, thus leaving drug treatment the only 
useful measure. In spite of many efforts Plasmodium falciparum malaria remains the 
foremost cause o f serious morbidity and mortality in Kenya and has undergone a 
dramatic resurgence in the last decade apparently fuelled by resistance to the drug 
chloroquine [CQ] (WHO Epidemiological Record, 1993). Historically the first case 
of indigenous CQ resistant malaria was reported in Kenya in 1982 in a child from 
Kisumu (Spencer et al., 1983). Since then resistance has spread countrywide and 
failure rates between 60% and 80% has been reported (MOH, 1997). By end of 1997 
CQ use in the treatment of uncomplicated malaria was halted by a government 
decree, (MOH Report, 1997). Sulfadoxine-pyrimethamine (SP Fansidar®) was 
subsequently introduced as the first-line drug for uncomplicated malaria.
As case finding and effective disease management is the cornerstone of the 
Kenyan National Malaria Control Programme (National Malaria Control, 1993) and 
rapid treatment of acute malaria with an effective drug is regarded as lifesaving, it is 
vital to monitor these changes in resistance. Only then will it be possible for drug 
provision and use to be guided by up to date information.
1.16.1 Primary Objectives
A. To assess the in vivo resistance profiles of Plasmodium falciparum malaria 
to chloroquine and sulfadoxine/ pyrimethamine (SP, Fansidar®) in study sites 
chosen to comply with the Kenya National sentinel posts for monitoring drug 
treatment efficacy.
B. To characterize P. falciparum  drug resistant determinants associated with 
antifolate and chloroquine resistance.
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C. To study the allelic variability of the major merozoite surface protein gene- 
1 and -2, (mspl, msp2,) glutamate rich protein gene, glurp and to  establish genetic 
diversity profiles in endemic and epidemic malaria in Kenya,
1.16.1.1 Specific Objectives
1. To assess in vivo efficacy o f sulfadoxine-pyrimethamine in sentinel sites in 
Kenya.
2. To assess in vitro drug resistance profile to quinine, chloroquine, sulfadoxine- 
pyrimethamine, amodiaquine and mefloquine.
3. To determine the association of particular drug resistant determinants with 
treatment outcome to antifolates and chloroquine.
4. To evaluate predictors of antifolate resistance using molecular markers in 
malaria endemic and epidemic areas.
5. To determine allele frequencies of drug resistant determinants in epidemic and 
endemic malaria.
6. To establish the genetic diversity profiles in endemic and epidemic malaria 
regions of Kenya by using the variable markers of the major merozoite surface 
protein gene-1 and -2, mspl, msp2, and glutamate rich protein gene, glurp.
7. To assist in developing and evaluating a quantitative nucleic acid sequence- 
based amplification method (NASBA) and to evaluate the accuracy of the method 
for the determination of malaria parasite levels in blood samples. This will 
probably be a valuable tool for monitoring in vivo drug trials.
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2.1 Introduction
All studies reported in this thesis were ethically approved by the Kenya 
Medical Research Institute Ethical Steering Committee. Subjects were recruited 
with informed consent or parental/guardian permission (see Appendix A: for 
information on study sites Appendix B: consent form).
Antimalarial drug resistance is a large and growing problem. Several East 
African studies have reported incidences of parasitological resistance of 
Plasmodium falciparum to chloroquine (CQ) ranging from 50% to 80% (Wolday 
et al., 1995; Rapouda et al., 1997). The emergence of CQ resistance has been 
associated with increased malaria mortality, especially in children (Trape el al., 
1998). However most African countries continue to use CQ as the first-line agent 
to treat uncomplicated malaria (Bloland et al., 1998) and has been reported to be at 
least partially effective in semi-immune African populations (Koella et al., 1990; 
Cravo et al., 2001).
SP was introduced in Kenya in 1983 as a second-line treatment for malaria. 
Initial studies showed little or no resistance to SP combination, but later studies 
reported cure rates ranging from 54% to 92% (Nguyen-Dinh et al., 1982; Spencer 
et al., 1986; Hagos et al., 1993; Anabwani et al., 1996; Clarke et al., 1996). In 
1997, the Kenyan National Malaria Control Programme, (NMCP) replaced CQ 
with SP as a first-line antimalarial treatment owing to the increasing number of 
CQ-treatment failures. However, this change was effected in August 2001, 
information obtained from the East Africa Network for Monitoring Antimalarial 
Treatment (EANMAT Scientific day meeting, June 2001).
Malaria endemicity in Kenya is influenced by both climate and topographic 
conditions. The altitude above sea level provides approximate criteria to stratify 
endemicity. Stable and hyper- to holoendemic malaria is found in the regions below 
1300m on the coast and in Nyan/.a and Western provinces where the prevalence of 
infection in children between ages 1 -9 years can be as high as 70-90 per cent during 
the long rains (MOH, 1987). Seasonal, but usually stable malaria is found between 
1,300-1,700 meters, in areas such as Mwea (1,300 meters) where the disease 
incidence is 30-40 percent (MOH, 1997). In the higher altitudes (between 1,700- 
2,300 meters) such as the Kisii Highlands and Kericho District, there is unstable
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transmission, and epidemics normally occur especially after unusually heavy rains 
(MOH, 1994-2001).
Malaria transmission in Kenya is mainly by the A. gambiae complex, notably 
A. gambiae, A. arabiensis, and A. funestus. A. gamhiae sensu stricto have been 
reported in the highlands of Kisii and Kericho as well as the Nandi foothills from 
where the vector spreads up to the shores o f  Lake Victoria, north-west of Kisumu 
(Service et al., 1978). The proportion of this species increases towards the cool 
highlands as described by White (White, 1972). A. gambiae has also been identified 
as the main vector in the coastal region (Mosha et al., 1982). Low frequencies of this 
species have been found in the coastal region (Mosha et al., 1982). It has also been 
documented in the Mwea irrigation scheme. A. merus is mainly restricted to the 
coastal strip (Mosha et al., 1982).
To assess the current extent of SP resistance among patients infected with 
P. falciparum in Kenya, cross-sectional and longitudinal in vivo studies were 
conducted. The studies were conducted in sentinel sites established by the NMCP 
(see Figure 2.1a-b). In addition, CQ efficacy studies were carried out in one site at 
least before CQ was replaced as first-line drug in the treatment o f uncomplicated 
malaria in Kenya. The efficacy of CQ, SP, co-trimoxazole and CQ plus SP (CQSP) 
combinations was assessed.
The in vivo and in vitro resistance profile of Kenyan P. falciparum was 
investigated as reported in this chapter.
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2.2 Materials and Methods
2.2.1 Description of study sites
2.2.1.1 Endemic sites
2.2.1.1.1 Mwea
Mwea is situated in the Central Province of Kenya at an altitude of 1,500 
meters above sea level. Mwea is a rice irrigation scheme and an urban area which is 
moderately populated (0.25-0.32 million); 39% of which are children under 5 
years. Malaria transmission is seasonal accounting for between 30-40% paediatric 
and adult outpatient attendances, (MOH 1994). P. falciparum resistant to CQ is the 
most important public health problem, (MOH, 1999). For information on 
temperature and rainfall for all sites described here, see Table 2.2.1. Information 
supplied by University o f Nairobi Weather Department.
2.2.1.1.2 Tiwi
Malaria is hyperendemic in Tiwi, a lowland area in Kwale District in Coast 
Province of Kenya. Tiwi is an urban area and moderately populated (0.75-1.05 
million); 20-27% of which are children under five years. There are two rainy 
seasons, viz "long rains" (February-.!une) and "short rains" (October-December) 
with mean annual rainfall of 1,000 millimeters [mm]. Malaria transmission is all 
year around, peaking in May, June and July months. In Tiwi, malaria is the major 
cause of morbidity, accounting for more than 30% of paediatric and adult 
outpatient attendances.
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2.2.1.1.3-5 Busia (Nambale), and Oyugis and Kendu Bay
These 3 sites are endemic for malaria and are situated in the western region 
of Kenya at 1,300 meters above sea level. Malaria transmission is very high and all 
year around, peaking in May, June and July months. Children aged 1-9 years are 
the most vulnerable group accounting for between 70 and 90% of malarial illness 
in the outpatients during long rains (MOH 1994). Malaria morbidity accounts for 
40% of paediatric and adult outpatient attendance (MOH, 1997). SP is therefore 
now routinely used for the treatment o f uncomplicated malaria. There are two rainy 
seasons, with an average annual rainfall ranging between 1,000-1,300 mm.
2.2.1.2 Epidemic sites
2.2.1.2.1 Mosoriot
Mosoriot is in the Nandi District of Western Kenya, a highland area (of 
altitude ranging from 1,700-2,500 meters above sea level) where transmission is 
seasonal and unstable. Epidemic malaria affects all age groups and when samples 
were collected, malaria was responsible for 40% of hospital attendance, (MOH, 
1997).
2.2.1.2.2 Chogoria
Chogoria is located on the eastern slopes of mount Kenya. It is a 
geographically diverse catchment area at the boundary of Mt. Kenya National 
Forest at an altitude of 1,710 meters. The area experiences an annual rainfall of 
2,000 mm. The land is very fertile and cash crops such as tea and coffee serve as 
the main source of income. Chogoria is close, about 60-70 kilometers [km] to the 
mesoendemic region of Meru district of Kenya.
2.2.1.2.3 Mt. Elgon
2.2.1.2.4 Kisii
Mt. Elgon and Kisii are located at higher altitudes between 1,700-2,300m. 
Malaria transmission is unstable and epidemics occur especially after unusually 
heavy rains.
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Clinical malaria is responsible for 45-50% o f outpatient cases and for 45% 
of inpatient admissions during epidemics. Case fatality rate for inpatients is high, 
at 5% (MOH, 1999). See Figure 2.1 for study sites.
Table 2.2.1 Rainfall and temperature parameters of the study sites
Study sites Year
Temperature (°C) 
Minimum Maximum
Mean Annual 
Rainfall 
(mm)
MweaMcso 1997 19 33 1,000
TiwiHyper 1997 22 32 1,000
BusiaHol° 1998 24 33 1,100
KenduBay"0'0 1999 23 32 1,000
OyugisHol° 1998 24 34 1,300
Mosoriot1 pl 1997 9 24 1,200
Chogoria1 pl 1997 12 25 2,000
Kisiitpi 1999 9 23 1,500
Mt. Elgonlpi 1999 9 23 1,500
Key to table 2.2.1 : Meso = mesoendemic; Hyper = hyperendemic; Holo =
holoendemic; Epi = epidemic
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Lake Turkana
Figure 2.1a A representative map of endemic regions of Kenya
showing study sites (numbers = Districts). 2 = Tiwi; 9 = 
Mwea; 24 = Oyugis and Kendu Bay [both in the same 
district]; 33 = Busia
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Figure 2.1b A representative map of epidemic regions of Kenya showing
study sites and ▲ = (Chogoria); (numbers = Districts). Mt.Kenya 
= Chogoria; 50 = Mt.Elgon; 49 =Mosoriot; 47 = Kisii
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2.2.2 In vivo antimalarial drug sensitivity studies
2.2.2.1 Patients
Patients presenting to the outpatient clinics were enrolled in the study if they 
met the following criteria: informed consent (see Appendix B): monoinfection of P. 
falciparum with parasitaemia between 1,000 and 200,000 parasites /pL of blood, 
axillary temperature > 37.5°C or with a history of fever, no history of antimalarial 
drug intake during the previous week as confirmed by urine tests. Blood was obtained 
by finger prick for thin and thick smears. If patients did not return for scheduled 
follow-up, they were visited and assessed at home. If patients could not be located 
by the home health visitor, (demographer) they were classified as lost to follow-up. 
Patients were excluded from the study for the following reasons: (1) administration 
of any additional antimalarial drugs, (2) emergence o f any non-malarial febrile 
illness that would interfere with the classification of malaria-treatment outcome, 
(3) patient relocation outside study area, or (4) withdrawal from the study.
The in-vivo studies on antimalarial drugs were chosen to comply with the 
sentinel sites identified by the Kenyan National Malaria Control Programme 
(Kenyan NMCP). In order to maximize a good representative of the sites, the 
b WHO (1996) protocol of malaria enrolment procedure was followed.
2.2.2.1.1 Sample size
The sample size estimation was calculated using the Double Lot Quality 
Assurance methodology (DLQAS), (described in the “Assessement of Therapeutic 
Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with 
Intense Transmission” [WHO protocol, 1996]). P0 [defined as the upper threshold 
level of clinical failure beyond which replacement of the drug under the study is 
deemed necessary], was assumed to be 25 % and PI [defined as the lower 
threshold level of clinical failure below which it would be acceptable to continue 
the utilisation o f the drug], was assumed to be between 10-12.5 %. With the above 
assumptions, (WHO, 1996), the minimal sample size derived according to the lot 
quality assurance method with a confidence level of 95 % and power of 80 % was 
63 patients per study site. The goal of patient recruitment was therefore to have
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>63 subjects on the appropriate drug and followed up until 14, 21 or 28 days later. 
Due to the dispersed population and geographical constraints, we expected the 
proportion of people ‘lost to follow up’ to be high, despite our efforts. Therefore 
allowing for a 20% loss to follow up we required a final sample size of 80 persons 
for each drug. The decision on sample size was made this way but was largely 
influenced by dominant considerations borne from practical decisions on the 
availability of time, staff and money. The number of patients satisfying the 
inclusion criteria (section 2.2.2.1) who were enrolled into the study in the initial 5 
days was an important factor.
2.2.2.2 Sample collection
Pre- and post-treatment blood samples were collected from the patients by 
fmgerprick as dried blood spots on 3MM Whatman filter paper (Sambrook et a!., 
1989) or glass fibre membranes (GFM), (Warhurst et al, 1991). Samples were 
allowed to air dry. The serially labeled samples were then transferred to matching 
labeled self-seal bags. Samples were stored at 4°C with desiccant to prevent 
dampness until required for DNA extraction/ polymerase chain reaction.
2.2.2.3 Treatment and follow-up
Chloroquine resistance became widespread in Kenya posing serious 
limitations to malaria chemotherapy. This led to the withdrawal of the drug with 
partial replacement with SP by late 1997. In this study therefore, SP was the main 
drug used in all sites. Drugs or drug combinations were tested in other sites chosen 
at random. In Mwea, CQ and SP were used. Similarly, SP was used in a study 
conducted in Tiwi in 1997. SP alone and in combination with CQ (CQSP) were 
used in Busia, while in Kendu Bay, SP was the only drug used. In the 1998 Tiwi 
and Oyugis study, SP was used alone and compared with trimethoprim plus 
sulphamethoxazole combination (co-trimoxazole). The oral regimens prescribed 
arc as detailed below: CQ (25 mg/ kg base body weight (Avloclor0', ZENECA), 
giving 10 mg /kg per body weight on days 0 and 1, and 5 mg /kg on day2. SP was 
administered as a single dose of 1.25 mg / kg pyrimethamine and 25 mg / kg 
sulfadoxinc (Fansidar®, Roche) CQ and SP were given as (25 mg/ kg of CQ
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(Avloclor®, ZENECA): 10 mg /kg on days 0 and 1 and 5 mg /kg on day 2 followed 
by a single dose of 1.25 mg /  kg pyrimethamine and 25 mg / kg SP. Co- 
trimoxazole (Septrin®, Glaxo Wellcome, UK) paediatric suspension 2.5mls 12 
hourly for 5 days was administered. The dose is equivalent to 6mg of trimethoprim 
and 30mg of sulfamethoxazole per kilogramme body weight. The WHO (WHO, 
1996) in vivo test procedure was employed in all study sites. Patients enrolled into 
the studies were randomized into groups A or B for treatment as outlined below.
Endemic sites: In studies conducted in Mwea (year 1997), Busia, Oyugis 
and Tiwi- (year 1998) patients were randomized into 2 groups, A and B. In Mwea, 
group A received CQ and B were treated with SP. In Busia, patients in group A 
were treated with SP and B with CQSP combination. In Oyugis and Tiwi, patients 
in group A received SP and group B co-trimoxazole. Repeated doses for those 
patients treated with co-trimoxazole, CQSP or CQ was conducted as explained 
above. In 2 sites, Tiwi 1997 and Kendu Bay, SP was used as the only treatment 
regimen and for all the enroled patients.
Epidemic sites: In the epidemic sites of Mosoriot, Mt. Elgon and Kisii, 
patients were treated with SP. In Chogoria patients had been treated initially as 
outpatients with CQ, SP, or AQ. The Chogoria study was conducted by Professor 
Dieter Gump and Mr. Peter Ndaru (see Appendix C).
Shortly after enrolment drug intake was monitored and patients observed 
for 30 minutes to rule out vomiting. All patients received the antipyretic 
paracetamol. A follow-up protocol was adopted [14-days in endemic sites of Mwea 
and Kendu Bay and in the epidemic sites of Chogoria, Kisii and Mt. Elgon]; [21 
days in endemic sites of Tiwi and epidemic sites of Mosoriot]; [28 days in endemic 
site of Busia].
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2.2.2.4 Screening
Patients were initially screened to select those who met the enrolment 
criteria. Thick and thin blood smear were prepared for microscopic determination 
of P. falciparum monoinfections. The thick smear was used for screening for an 
initial rapid count of the parasites and thin smear for definitive count and for 
species identification. Thin smear was fixed in methanol before staining along with 
thick smear in 10% Giemsa stain. Parasite density was determined by counting the 
number o f asexual parasites per 200 white blood cells (WBC) assuming a WBC 
count o f 8,000/pl of blood. Body temperature was estimated in the axilla.
Urine samples were obtained from each patient and tested for drug intake 
prior to presentation at the clinic. The Saker-Solomon test (Mount et al., 1989) was 
used for the detection of CQ and (desethylCQ) while a modified Bratton-Marshall 
test (De Almeida and De Souza, 1983) for sulfonamides was performed to detect 
use of SP or co-trimoxazole.
2.2.2.5 In vivo test
2.2.2.5.1 Clinical and parasitological criteria
The in vivo test was carried out following the revised WHO protocol 
(WHO, 1996) and classifying therapeutic response as outlined below. The first day 
of treatment corresponds to day 0; the days of follow-up were then counted from 
this date.
Early treatment failure (ETF):
-development of danger signs or severe malaria (see below for definition)
on day 1, day 2 or 3;
-axillary temperature > 37.5°C on day 2 with parasitaemia > that of day 0
[recruitment day];
-axillary temperature > 37.5°C on day 3 in the presence of parasitaemia;
-parasitaemia on day 3 > 25% of count on day 0.
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Presence of one or more of the following criteria in the presence of asexual 
parasitaemia as reported by WHO ( 1994) define severe falciparum malaria: 
cerebral malaria, severe normocytic anaemia, renal failure, pulmonary oedema, 
hypoglycaemia, circulatory collapse, repeated generalized convulsion, acidosis, 
macroscopic haemoglobinuria.
Therapeutic response was classified as late treatment fa ilu re  (LTF): 
if the patients developed:
-danger signs or severe malaria in the presence of parasitaemia on any day 
from day 4 to day 14, [or 21 or 28 depending on the study period] without 
previously meeting any of the criteria of early treatment failure;
-axillary temperature > 37.5°C in the presence of parasitaemia on any day 
from day 4 to day 14/21 or 28 without previously meeting any of the criteria 
of early treatment failure.
The response to treatment was classified as adequate clinical response (ACR) 
if the patients showed one o f the following conditions during the follow-up period 
(upto day 14, 21 or 28).
Adequate clinical response (ACR):
-absence of parasitaemia on day 7, 14, 21 or 28 irrespective of axillary 
temperature, without previously meeting any of the criteria of early or late 
treatment failure
-axillary temperature < 37.5°C irrespective of the presence o f parasitaemia, 
without previously meeting any of the criteria of early or late treatment 
failure.
Parasitological response (S, RI-R11I) was determined using the WHO 
criteria (WHO, 1994). If the day-3 parasite density was > 75% o f  the day 0 density, 
the response was classified as RIII resistance. If the day-3 density was 25% of the 
day 0 density and the patient was parasitaemic on day 4-7, the response was 
classified as RII. RI parasitological responses were defined as day-7 parasite 
densities <25% of day-0 density, [following either an initial parasite clearance on 
day 3 or presence of parasite density on day 3 at <25% of day-0]. Patients with day
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3 parasitaemia (<25%) of that on day 0 [or absence of parasitaemia], a negative 
blood smear on day 7 and negative smears for the remainder of the follow-up 
period were classified as sensitive (S).
As stated above and as defined by the WHO criteria for classification of 
therapeutic response, (WHO, 1996), the indication for successful or unsuccessful 
treatment at any time between day 0 and end of study period [either day 14, 21 or 
day 28], should be based on clinical and parasitological criteria. The main aim is to 
avoid an aggravation of the clinical condition and risk to the patient and to evaluate 
parasite clearance correctly. As stated by the WHO protocol, (WHO, 1996) and 
adopted in this thesis, evaluation of patient’s clinical condition was not limited to 
fever, since danger signs may also develop in afebrile patients. The guidelines aim 
at maximizing sensitivity to ensure that most cases with a true malaria attack 
receive antimalarial treatment. The clinical criteria were also supported by 
parasitological evidence. Parasitological evidence is desirable for diagnosing 
treatment failures and severe disease in all situations, as well as for identifying the 
disease in areas of unstable or low transmission.
Additionally, the criteria for assessment of parasitological and clinical 
outcome during treatment and subsequent to that, are aimed at evaluating the 
proportion of treatment failures in the sampled population. The latter will provide 
the level o f  treatment failures in a particular study area to a given antimalarial drug 
regimen used. Persistence o f parasitaemia and/ fever following treatment, 
therefore, will suggest that the drug is not efficacious in alleviating symptoms or 
clearing parasitaemia.
2.2.2.5.2 Parasite and fever clearance times
Parasite clearance time (PCT) and fever clearance time (FCT) was used to 
measure clearance o f parasitaemia and fever, respectively, within the first week in 
treated patients. Parasite clearance time (PCT) was defined as the time from 
beginning o f drug administration until there was no patent parasitaemia. For SP the 
earliest end-point measured was 48 hours. For CQSP, CQ, co-trimoxazole, the 
end-points measured after the first drug administration was 12, 24 and or 48 hours 
for each o f  the drug regimen. This is because treatment was given daily for 3 days
71
for CQ and CQSP and 5 days at 12 hourly intervals for co-trimoxazole and only 
once for patients on SP alone, see section 2.2.2.3. The time taken to clear parasites 
at the given time points was then calculated. For comparative analysis of SP with 
CQSP, CQ or co-trimoxazole, for PCT and FCT, the earliest end-point measured 
was 12 hours from commencement of respective treatment regimen.
The fever clearance time (FCT) was defined as the time from start of drug 
administration until the axillary temperature fell to 37.2°C or below and remained 
so for at least 48 hours [SP]. With regard to antimalarial drugs like co-trimoxazole, 
CQ and CQSP combination the temperature was monitored at 12, 24 and 48 hours. 
For comparative measurements with CQSP, CQ or co-trimoxazole, FCT was 
measured similarly to the SP treatment groups. Patients complaining of having had 
persistent fever without direct evidence (presumptive) were encouraged to visit the 
clinic for further assessment.
2.2.2.5.3 Haematological assessment
Improvement in haemoglobin levels could suggest effective treatment and 
in this study, Hb concentrations were obtained in patients during pre- and post­
treatment period. Haematological response, on a population basis, gives an 
assessment of haematological effect of the drug used and can be compared over 
time or between different regimens or drugs. The usefulness of the test initial is to 
identify patients with severe anaemia prior to inclusion in the study [enrolment 
F requires a Hb value of above 5.0 g/dL, (WHO, 1996)]. Patients with a Hb 
concentration of 5.0 g/dL or less, were not included in the study and were referred 
to the main hospital for appropriate treatment. Haematological response was 
compared between treatment groups (mean improvement by group) and between 
treatment successes and treatment failures. The haemoglobin level or concentration 
was measured on days 0, 3, 7 and 14 (and 21 or 28 wherever applicable). This was 
done using a haematometer (Compur 1000 Bayer Diagnostics and Electronic 
Gmbh, München Germany) and performed on fingerprick blood obtained from 
patients.
2.2.2.5.4 Side effects monitored following treatment with 
antimalarial drugs
Upon treatment, the side effects were monitored. Vomiting, nausea, 
anorexia, diarrhoea, abdominal pain and fits were looked for. Where side effects
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become severe, treatment is withdrawn and patient is excluded from the study and 
referred to outpatient department for adequate care and treatment.
2.2.2.6 Statistical analysis
Data were analysed using the Epi-info version 6 (Centers for Disease 
Control and Prevention, Atlanta, GA, USA). Clinical success was defined as ACR 
and clinical failure defined as ETF or LTF. Parasitological responses were also 
included. A 2-tailed Mest analysis (not assuming equal variance) was performed 
when calculating for level of significance (P value less than or equal to 0.05).
2.2.2.7 Workers
A team of field workers or technicians recruited into the study carried out 
activities such as blood smear preparation, urine test, completing enrolment forms. 
These included demographers or follow-up officers and microscopists. A clinical 
officer or physician who looked after the patients was also involved in intravenous 
blood sample collection. Other activities include haemoglobin analysis, blood 
spotting on filter paper or glass fibre membrane, sample collection for nucleic acid 
sequence-based amplification analysis (NASBA). See Appendix C for list of field 
workers involved in the study.
2.2.3 In vitro
2.2.3.1 Introduction
In this section the in vitro efficacy o f  clinically useful blood schizontocides 
and antifolates against Kenyan P. falciparum  were assessed. This is done with the 
aim of comparing in vitro drug efficacy with the in vivo findings. Therefore blood 
samples from infections examined in some of the endemic sites described in 
sections 2.2.1.1.1 to 2.2.1.1.4 were assessed using WHO in vitro Mark II micro test 
system (WHO, 1990). The endemic sites included Mwea, Tiwi, Oyugis and Busia 
where sample size of 48, 38, 69 and 65 from each site respectively, was collected.
2.2.3.2 Sample collection
Two millilitres [ml] of venous blood was obtained by venipuncture prior to 
treatment and using a heparinised 3ml sterile syringe with a 18 G needle. This was
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performed by experienced technicians and paediatricians. Blood was transferred 
into sterile heparinized vacutainers (surface sterilized with 70% ethanol). Each 
tube was labeled with date and serial number. The tubes were inverted to mix the 
blood with the heparin. Samples were kept at 4°C in a cool box (with cool packs) 
or were kept in the fridge if available at the health units, until subjected to in vitro 
tests. The duration from the time the sample was obtained to the time the in vitro 
assay was carried out was a minimum of 2 hours and a maximum of 5 hours.
2.2.3.3 Media preparation
A one litre medium was prepared by dissolving a sachet of 10.4 gram (g) 
RPM1 1640 and 6g of HEPES [N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic 
acid] in 500ml ddH20 (double distilled water). 2g of glucose was added and 
solution made up to 960 ml. 40mg of gentamicin was added and the medium was 
filter-sterilized through a 22 pm filter unit (Nalgene). 250ml aliquots were made 
and kept frozen at -20°C until needed. Medium preparation was carried out 
aseptically in a class II microbiological cabinet. Sodium bicarbonate [NaHCOj] 
was prepared separately by dissolving 5g o f the compound in 100ml of ddHjO. 
This was filter-sterilized and kept at 4°C to be used within 2 weeks. NaHCOj 
solution was added to the growth medium at 4.2% (v/v) before use. This complete 
medium (CM) was used in the in vitro assay at pH 1.2-1 A.
In preparing the assay 100pl of infected blood sample was added to 900pl 
of CM. This was gently agitated to mix. Each test well of a sterile microtitre plate 
received 50pl of blood/ medium mixture: for media calculations, see Appendix D.
2.2.3.4 WHO Mark II 30 hour in vitro test
Standard test kits were obtained from the World Health Organization, 
Manila Philippines. Micro in vitro tests (WHO, 1990) [See appendix E], were 
performed to assess the sensitivity of P. falciparum to CQ, MQ, QN and SP. All 
procedures were carried out under aseptic conditions. Portable non-flow hood (MJ 
Research model number P-048-202) transported to the study sites was sterilised 
with 70% ethanol and by ultraviolet radiation prior to use. A stand-by petrol- 
powered generator (Suzuki model number SX 1000) was used when power failed.
Tissue culture plate. 1 2 x 8  wells, predosed with:
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Chloroquine: 
Mefloquine: 
Quinine: 
Sulfadoxine/ I 
PyrimethamineJ
1- 64 pmol/ well
2- 128 pmol/ well 
4-256 pmol/ well
Sulfadoxine: 10-10,000 p m o l/well
Pyrimethamine: 0.125-125.0 pmol/ well
2.2.3.5 Aliquoting of test plates
The plastic sealing strips on each test plate was removed according to the 
number of isolates to be tested. Serial number for each isolate was written on the 
cover-lids of the plates, against the test row on the lid of each plate. The blood/ 
medium mixture was gently shaken to prevent cell deposit. Then starting with well 
A (control) through to H, each well was aliquoted with 50 pL of the blood:medium 
mixture. This procedure was repeated until the required test rows of each plate 
were dosed with 50pL of the mixture. The lids were replaced and each plate was 
gently shaken so that drug deposit was completely dissolved in the mixture.
2.2.3.6 Incubation
The candle jar holding the culture plates was incubated in an incubator 
(Hereus model number B5041) set to give an internal temperature o f 37°C in the 
candle jar (Bellco Glass Inc., Vineland New Jersey) A damp paper towel was 
placed at the bottom of the jar below the separator mesh to ensure humidity during 
cultivation. Two medium-sized paraffin candles were lit and placed on each side of 
the stacked plates. The candle jar lid was replaced and good seal was maintained 
with Dow-Coming* high vacuum grease (Merck limited, England). The exhaust 
valve was left in an open position and closed only when the second candle was at 
the point of extinction. In order to test if there was no leakage, the vent was opened 
briefly and a hissing sound was indicative of no leakage. The ja r and its contents 
were incubated for an average period o f 30 hours.
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2.2.3.7 Harvesting
After incubation, the supernatant in each test well was removed and 
discarded. A rubber tubing attached to a suction bulb was gently used to draw up 
and suspend the blood. In the absence of the latter a capillary tube was used. The 
red blood cell deposits were transferred to clean microscope slide for thick smear 
preparation. Harvesting was done starting with well A through to H. The prepared 
slides were allowed to air dry for at least 9 hours after which they were stained for 
30 minutes in 2% Giemsa. The slides were viewed under oil immersion using a 
standard microscope with total magnification of X 1000.
2.2.3.8 Schizont maturation and morphologic criteria for data analysis
The tests were performed according to standard WHO procedures. Tests 
were considered successful if > 10% of the parasites in the control well developed 
into normal schizonts with > 8 nuclei for the SP tests or with > 3 nuclei for the CQ, 
MQ and QN tests. Counting was done starting from well A through to H. This was 
completed when trophozoite count reached 200.
The minimum inhibitory concentration (MIC) was defined as the lowest 
drug concentration in which no schizonts were observed. Schizont growth at 8pmol 
CQ/well (1.6 pmol/L of blood), 64 pmol MQ/well (12.8 pmol/L o f blood), and 
256 pmol QN/well (51.2 pmol/L o f blood) were taken to indicate resistance. For 
SP, the endpoint was 90% inhibition of normal schizonts with > 8 nuclei, but a 
figure for resistance cut-off has not been reported, and comparative results only are 
given.
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2.3 Results
2.3.1 In vivo antimalarial efficacy studies
2.3.1.1 Endemic sites
2.3.1.1.1 Mwea, 1997
Chloroquine (CO)
In the 60 patients treated with CQ, parasitaemia range from 2,200 -69,700 
parasites/pL with a geometric mean of 5,940 parasites/pL. Pre-treatmeni axillary 
body temperature varied between 37.6°C and 38.4°C (mean = 37.7°C). Fever was 
promptly resolved in the patients with treatment success. Note that all patients in 
this and other study sites, with fever > 37.5°C received antipyretic paracetamol in 
accordance with the Kenyan National guideline. A mean age of 6.8 years was 
recorded for this group (see Tabel 2.3.1.1.1). Day 0 haemoglobin (Hb) level was 
10.5 g/dL. There was a mean increase of 1.8 g/dL, over the trial period. This was 
higher in patients with initial lower Hb levels of (6-8g/dL), where an increment of 
5.0 g/dL was observed, (anaemia Hb level of < 5.0 g/dL were not included in the 
study).
Of the 60 children treated, 40 (67%) displayed adequate clinical response 
(ACR) and their infection was considered sensitive to CQ. Of the remaining 20 
(33%), 1 case out o f the 20 (5%) was febrile and had detectable parasitaemia by 
day 7 after initial parasite clearance. This is a case o f LTF with RI type of 
parasitological response. The remaining 19 (95%) had detectable parasitaemia and 
fever by day 3, representing cases of ETF. Of these 11/ 19 (58%) cases had 
parasite density at 25% of pre-treatment density and 8 (42%) cases had parasite 
density >75% of the pre-treatment level respectively. These are ETF displaying Rll 
and Rill parasitological response, respectively.
Sulfadoxine-pvrimethamine (SP)
In the 48 patients treated with SP, parasitaemia ranged from 3,960 
parasites/pL to 60,300 parasites/pL with a geometric mean of 6,990 parasites/pL 
The body temperature before treatment ranged between 37.7°C and 38.3°C and a 
mean of 37.9°C, see Table 2.3.1.1.1. Patient age ranged between 11 months and 17
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years (mean = 8.3 years). The mean Hb concentration was 9.95g/dL and had 
improved by day 7 with a mean increment o f  1.7g/dL.
Of the 48 children, 34 (71%) displayed ACR and the infection was 
considered sensitive to SP. Of the remaining 14 (29%), 8/14 (57%) patients were 
febrile and had detectable parasitaemia by day 7 and at <25% of pre-treatment 
level indicating LTF with RI type of parasitological response. In the remaining 6 
(43%) that were parasitaemic they had > 25% of the pre-treatment level plus fever 
by day 3, suggesting ETF. Of these 6, 4 (67%) displayed Rill type of response 
with parasite density at > 75% of the pre-treatment level and 2 (33%) displayed RII 
with parasite density at 25% of the pre-treatment level.
Patients who failed CQ or SP treatment were adequately re-treated with
AQ.
Comparative analysis between CQ and SP
The incidence of clinical and parasitological failure was not significantly 
different between CQ and SP [20/60 (33%) with CQ versus 14/48 (29%) with SP] 
(OR 0.82 95% Cl [0.33-2.02]; P = 0.798).
Reduction of fever in the 2 treatment regimens was similar, Table 2.3.1.1.1. 
The Hb level was measured on days 0, 3, 7 and 14 indicated a mean increase over the 
trial period in both the CQ and SP treatment modalities. No difference was observed 
for CQ, 1.8 g/dL and 1.7 g/dL in the SP group, (P > 0.05).
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2 .3 .1 .1 .1  M w ea  1 9 9 7 : In vivo e f f ic a c y  o f  c h lo r o q u in e  a n d  S P  in
u n c o m p lic a te d  fa lc ip a r u m  in fe c t io n
Table 2.3.1.1.1: Clinical characteristics and response o f uncomplicated falciparum malaria to 
chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) treated groups: Mwea, 
1997
CQ SD SP SD
Admission param eters
No. enrolled 76 89
No. completing 
Dm test period 60 48
" Mean age (years) 6.8 5.92" 8.3 6.71"
GMPD‘ DO 5,940 8,689 6,990 8,005
[2,200-69,700] [3,960-60,300]
Temperature DO
(°C)* 37.7[37.6-38.4]
0.71
37.9[37.7-38.3]
0.9’Mean Hb conc.(g/dL)’ 10.5[8.9-11.6] 9.95[8.7-12.1]
Outcome
Clinical response n 1% 1 n |%1***
ETF 19(31] 6[ 12]
LTF U2] 8[ 17]
ACR 40[67] 34[71]
Parasitological response
S 40[67] 34(71]
R1 1 [2] 8[ 17]
RII 11(18] 2[4]
Rill 8[ 13] 4[8]
•Mean fever clearance time (h) 48 48
••M ean parasite clearance time (h) 48
1.02"
48
1.09"Mean Hb level (g/dL) 12.3 11.65
Major side effects 0 0
Abbreviations: SP, sulfadoxine-pyrimethamine; GMPD, geometric mean parasite density 
1 Mean [range in parentheses].
•Mean fever clearance time [FCT, defined as the time from first drug administration until the 
axillary temperature fell to 37.2°C or below].
••M ean parasite clearance time [PCT, defined as the time from first drug administration until there 
was no patent parasitaemia],
•••V alues expressed as percentage o f  the total samples analysed [also done for other study sites 
and demonstrated in the respective tables].
■ SD = standard deviation.
■ For significance level [indicated as P value], 2-tailed /-test not assuming equal 
variances was used in all study sites.
■ P value > 0.05 indicates no significant difference; a P value of <0.05 or < 0.001 
indicates significant difference],
!P > 0.05; "P >0.05; P < 0.001 between 1 and ” for CQ and SP pre- and post-treatment 
respectively.
P > 0.05
7 9
As outlined above, the efficacy of antimalarial drugs, singly or in combination, 
was assessed in the following endemic sites: Tiwi, 1997; Busia, 1998; Tiwi, 1998, 
Oyugis, 1998 and Kendu Bay 1999. See Tables, (2.3.1.1.2 to 2.3.1.1.6) 
respectively.
2.3.1.1.2 Tiwi, 1997: In vivo efficacy of SP in uncomplicated falciparum 
malaria.
In the 38 children treated with SP, parasitaemia ranged between 5,600 and 
103,200 parasites/pL with a geometric mean of 17,695 parasites/pL. The axillary 
body temperature before treatment was between 35.6 °C and 40°C (mean = 
36.8°C). The age range was 0.5years to 21 years (mean = 5 years). The mean Hb 
concentration was 11.4 g/dL. By day 21, Hb concentration showed an increase of 
1.4g/dL.
O f the 38 patients that completed the study, 13 (34%) displayed ACR and 
their infections were considered sensitive to SP. O f 25 resistant cases (66%), 23 
(92%) were febrile and microscopy positive by day 7 with parasite density <25% 
of pre-treatment analysis indicating LTF and displaying an RI level of resistance. 
By day 3, 2/25 (8%) resistant infections, were febrile and parasitaemic at > 25% of 
the pre-treatment parasite density suggesting cases of ETF. Of these 2, 1 (50%) 
displayed R1II type of response with parasite density at > 75% of the pre-treatment 
level and 1/2 (50%) displayed RI1 with parasite density at 25% of the pre-treatment 
level. See Table 2.3.1.1.2.
2.3.1.1.3 Kendu Bay, 1999: In vivo efficacy of SP in uncomplicated 
falciparum malaria.
In the 120 patients treated with SP, parasitaemia ranged from 1,960 to 
98,400 parasites/pL with a geometric mean of 14,600 parasites/pL. Pre-treatment 
axillary body temperature varied between 37.8°C and 41°C (mean = 38.2°C), see 
Table 2.3.1.1.3. A mean age o f 7.8 years was recorded for this group. There was a 
mean increase in Hb of 1.6g/dL over the trial period from the initial mean Hb 
concentration of 12.1 g/dL.
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Of the 120 patients that completed the study, 97 (81%) displayed ACR and 
their infections were considered sensitive to SP. Of 23 resistant cases (19%), 14 
(61%) were febrile and had detectable parasitaemia by day 7 with parasite density 
<25% of pre-treatment analysis and remaining so throughout the trial period 
indicating LTF and displaying an RI level of resistance. The remaining treated 
patients 9/23 (39%) had fever and detectable parasitaemia by day 3, > 25% of the 
pre-treatment parasite density indicating ETF. Of these 9, 8 (89%) displayed Rill 
type of response with parasite density at > 75% of the pre-treatment level and 1 
(11%) displayed Rll with parasite density at 25% of the pre-treatment level.
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2.3.1.1.2 Tiwi, 1997: In vivo efficacy of SP in uncomplicated falciparum 
malaria.
Table 2.3.1.1.2: Clinical characteristics and response of uncomplicated falciparum malaria to 
sulfadoxine-pyrimethamine (SP): Tiwi. 1997.
Admission param eters SP SD
No. enrolled. 38
No. completing 
D u test period 38
Mean age (yrs)* 5 4.75
GMPD DO*' 17,695[5,600-103,200] 25,573
Temperature DO (°C)* 36.8 [35.6-40]
Mean Hb level (g/dL)‘ 11.4(6.3-13.1] 1.49'
O utcom e
Clinical response n |% |* * *
ETF 2[6]
LTF 23(60]
ACR 13(34]
Parasitological response
S 13(34]
R] 23(60]
RII 1[3]
RIII 1[3]
•M ean fever clearance time (h) 48
••M ean parasite clearance time (h) 48
Mean Hb level (g/dL) 12.8 0.613"
Major side effects 0
See Table 2.3.1.1.1 for key to abbreviations 
P < 0.05 betw een  ! and  " for SP pre- and post-trea tm en t
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2 .3 .1 .1 .3  K en d u  B a y , 1999: In vivo e ffic a cy  o f  S P  in u n c o m p lic a te d
falciparum malaria.
Table 2.3.1.1.3: Clinical characteristics and response o f uncomplicated falciparum patients to 
sulfadoxine-pyrimethamine (SP): Kendu Bay, 1999.
Admission param eters SP SD
No. enrolled. 120
No. completing 
D h test period 120
Mean age (yrs) 7.8 4.76
GMPD DO* 14,600[ 1,960-98,400] 23,200
Temperature DO (°C)* 38.2(37.8-41 ]
Mean Hb level (g/dL)* 12.1(6.9-13.6] 0.65’
Outcom e
Clinical response n |% |***
ETF 9(7]
LTF 14(12]
ACR 97(81]
Parasitological response
S 97(81]
RI 14(12]
RII 1(1]
Rill 8(6]
•M ean fever clearance time (h) 48
••M ean parasite clearance time (h) 48
Mean Hb level (g/dL) 13.7 1.10"
Major side effects 0
See Table 2.3 .1.1.1 for key to abbreviations
P < 0.001 betw een 1 and " for SP pre- and p o st-trea tm en t
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2.3.1.1.4: Busia, 1998: In vivo efficacy of CQSP and SP in uncomplicated 
falciparum infection.
In this site, in vivo efficacy studies involved the use of combination of SP 
and CQ given to one group while SP alone was given to another group. WHO in 
vivo efficacy procedure was employed, (WHO, 1996). Of the 121 patients recruited 
in Busia in 1998, 113 (93%) completed the study; and of these 48/113 (42%) received 
CQSP while 65/113 (58%) were given SP. A summary of admission parameters and 
therapeutic response to both regimens are shown in Table 2.3.1.1.4.
The response to treatment employed the 14 day response criteria using the 
modified WHO protocol (WHO, 1996).
Patients were randomized into 2 groups and were similar in age, weight, 
temperature, and sex at enrolment, (Table 2.3.1.1.4)
CQSP
In the 48 children treated with CQSP, parasitaemia ranged from 5,600 
parasites/(aL to 58,900 parasites/pL (with a geometric mean of 21,600 
parasites/pL). The axillary body temperature before treatment ranged between 
37.8°C and 38.2 °C (mean=38.0 °C). All patients in this group had their body 
temperature re-monitored at the end of the 12 hours after drug administration and 
were within the health centres’ vicinity. The same applied to the SP treated group. 
Age ranged between 0.9yrs and 24 yrs with mean age of 7.2 yrs. The day 0 Hb 
concentration was 10.5g/dL and a mean increase was recorded at the end of the 
trial period to be 1.3 g/dL.
O f  the 48 patients that completed the study, 34 (71%) displayed ACR and 
their infections were considered sensitive to CQSP. O f the 14 resistant cases 
(29%), 6 (43%) were febrile and parasite positive by day 7 with parasite density 
<25% o f pre-treatment analysis indicating cases of LTF and were considered of RI 
level o f resistance. The remaining 8/14 (57%) had fever and detectable 
parasitaemia by day 3 and at > 25% of the pre-treatment value indicating ETF. Of 
these 8, 4 (50%) displayed Rill type of response with parasite density at > 75% of 
the pre-treatment level and 4 (50%) displayed RII with parasite density at 25% of 
the pre-treatment level.
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SP
Sixty-five patients completed the study. The Hb concentration at enrolment 
was 11.2g/dL but a mean increase of 1.2 g/dL was recorded over the trial period. 
Parasitaemia ranged from 4,960 parasites/pL to 65,800 parasites/pL with a 
geometric mean of 26,970 parasites/pL. The age range was 0.7yrs to 27 yrs with a 
mean age of 8.3 yrs. Pre-treatment axillary body temperature ranged between 
37.7°C and 38.0°C (mean=37.9°C).
Of the 65 patients, 53 (81%) displayed ACR and their infections were 
considered sensitive to SP. Of the 12 resistant cases (19%), 5 (42%) were febrile 
and parasitaemic by day 7 with parasite density <25% o f day 0. These were cases 
o f LTF and with RI level of resistance. In the remaining treated patients 7/12 
(58%) were febrile and had detectable parasitaemia by day 3 and at > 25% of the 
pre-treatment value indicating ETF. Of these 7, 4 (57%) displayed Rill type of 
response with parasite density at > 75% of the pre-treatment level and 3 (43%) 
displayed R1I with parasite density at 25% of the pre-treatment level.
Comparative analysis of patients treated on CQSP and SP response
Considering parasitological parameters, the 2 treatment regimens used were 
not significantly different. The incidence of clinical and parasitological failure was 
not significantly different (14/48 (29%) with CQSP versus 12/65 (19%) with SP [RR 
0.55; 95% Cl [0.21-1.45]; P=0.266]).
The Hb level was measured on days 0, 3, 7, 14, 21 and 28 in 48 CQSP and 65 
SP recruits. Initial (day 0) mean Hb concentration for CQSP was 10.5 g/dL, and SP 
11.2g/dL. Mean increase over the trial period was 1.8 g/dL in the CQSP group vs 2.0 
g/dL in the SP group.
Calculation of fever clearance times and conducted 12 hours after first drug 
administration showed that 19/34 (56%) of the CQSP-treated patients were reported 
as afebrile compared to 18/53 (34%) in SP treatment group (P=0.04). By 24 hours, 
27/34 (79%) [CQSP] and 28/53 (53%) [SP] were afebrile (P=0.022). Mean fever 
clearance times are given in Table 2.3.1.1.4.
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There was no patient whose condition deteriorated and thus requiring 
alternative treatment before day 7. There were no fatal cases nor severe malaria. The 
2 regimens were well tolerated.
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2 .3 .1 .1 .4  B u s ia , 19 9 8 : In vivo e f f ic a c y  o f  C Q S P  a n d  S P  in  u n c o m p lic a te d
fa lc ip a r u m  in fe c t io n .
Table 2.3.1.1.4: Clinical characteristics and response o f  uncomplicated falciparum patients to 
sulfadoxine-pyrimethamine (SP) and sulfadoxine-pyrimethamine and chloroquine 
________________ (CQSP): Busia. 1998.______________________________________________________
CQSP SD SP SD
Admission p aram eters
No enrolled 52 69
No. completing 
D28 test period 48 65
Mean age (years) 7.2 6.79A 8.3 7.24A
Temperature (°C)* 38.0(37.8-38.2) 37.9(37.7-38.0)
No. o f patients with>/ 38.0 (°C)
27 (56%) 33(51% )
Meean Hb level (g/dL)* 10.5 1.17* 11.2 1.19*
(8.9-11.7) (7.8-12.6)
GMPD DO* 21,600 15,097 26,970 17,982
(5,600-58,900) (4,960-65,800)
Outcom e 
Clinical response n |% |“ * n [% |* “
ETF 8[ 16] 7[11]
LTF 6[13] 5[8]
ACR 34[71] 53[81]
Parasitological response
S 34(71 ] 53[81]
RI 6[ 13] 5[8]
RII 4(8] 3[5]
Rill 4[8] 4[6]
‘ Mean fever clearance time (h) 12 24
“ Mean parasite clearance time (h) 48 48
Mean Hb level (g/dL) 11.8 0.57" 12.4 0.68"
Major side effects 0 0
C Q SP: C Q  in a total dose o f  25m g/kg for 3 days and sulfadoxine-pyrim etham ine 
(sulfadoxine, 25 m g/kg) w ith (pyrim etham ine, 1.25 m g/kg  SP). See T ab le  2.3.1.1.1 for key 
to  m ore abbrev ia tions.
“ P > 0.05
!P> 0.05 [betw een C Q S P  and SP, pretrea tm ent]; ,!P >0.05 [betw een  C Q S P  and SP, post 
treatm ent]
P <  0.001 betw een  ' and  " for C Q SP  and SP pre- and p o st-trea tm en t respec tive ly
87
In 1998 comparative efficacy of sulfamethoxazole/trimethoprim (referred 
to as co-trimoxazole) and sulfadoxine/pyrimethamine (SP) was conducted in 
malaria endemic sites of Tiwi and Oyugis.
Patients in the 2 groups and at the 2 sites had similar parameters and (not 
significantly different) in age, weight, temperature, and sex ratio, at enrolment, 
however patients in Oyugis had a slightly higher parasite density, see Table 
2.3.1.1.5-6.
2.3.1.1.5 Tiwi, 1998
In Tiwi, 246 patients were screened out of which only 142 (58%), satisfied 
the inclusion criteria; 56 (22.7%) had taken antimalarials, 39 (15.8%) had low 
parasitaemia (<l,OOOparasites/pL of blood), and 9 (3.7%) had very high 
parasitaemia (>200,000 parasites/pL). Seventy-six (53.5%) patients were 
eventually enrolled and treated with SP while 66 (46.5%) were treated with co- 
trimoxazole.
Co-trimoxazole
In the 66 children treated with co-trimoxazole, parasitaemia ranged from 
3,290 to 46,780 parasites/pL (geometric mean value = 8,842 parasites/pL). The 
axillary body temperature ranged between 37.6°C and 38.9°C, (mean value of 
38.2°C). The age range was between 2.6 yrs to 3.2,yrs, (mean age w as 2.44 yrs). 
The day 0 Hb concentration was 9.8g/ dL (day 0 range was 7.9 to 9.9g/dL) and by 
day 14 there was haematological improvement with mean value of 1.8g/dL.
Of the 66 patients that completed the study, 58/66 (88%) displayed 
sensitive infections (were aparasitaemic and afebrile by end of study period); 
however 6/66 (9%) patients were aparasitaemic and febrile, therefore 64/66 (97%) 
patients in total displayed ACR to co-trimoxazole. Of the 8 parasitological resistant 
infections (12%), 4/8 (50%) were parasitaemic by day 7 with parasite density 
<25% of pre-treatment value RI level of resistance. Furthermore, all the other 4/8 
(50%) cases were parasitaemic by day 3 at > 75% of the day 0 parasite density
In vivo  e f f ic a c y  o f  c o - tr im o x a z o le  a n d  S P  in u n c o m p lic a te d  fa lc ip a r u m
in fe c t io n  in T iw i a n d  O y u g is .
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suggesting RIII type of response. One out of the 4 (25%) RI infection was febrile 
indicating a case o f  LTF. Similarly, 1 out of the 4 (25%) RIII infection was febrile 
and was considered a case o f ETF.
SP
Seventy six patients completed the study. The mean Hb concentration at 
enrolment was 9.7g/dL [day 0 range 8.6-10.5 g/dL] but a mean increase of 2.0g/dL 
was recorded over the trial period. Parasitaemia ranged from 4,590 to 53,980 
parasites/pL, w ith a geometric mean of 8,765 parasites/pL. The age range of 
patients in this population was between 2.6 years to 4.1 years (mean 3.0 years). 
Pre-treatment axillary body temperature varied between 37.6°C and 39.6°C (mean 
= 38.2°C). Fever was resolved within an average o f 48 hours.
Of the 76 patients, 62 (82%) infections displayed sensitive infection to SP 
(aparasitaemic but afebrile by end of study period). However, 8 cases were tested 
febrile and aparasitaemic. This suggests that a total of 70/76 (92%) infections 
displayed ACR. O f  the 14 parasitological resistant infections (18%), 6/14 (43%) 
were parasitaemic by day 7 with parasite density <25% of day 0. These were cases 
of RI level of resistance. In the remaining treated patients 8/14 (57%) had 
detectable parasitaemia by day 3 at > 75% of the pre-treatment level displaying 
RIII type of response. 1 out of the 6 (17%) RI infections was febrile and was 
considered a case o f  LTF. Similarly 5/8 (63%) RIII infection were febrile and were 
cases of ETF.
2.3.1.1.6 Oyugis, 1998
189 patients were screened and 126 (67%) were enrolled into this study. 
Thirty six (19%) had taken antimalarials, 23 (12%) had low parasitaemia and 4 
(2%) had high parasitaemia. Sixty-nine of the 126 (55%) patients were treated with 
SP while 57 (45%) received co-trimoxazole.
Co-trimoxazole
In the 57 children treated with co-trimoxazole, parasitaemia ranged from 
4,560 to 61,690 parasites/pL, with a geometric mean of 17,552 parasites/pL. The 
axillary body temperature before treatment ranged between 37.9°C and 39.3°C,
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(mean = 38.6°C). Age ranged between 2.9 yrs and 3.9 yrs (mean = 2.67 years). 
Day 0 Hb concentration varied between 7.9g/dL and 9.7g/dL (mean = 8.4g/dL). 
Haematological improvement was observed by day 14 with a mean increase of 
2.4g/dL.
Of the 57 patients that completed the study, 51 (89%) displayed sensitive 
infections (aparasitaemic but also afebrile by end of study period) to co- 
trimoxazole. Four cases out of 57 (7%) were aparasitaemic and febrile indicating 
that a total of 55/57 cases (96%) as displaying ACR. Of the remaining, 6 
parasitological resistant infections (11%), 5 (83%) were microscopy positive by 
day 7 with parasite density <25% of pre-treatment analysis indicating an RI level 
o f resistance. One out of the 6 (17%) had detectable parasitaemia at > 75% of the 
day 0 level indicating R1II. 2/5 (40%) Rl infection were febrile and were 
considered as LTF.
SP
Sixty-nine patients completed the study. The mean Hb concentration at 
enrolment was 8.0g/dL [day 0 range 7.9-8.6g/dL] but a mean increase of 2.7g/dL 
was recorded over the trial period. Parasitaemia ranged from 6,700 to 56,800 
parasites/p/L with a mean value of 19,707 parasites/pL. The age ranged between
2.8 years and 3.4 years (mean = 2.16years. Pre-treatment axillary body temperature 
ranged between 37.6 and 39.6°C, (mean = 38.2°C).
Of the 69 patients, 60 (87%) displayed sensitive infection to SP. Seven out 
o f the 69 (10%) cases were aparasitaemic and febrile therefore a total of 67/69 
(97%) cases displayed ACR. Of the 9 parasitological resistant infections (13%), 
4/9 (44%) were parasitaemic by day 7 with parasite density <25% of day 0 
indicating Rl level of resistance. By day 3 of follow-up, 1/9 (11%) had detectable 
parasitaemia at 25% of the pre-treatment value indicating RI1 infection. 4/9 (44%) 
displayed R1II type of response with parasite density at > 75% of the pre-treatment 
level. 2/4 (50%) infections displaying Rill level of response were febrile amd were 
considered as cases of ETF.
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Comparative analysis of patients treated on co-trimoxazole and SP response 
in Tiwi and Oyugis.
A comparative analysis of the 2 regimens in the two study sites was carried 
out evaluating the clinical and parasitological responses over the 14-day test 
period. The combined incidence of parasitological failure rate for the combined sites 
for co-trimoxazole was 14/123 (11%) and for SP 23/145 (16%) (RR 0.72, 95% 
confidence interval [Cl] 0.31-1.46, P= 0.289). The 14 day clinical failure rate for the 
combined sites for co-trimoxazole was 4/123 (3%), and for SP 8/145 (6%), (RR = 
1.69 at 95% Confidence interval [Cl] (0.91-3.15). P=0.129). This comprehensive 
analysis would suggest that in both sites, the risk o f parasitological and clinical failure 
to SP and co-trimoxazole are similar at P value=0.289 and P=0.129.
The haematological figures were similar in both groups, in Tiwi and 
Oyugis, as was the anaemia at presentation, (Table 2.3.1.1.5 and 2.3.1.1.6). 
Improvement on these features matched treatment success. In Tiwi, the mean 
increase over the test period 1.8 g/dL in the co-trimoxazole group and 2.0 g/dL in the 
SP group in Tiwi. Similarly, in Oyugis the mean increase was 2.4g/dL in the co- 
trimoxazole and 2.7g/dL in the SP group. The mean haemoglobin value after 
treatment was 11.6g/dL (co-trimoxazole) and 1 1.7g/dL (SP), in Tiwi and 10.8g/dL 
(co-trimoxazole) and 10.7g/dL (SP) in Oyugis.
There was no statistical difference in fever clearance time between the 2 
treatment groups in Tiwi and Oyugis (Table 2.3.1.1.5 and 2.3.1.1.6). The mean 
fever clearance time in co-trimoxazole treated group in the 2 sites was 1.5 days 
while the corresponding value for SP treated group was 2 days in Tiwi; in Oyugis 
mean fever clearance time was 1.5 days for SP and co-trimoxazole. Overall, by 48 
hours, all sensitive cases were afebrile and aparasitaemic.
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Table 2.3.1.1.5: Clinical characteristics and response o f uncomplicated falciparum patients to co- 
________________trimoxazole and sulfadoxine-pyrimethamine (SP): Tiwi, 1998._________________
2 .3 .1 .1 .5  T iw i, 1 9 9 8 : In vivo  e f fic a c y  o f  C o -tr im o x a z o le  a n d  S P
in u n c o m p lic a te d  fa lc ip a r u m  in fectio n
Co-trimoxazole SD SP SD
Admission param eters
No. enrolled 66 76
No. completing 
Du test period 66 76
Mean age (years) 2.44 1.69A 3.0 1.47A
GMPD DO* 8,842 8,413 8,765 8,025
[3,290-46,780] [4,590-53,980]
Temperature DO
r c ) ' 38.2 38.2
[37.6-38.9] [37.6-39.6]
Mean Hb level (g/dL)* 9.8[7.9-9.9] 1.8’ 9.7[8.6-10.5] 1.56'
Outcome 
Clinical response n |% |* “ n(% |***
ETF >[1.3] 5[7]
LTF 1[1-5] 1[1]
ACR 64[97] 70[92]
Parasitological response
S 58[88] 62(82]
R1 4[6] 6(8]
R1I 0 0
Rill 4[6] 8[ 10]
‘ Mean fever clearance time (h) 36 48
“ Mean parasite clearance time (h) 24 24
Mean Hb level (g/dL) 11.6 1.32" 11.7 1.21"
Major side effects 0 0
Key: See section 2.3.1.1.1 for key to abbreviations.
P > 0.05
!P > 0.05 [between co-trimoxazole and SP, pretreatment]; " P > 0.05 [between co- 
trimoxazole and SP, post treatment]
P < 0.001 between ' and " for co-trimoxazole and SP pre- and post-treatment respectively
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2 .3 .1 .1 .6  O y u g is ,  19 9 8 : In vivo  e f f ic a c y  o f  C o -tr im o x a z o le  a n d  S P  in
u n c o m p lic a te d  fa lc ip a r u m  in fe c tio n
Table 2.3.1.1.6: Clinical characteristics and response o f  uncomplicated falciparum m alaria to 
sulfadoxine-pyrimethamine (SP): Oyugis, 1998.
Co-trim oxazole SI) SP S D
Admission param eters
No. enrolled 57 69
No. completing
D ,4 test period 57 69
Mean age (years) 2.67 1.46A 2.16 1 .24A
GMPD DO* 17,552 15,4366 19,707 15,829
Temperature DO
[4,560-61,690] [6,700-56,800]
(°C)* 38.6
[37.9-39.3]
38.2
[37.6-39.6]
Mean Hb level (g/dL)* 8.4[7.9-9.7] 0.49’ 8.0[7.9-8.6] 0 .5 2 ’
O u tc o m e
Clinical response n[%]*** n |% |***
ETF 0[0] 2[3]
LTF 2[4] 0[0]
ACR 55[96] 67[97]
Parasitological response
S 51 [89] 60[87]
R1 5[9] 416]
RII 0 1(1]
Rill 1[2] 4[6]
•Mean fever clearance time (h) 36 36
••M ean parasite clearance (h) 24 24
Mean Hb level (g/dL) 10.8 1.59” 10.7 1.78"
Major side effects 0 0
Key: See section 2.3.1.1.1 for key  to abbrev iations.
P > 0.05
'P > 0.05 [betw een co-trim oxazo le  and SP, pre trea tm ent]; ” P >  0.05 [betw een co- 
trim oxazo le and SP, p o st treatm ent]
P <  0.001 betw een 1 an d  ” for co -trim oxazo le and SP  pre- and post-trea tm en t respec tive ly
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2.3.2.1 Epidemic sites
2.3.2.1.1 Mosoriot 1997:
Twenty one children completed the study. Parasitaemia ranged between 
9,520 to 103,200 parasites/pL (geometric mean = 16,107 parasites /pL). The 
axillary body temperature before treatment ranged between 35.8°C and 40.0°C 
(mean = 38°C). Age ranged between 0.7 yrs to 71 years (mean = 14.5 years). The 
mean Hb level on enrolment was 12.3g/dL but a mean increase of 2.1g/dL was 
recorded over the test period. Eleven out of 21 (52%) ) displayed ACR and their
infections were considered sensitive to SP. Of the remaining, 10 resistant 
infections (48%), 8 (80%), were febrile but parasitaemic by day 7 with parasite 
density at < 25% of day  0 level. Infection in these patients was of LTF and was 
considered as cases o f  RI type of response. By day 3, 2/10 patients (20%) had 
fever and parasite density was detected at > 25% of the day 0 level and were cases 
of ETF. Of these 2, 1 (50%) displayed Rill type of response with parasite density 
at > 75% of the pre-treatment level and 1 (50%) displayed Rll with parasite density 
at 25% of the pre-treatment level. See Table 2.3.2.1.1.
2.3.2.1.2 Mt. Elgon 1999:
Sixty one children were treated with SP. The day 0 mean Hb was 12.6g/dL, 
improving over the trial period with a mean increase of 1.6g/dL. Parasitaemia ranged 
from 3,400 to 32,600 parasites/pL, with a geometric mean of 16,980 parasites/pL. 
The axillary body temperature before treatment was initiated, was from 37.6°C to 
38.4°C (mean = 38°C). Age ranged between 0.9 yrs to 54 yrs (mean age was 15.3 
yrs). Infection in 53 (87%) of the 61 children displayed ACR and their infections 
were considered sensitive to SP. Of the remaining 8 resistant cases (13%), 3 out of 
the remaining 8 (37.5%) were febrile and microscopy positive by day 7 with 
parasite density <25% o f  pre-treatment analysis indicating LTF and considered as 
RI level of resistance. B y day 3, 5/8 (62.5%) cases were febrile and had detectable
2 .3 .2  In vivo e f f i c a c y  o f  S P  in u n c o m p lic a te d  fa lc ip a r u m  m a la r ia .
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parasitaemia at > 25% o f the pre-treatment parasite density suggesting cases of 
ETF. Three o f the 5 (60%) displayed Rill type o f response with parasite density at 
> 75% of the pre-treatment level and 2/5 (40%) displayed RII response with 
parasite density at 25% o f the pre-treatment level. See Table 2.3.2.1.2.
2.3.2.1.3 Kisii 1999
In the 54 children treated with SP, parasitaemia ranged from 4,400 to 
43,600 parasites/pL, with a geometric mean of 17,110 parasites/pL. The axillary 
body temperature before treatment was initiated was from 37.7°C to 38.4°C (mean 
= 38°C). Age ranged between 0.6 years and 51 years (mean age was 16.3 years). 
The Hb level showed mean increase over the trial at 1.8g/dL. The mean day 0 Hb 
concentration was 12.9g/dL.
Of the 54 patients that completed the study, 48 (89%) responded to the drug 
and displayed ACR and their infections were considered sensitive to SP. Of the 
remaining 6 resistant infections (11%), 1/6 patient (17%) had parasitaemia below 
25% of pre-treatment density by day 7 and was febrile. This was therefore a case of 
LTF and was considered as an RI type of parasitological response. In 5 (83%) of the 
remaining patients, fever and detectable parasitaemia at > 75% of initial density was 
observed by day 3 of follow up. These were noted as ETF cases and considered as 
resistant at RIII level of parasitological response. See Table 2.3.2.1.3.
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2 .3 .2 .1 .1 M o s o r io t ,  19 9 7 : In vivo e f f ic a c y  o f  S P  in u n c o m p lic a te d
falciparum malaria.
Table 2.3.2.1.1: Clinical characteristics and response o f uncom plicated falciparum 
patients to sulfadoxine-pyrimethamine (SP): M osoriot, 1997
Admission param eters SP SD
No. enrolled 
No. completing
21
D2i test period 21
Mean age(years) 14.5 16.8
GMPD DO* 16,10 7[9 ,520-103,200] 26.978
Temperature DO 
(°C)*
38[35.8-40.0]
Mean Hb level.(g/dL)* 12.3[ 12.1- 12.8] 0.351
O u tc o m e
Clinical response n |% |* * *
ETF 2[ 10]
LTF 8[38]
ACR 11(52]
Parasitological response
S 11(52]
RI 8(38]
RII 1(5]
RIII 1(5]
•M ean fever clearance time (h) 48
••M ean parasite clearance ttime (h) 48
Mean Hb level (g/dL) 14.4 0.54"
Major side effects Q____________________________
See Table 2.3.1.1.1 for key to abbreviations 
P < 0.001 between ! and !! for SP pre- and post-treatment
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2.3.2.1.2 Mt. Elgon, 1999: In vivo efficacy of SP in uncomplicated 
_________________ falciparum malaria._______________________
T ab le  2.3.2.1.2: C lin ical characteristics and response o f  uncom plica ted  fa lc iparum  m alaria  
to  su lfadox ine-py rim etham ine (SP): M t. E lgon, 1999
Admission param eters SP SD
N o. enrolled 61
N o. completing
D 14 test period 61
M ean age( years) 15.3 10.07
GM PD DO* 16,980[3,400-32,600] 8,923
Temperature DO
(°C)‘ 38[37.6-38.4]
M ean Hb level.(g/dL)‘ 12.6 [12.1- 12.8] 1.4'
Outcome
Clinical response n|% l***
ETF 5[8]
LTF 3[5]
ACR 53[87]
Parasitological response
S 53[87]
RI 3[5]
RII 2[3]
Rill 3[5]
•Mean fever clearance time (h) 48
••Mean parasite clearance time (h) 48
Mean Hb level (g/dL) 14.2 1.02"
Major side effects 0
See Table 2.3.1.1.1 for key to abbreviations.
P < 0.001 between ! and " for SP pre- and post-treatment
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2.3.2.1.3 Kisii, 1999: In vivo efficacy of SP in uncomplicated falciparum 
malaria.
T able 2 .3 .2 .1 .3 : C lin ica l characteristics and  response  o f  uncom plicated  falciparum  m a la ria  
to  su lfadox ine-py rim etham ine (SP): K isii, 1999
Admission param eters SP SD
No enrolled 54
No completing 
D14 test period 54
Mean age (years) 16.3 12.75
GMPD DO* 17,110(4,400-43,600] 13,099
Temperature DO 38(37.7-38.4]
(°C)‘
Mean Hb level (g/dL)‘ 12.9(12.4-13.6] 0 .3 7 '
O utcom e
Clinical response n l% l
ETF 5(9]
LTF 1[2]
ACR 48(89]
Parasitological response
S 48(89]
R] 1[2]
RI1 0(0]
Rill 5(9]
•Mean fever clearance time (h) 48
••M ean parasite clearance time (h) 48
Mean Hb level (g/dL) 14.7 1.48"
Major side effects 0
See Table 2.3.1.1.1 for key to abbreviations 
P < 0.001 between ! and " for SP pre- and post-treatment
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2.3.2.1.4 Chogoria, 1997: Severe malaria in an outbreak
Twenty four patients with severe malaria were examined. Patient age
ranged from 15 to 70 years (mean 26 years). These were cases presenting at 
Chogoria Mission Hospital. Medical records/ history show that these patients had 
had some form of therapy prior to presentation with severe malaria symptoms or 
on admission. Overall, 12 of the 24 patients were confirmed to have received CQ, 
SP or AQ and failed both first and second treatment regimens. All patients were 
however successfully treated with intravenous QN.
2.3.2.2: Haematological assessement in patients that responded or failed 
antimalarial drug treatment
Haemoglobin levels were measured before and after treatment (on days 0,
3, 7, 14, 21 or 28). Tables 2.3.2.2 a-c shows the range of the Hb levels. The mean 
Hb values as well as study sites, and drug used and number o f patients failing or 
responding to treatment are indicated. The level o f  significance in both cases 
failing or responding to treatments is also shown.
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Table 2.3.2.2 |a-c|: Range/ mean haemoglobin levels in patients
responding or failing treatment in all study sites, 
a.
Study site |year|
Drug used Treatment outcome
Treatment success Treatment failures
Hb le/dl.l* Hble/dLI
SP Pre-Tx Post-Tx Pre-Tx Post-Tx
[6.3-10.9] [11.9-12.9] [10-13.1] [12.2-13.7]
TxS:13
TxR: 25 Mean: 10.8 11.9 Mean: 11.9 13.7
Tiwi [1997] P > 0.05 P = 0.001
SP Hb le/dLI Hb le/dl.l
Pre-Tx Post-Tx Pre-Tx Post-Tx
TxS:30 [8.7-11.6] [10.9-11.6] [8.9-12.1] [10.2-12.8]
Mwea [1997] TxR: 18
Mean: 9.6 11.4 Mean: 9.7 11.9
P = 0.491 P =0.612
CQ Pre-Tx Post-Tx Pre-Tx Post-Tx
[9-11.2] [11.7-13.9] [8.9-11.5] [12.2-14.9]
TxS: 40
TxR: 20 Mean: 10.8 12 Mean: 10.2 12.6
P = 0.551 P = 0.699
Hb lE/dl.l Hb le/dl.l
Tiwi [1998] SP Pre-Tx Post-T x Pre-Tx Post-Tx
[8.6-10.5] [10.2-11.1] [8.9-9.7] [10.6-12.3]
TxS: 62
TxR: 14 Mean: 10.4 11 Mean: 9.2 12.2
P = 0.994 P< 0.001
Hb lE/dl.l Hb le/dLI
Pre-Tx Post-Tx Pre-Tx Post-Tx
C'o-tri [7.9-9.9] [10.2-11.9] [8.5-9.7] [11.8-12.1]
TxS: 58 Mean: 9.9 10.3 Mean: 9.5 12.6
TxR: 8 P = 0.681 P = 0.012
Key (Tables 2.3.2.2 a-c): TxS = Number o f patients successfully treated; TxR = 
Number of patients who failed treatment; Pre-Tx = Pretreatment; Post-Tx = Post­
treatment; SP = Sulfadoxine-Pyrimethamine; Co-tri = Co-trimoxazole;
* = Range of haemoglobin (Hb) concentration in g/dL; P < 0.05 level of 
significance.
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b.
Drug used Treatment outcome
Study site |year| Treatment success Treatment failures
Hb le/dLI Hb le/dU
SP Pre-Tx Post-Tx Pre-Tx Post-Tx
[7.9-8.5] [10.8-11.6] [8.1-8.6] [10.2-12.9]
TxS: 60
Oyugis[1998] TxR: 9 Mean: 8.6 9.6 Mean: 8.2 10.8
P= 0.16 P < 0.01
Co-tri
Hb le/dLI Hb le/dl.l
Pre-Tx Post-Tx Pre-Tx Post-Tx
[7.9-9.7] [10.1-11.9] [8.1-9.2] [10.6-12.1]
TxS: 51
TxR: 6 Mean: 7.8 10.2 Mean: 8.2 11.2
P = 0.291 P < 0.01
Hb le/dLI Hb le/dLI
Busia [1998] SP Pre-Tx Post-Tx Pre-Tx Post-Tx
TxS: 53
[10.8-12.6] [12.2-13.9] [7.8-10.2] [12.2-13.1]
TxR: 12 Mean: 12.4 12.8 Mean: 10 12
P > 0.05 P = 0.031
CQSP Hb le/dLI Hb le/dLIPre-Tx Post-Tx Pre-Tx Post-Tx
TxS: 34 [8.9-11.4] [11.2-12.9] [9.7-11.7] [11.7-12]
TxR: 14 Mean: 12 12.4 Mean: 9 11.2
P >0.05 P < 0.01
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In vitro antimalarial drug susceptibility studies in malaria
regions of Kenya
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2.3.3 In vitro antimalarial drug tests
Only 4 sites representing different endemicities (described earlier) were
chosen at random for the in vitro study due to limited resources. The sites included 
Mwea, Busia, Oyugis and Tiwi 1997. From these sites a total o f  220 patients were 
treated with SP in vivo. The number of isolates that were successfully tested in each 
site was Tiwi 1997 = 22; Mwea = 25; Oyugis = 24; Busia = 27, giving a total o f 98. 
The remaining 122 (55%) of the isolates were not included in the analysis due to 
the following; 48 (39%) were contaminated; 41 (34%) did not have sufficient 
growth (<10% schizont growth) and finally 33 (27%) had no growth. The various 
effective concentrations of these drugs are in Appendix E.
2.3.3.1 Tiwi 1997
2.3.3.1.1 Chloroquine
Table 2.3.3.1 presents in vitro resistant or sensitive data. Isolates maturing 
into schizonts at 8pmol/well (1.6nmol/litre blood) or above are considered to be 
resistant to CQ. Results described here indicated that all the 22 isolates (100%) 
showed schizont maturation at CQ concentration of 64pmol/well (12.8pmol/litre 
blood), indicating a very high resistance in vitro to CQ. O f the 22 isolates, 8 
displayed in vitro drug resistance also with SP.
2.3.3.1.2 Mefloquine
Successful schizont growth was exhibited by 11/22 (50%) isolates. The 11 
were MQS with no schizont growth at 4pmol/well (0.80pmol/litre blood) 
concentration depicting MQ sensitivity in this locality. These 11 isolates were CQ 
resistant.
2.3.3.1.3 Quinine
Only 50% of the tests were successful and these tested sensitive to QN with 
no schizont growth observed at 32pmol/well, (6.4pmol/ litre blood) concentration. 
Eight of the 11 isolates that were QNS were also MQS isolates. Eight isolates that 
were sensitive to both QN and MQ were resistant in vitro to CQ.
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2.3.3.1.4 Sulfadoxine-pyrimethamine SP
The antimalarial activity of SP on developing schizont in WHO in vitro 
micro-test (WHO, 1990), is less easy to determine than in the case o f quinoline 
drugs. Schizonts with 3 nuclei or more develop even when the drug is effective; 
although these nuclei are often not well defined and the schizont may appear 
abnormally developed. The threshold for SP is 90% inhibition of schizonts with > 
8 nuclei, (WHO, 1990).
Twelve isolates failed to grow successfully in the control wells (<10% 
schizont growth in well A) and were therefore not included in the analysis. Of the 
10 which grew, 2 were sensitive with no schizont growth at SDX lOpmol/PYR 
0.125pmol per well (SDX 2pmol/ PYR 0.025pmol per litre blood). The remaining 
8 isolates were apparently resistant having schizonts with 8 normal nuclei at SDX 
3000pmol/ PYR 37.5pmol per well (SDX 600pmol/ PYR 7.5pmol per litre blood) 
SP concentration. Seven in v/iro-resistant isolates displayed R1 type of in vivo 
response, whereas 1/8 in vitro resistant isolate displayed an RII in vivo response. 
The 2 in vitro sensitive isolates were resistant in vivo and at RI level.
2.3.3.2 Mwea
2.3.3.2.1 Chloroquine
Table 2.3.3.2 presents the in vitro resistant or sensitive data. Isolates 
maturing into schizonts at 8pmol/well (1,6pmol/litre blood) are considered to be 
resistant to CQ. Successful schizont maturation was observed in 25/25 (100%) 
isolates cultured. Our results showed that all the 25 isolates (100%) showed 
schizont maturation at CQ concentration of 64pmol/well (12.8pmol/litre blood), 
indicating very high resistance in vitro to CQ.
2.3.3.2.2 Mefloquine
O f the 25 isolates, 9 were tested for sensitivity to MQ. The remaining 
16/25 (64%) isolates did not achieve successful schizont growth. Isolates growing 
at 64pmol/well (12.8pmol/litre blood) are classed as resistant. No schizont growth 
was observed at this concentration indicating sensitivity to MQ in vitro. 
Interestingly, the 9 MQS isolates were CQR.
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2.3.3.2.3 Quinine
Ten out o f the 25 isolates (40%) tested showed satisfactory growth of 
normal schizonts and were used in the analysis. The remaining 15/25 (60%) did 
not achieve the 10% schizont growth in the control well and were therefore not 
included in this analysis. The 10 isolates were sensitive with no schizont growth at 
32pmol/well (6.4pmol/litre blood) concentration.
2.3.3.2.4 Sulfadoxine-pyrimethamine SP
Sixteen isolates failed to grow successfully in the control wells (<10% 
schizont growth in well A and were therefore not included in the analysis. O f nine 
isolates, 5 were sensitive with no schizont growth at SDX lOpmol/PYR 0.125pmol 
per well drug level (SDX 2pmol/ PYR 0.025pmol per litre blood). The remaining 
4 isolates were apparently resistant and having schizonts with 8 normal nuclei at 
SDX 3000pmol/ PYR 37.5pmol per well (SDX 600pmol/ PYR 7.5pmol per litre 
blood) SP concentration. Two of these were resistant at RI and 2 were sensitive in 
vivo. The 4 SP resistant isolates were also CQ resistant.
2.3.3.3 Busia 1998
2.3.3.3.1 Chloroquinc
Successful schizont maturation was achieved in 27/27 (100%) isolates at 
64pmol/well (12.8pmol/litre blood), indicating very high resistance to CQ, see 
table 2.3.3.3.
2.3.3.3.2 Mefloquine
Six isolates of the 27 (22%) tested for sensitivity achieved successful 
growth in the control well. The remaining 21 (78%) isolates did not achieve 
successful growth (schizont growth <10% in the control well) and were not 
included in the analysis. Isolates with schizonts growing at 64pmol/well 
(12.8pmole/litre blood) are considered MQR (WHO, 1973). All the 6 isolates did 
not achieve schizont growth at this concentration indicating sensitivity. Similarly, 
six isolates that were MQS, were resistant to CQ.
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2.3.3.3.3 Quinine
Of the 27 isolates, 12 tested sensitive to QN and with no schizont growth 
observed at 32pmol/well (6.4p.mol/litre blood). Fifteen isolates did not achieve 
successful growth (schizont growth < 10% in the control well) and were not 
included in the analysis. O f the 12 QNS isolates, 5 were MQS.
2.3.3.3.4 Sulfadoxine-pyrimethamine SP
Twelve isolates were found to be apparently resistant (3 isolates had 
schizonts with 8 nuclei at SDX 2000pmol/ PYR 25pmol per litre blood and 9 at 
SDX 600pmol/ PYR 7.5 pmol per litre blood). Only one isolate was found 
sensitive and no schizont growth was found in the SDX lOpmol/PYR 0.125pmol 
per well drug concentration. Of the 12 resistant isolates, 5 were resistant in vivo at 
R1 level (in vitro resistant at at SDX 600pmol/ PYR 7.5pmol per litre blood), and 2 
cases were o f  RII and resistant at SDX 2000pmol/ PYR 25pmol per litre blood. 
One case was Rill and having schizont growth at SDX 600pmol/ PYR 7.5pmol per 
litre blood. The remaining 4, were sensitive in vivo with 1/4 isolates having 
schizont growth in vitro at SDX 2000pmol/ PYR 25pmol per litre blood and 3/4 
isolates having schizont growth at SDX 600pmol/ PYR 7.5pmol per litre blood.
2.3.3.4 Oyugis 1998: In vitro antimalarial drug susceptibility assay
2.3.3.4.1 Chloroquine
All the 24 isolates tested were resistant to CQ with schizont growth observed 
at 64pmol/well (12.8pmole/litre blood) concentration, see table 2.3.3.4. Similar
observations were made in Mwea, Busia and Tiwi, areas o f moderate to high malaria 
transmission.
2.3.3.4.2. Mefloquine
Schizont inhibition at 64 pmol/well (12.8pmol/litre blood) was found in 7 
isolates out o f  the 24 isolates examined. The remaining 17 (71%) isolates did not 
achieve successful growth. Similar observations were seen in Mwea, Tiwi and 
Busia.
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2.3.3.4.3 Quinine
Eight out of the 24 isolates (33%) grew satisfactorily. Inhibition of schizont 
growth at 32pmol/well (6.4pmol/ litre blood) was observed in 1/8 isolates examined. 
The remaining 7/8 isolates, no schizont growth was observed at 16pmol/well 
(3.2pmol/ litre blood), indicating sensitivity.
2.3.3.4.4 Sulfadoxine-pyrimethamine SP
Four out of the 24 isolates achieved successful growth with normal schizont 
growth in the control well. Of these, 3 were sensitive responding to drug 
concentration of SDX lOpmol/ PYR 0 .125pmol/ well. The remaining one had 8 
nuclei at SDX 3000pmol/ PYR 37.5pmol per well (SDX 600pmol/ PYR 7.5pmol 
per litre blood) [suggesting resistance]. The 3 SP sensitive isolates were CQR. The 
SP resistant isolate was also resistant in vivo and displayed an R1 level of 
parasitological response.
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2.3.3.1 Tiw i 1997: !n vitro antimalarial drug susceptibility.
S tu d y  In  vivo  P a ras ito lo g ica l
N u m b e r  R esponse
■ ■
KT.2 RI
m s
RI
Bb m
KT.9 RI
KT.10 RI
K.T.18
r . i 9  
C T .2 0
■ ■ ■ ■ ■
KT.25
KT.27
KT.30
KT.32
KT.33
KT.34
KT.35
KT.36
KT.37
KT.38
R1U
RI
C orrespond ing  in vitro  response to:
SP CQ MQ QN
** R **
R R S s
** R ** s
R R s s
** R s s
R R s s
** R ** **
R R s **
R R s s
R R s **
** R ** **
R R s **
** R ** **
R R s s
** R s s
** R s s
** R ** s
S R ** s
R
** R ** **
** R ** **
s R **
N um ber s tested successfully 10 22 11 11
Key:
:** In vitro cultivation not successful
¡Cleared portion = isolates not tested in vitro; shadowing indicate isolates tested 
:MIC: minimum inhibitory concentration (MIC) was defined as the lowest drug 
concentration in which no schizonts were observed. Resistance thresholds for: CQ 
= 8pmol/well; MQ = 64pmol/well QN = 256pmol/well; >100pmol/well with 
normal schizonts having > 8 nuclei.
:R = resistant isolates
:S = sensitive isolates [inhibition of schizont maturation at cut-off concentration]
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233.2 Mwea 1997: In vitro antinialarial d rug susceptibility
S tu d y In vivo  P a ras ito lo g ica l C orresponding in vitro response to
N u m b e r R esp o n se SP C Q  M Q  QN
KM001 
KM 002
KM008
KM009
KM013
KM014
KM016
KM018
KM020
KM021
KM022
KM025
KM029
KM033
K M 055
KM056
KM060
KM061
KM063
Numbers tested successfully
** R S s
4t* R S s
R R S **
R R **
** R S s
** R S s
R R S s
S R S s
** R S s
** R S s
s R ** s
** R ** **
R R ** **
** R ** **
** R ** **
** R ** **
** ** ** **
** R ** **
** ** ** **
** R ** s
S ** ** **
** R ** **
** ** ** **
** R ** **
** R ** **
s R ** **
** R ** **
s R ** **
** R ** **
9 25 9 10
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2 .3 .3 .3  B u s ia  1 9 9 8 : In vitro  a n t im a la r ia l  d r u g  su s c e p t ib il i ty .
S tu d y  In  vivo  P a ras ito lo g ica l Corresponding in vitro response to 
SP CQ MQ QN
N u m b e r  R e sp o n se
KB529 
KBS 20 
KB50I
KB632
KB783
KB748
KB737
KB656
KB963 S
KB977 S
KB98I Rill
CKBI006 S
KBI0I7 S
••  R •*
•* R •*
•* R S
** R S
** R **
S
S
**
S
*•
R
R
R
R
R
R
R S S
R S S
R S S
R ** •*
R S S
R ** S
R ••
R
R R *•
S R ••
** R *•
R R S
R
R
R
R ••
R ••
R S
111
KB024
KBI09 
KB 142
KB403
KB47I
AKB596
AKB692 S
AKB863 S
AKB1347 s
AKB857 s
AKBIS69 R ill
♦ * R ** **
AKB845 S
Numbers tested successfully 13 27 6 12
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2 .3 .3 .4  O y u g is  1 9 9 8 : In vitro  a n t im a la r ia l  d r u g  s u s c e p t ib il ity .
S tu d y /#> vivo  P a ra s i to lo g ic a l C orresponding  in vitro response to
N u m b e r R e sp o n se SP C Q  M Q QN
K Y006I
K Y 0 I2 0
KY0134
K Y015I
KY0247
K Y 0 I6 7
KY0257
KY0152
KY0205
KY0229
KY0246
KY0289
KY0359
K Y I  304 S
KY0365 S
KY0288 S
K Y032I S
KY0403
K Y 0 4 I9
KY0424
K Y 0 4 II 
K Y I  002 
K Y I0 I3
K Y I0 2 0
K Y 0 I3 7  
K Y I  114
K Y I  152 
K Y I  182
1 13
K Y 0I54 S
K Y I 227 S
KY1236 S
K Y I 226 S
K Y I 270 S
K Y I 203 S
K Y I 238 S
KYI 294 Rill
KY134I S
KY1337 S
K Y I3 3 2 S
K Y I  402 S
Ril
KY1431 S
KY1436 Rill
K Y I4 39 Rill
K Y I  445 S
K Y I 449 Rill
K Y I  451 S
K Y I 459 S
K Y I4 62 S
Numbers tested successfully 4 24 7 8
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When comparing in vivo efficacy to SP or CQ relative to in vitro system on 
samples from the 4 sites, an in vitro value ranged from 25% to 92% [SPR] to an in vivo 
value of 13% to 66% [SPR]. In vitro value of 100% [CQR] to an in vivo value of 33% 
[CQR] was observed. Taken together and on average, an in vivo value o f 33% [CQR] and 
27% [SPR] was observed whereas an in vitro value of 100% (CQR) and 69% [SPR], was 
found, see Table 2.3.3.5. Some o f the factors that can account for in vivo/in vitro 
discordant results are host factors that play an important role in therapeutic failure such 
as pharmacokinetics and the level o f acquired immunity. There may be other factors like 
host genetic factors unrelated to immunity and social behaviour of the host (for example, 
concomitant self-medication with other classical antimalarial drugs or traditional herbal 
medicine) that could account for the difference between in vitro and in vivo data.
T a b le  2.3.3.S S e n s itiv itie s  o f  P la sm o d iu m  fa lc ip a ru m  iso la te s  f ro n t  m a la r ia  e n d e m ic  
a r e a s  o f  K en y a , to  c h lo ro q u in e , su lfa d o x in e -p y r im e th a m in e .
D rug  and site No. of patients
In vivo In vitro
Response by D|< Test
Total S R  N S R
C hloroquine
Mwea** 60 40 20 25 0 25
Tiwi . 22 0 22
Busia . 27 0 27
Oyugis - 24 0 24
T ota l 60 40 20(33% ) 98 0 9 8 (1 0 0 % )
Sulfadoxine-
Pyrin tetham ine
Mwea** 48 34 14 9 5 4
Tiwi** 38 13 25 10 2 8
Busia** 65 53 12 13 1 12
Oyugis* 69 60 9 4 3 1
T o ta l 220 160 60(27% ) 36 11 25(69% )
Key: * = Under 5 years; ** = All age groups
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2.4 Discussion
The introduction of macro/micro in vitro test in parallel with in vivo 
assessment of antimaiarial drug efficacy (WHO, 1973) has tremendously increased 
our understanding of the determinants of treatment success. The in vitro method 
gives a result avoiding effects of immunity, or host-genetic factors that can affect 
drug metabolism or bioavailability or effects o f mal-absorption of the antimaiarial 
drug. In this chapter both tests were applied and the choice of sites complied with 
the sentinel sites identified by the Kenyan National Malaria Control Programme. 
These sites represent areas experiencing different levels of malaria transmission 
intensities including mesoendemic, hyperendemic and holoendemic areas. Sites 
were chosen in at random but with fair representation of endemic and epidemic 
regions of Kenya. Subjects were recruited from outpatients presenting 
uncomplicated febrile illness.
The chosen sites varied in size, population and other parameters. Sites are 
either urban or rural. Kendu Bay, Oyugis for instance are small in size and are 
rural. However, Busia is peri-urban while Mwea and Tiwi are urban. The epidemic 
sites, Mt.Elgon, Kisii and Chogoria are peri-urban while Mosoriot is urban.
In all the sites where SP was used, compliance presented no problem 
because of its single dose therapy given under supervision. Similarly, compliance 
for CQ single dosing over 3 days. Co-trimoxazole, on the other hand, was given 
twice daily over 5 days because of its short plasma half-life. Treatment requires 
supervision for 5 days. This limited the compliance problems that can be 
associated with multiple dosing over an extended period.
Antimaiarial drugs either singly or in combination e.g., SP, co-trimoxazole, 
CQ, and in combination with SP, (CQSP) were assessed.
The first case o f  CQ resistant P. falciparum infection was described in a 
non-immune traveller in Kenya in 1978, (Kean, 1979). Since then resistance has 
spread to almost all countries in sub-Saharan Africa, particularly in East and 
Central Africa where parasitological failure rates for a standard dose of CQ (25 
mg/kg) of 70% or more have been reported from Kenya (Brandling-Bennett et al., 
1988), Tanzania (Fowler et al., 1993), Cameroon and Congo (Brasseur et al., 
1995) and Ethiopia (Tulu et al., 1996). Similar observations have been reported
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from the Kenyan Ministry of Health, (MOH report, 1997; Rapouda et al., 1997) 
with in vivo CQ failure rates between 61% and 80% in western and coastal regions, 
respectively. Again in central Kenya, in an urban town of Mwea, failure rates of 
30% to CQ are reported here. This reflects on heterogeneity in CQ resistance 
whereby parasitological resistance was found to vary between 61%, 33%, 80% in 
western, central and coastal Kenya, respectively. In another study carried out by 
Clarke and colleagues (1996) in Turkana District in northern Kenya, they found no 
clinical or parasitological failure in patients 1-40 years of age after 14 days of 
follow-up. Similarly, Guthman et al., (1996) in Sudan found only 10% CQ 
resistance in children 6 months to 5 years although in other parts of the country 
high rates had already been reported in 1989 (Bayoumi et al., 1989). Similar trends 
in geographical differences o f therapeutic response is observed for SP.
Resistance to SP in the East African region is also on the increase. When 
SP was introduced as the second-line drug in Kenya in 1983, initial studies showed 
little or no resistance to SP. But later studies reported cure rates ranging from 54% 
to 92% (Nguyen-Dinh et al., 1982; Spencer et al., 1986; Hagos et al., 1993; 
Anabwani et al., 1996; Clarke et al., 1996).
In the present study in Mwea, central Kenya, the efficacy of CQ was 
assessed in 1997 around the time a ban on the use o f the drug as first line was 
imminent. There was 67% in vivo sensitivity to the drug and 33% treatment failure. 
Majority (31%), of the drug failure cases wereofRII (18%) or RIII (13%) resistant 
type and were classified as early treatment failure. The 67% sensitivity recorded in 
Mwea would suggest that CQ could be used against primary infection only 
switching to a more efficacious drug in refractory cases (secondary infection). 
However, the 33% CQ drug failure in this area is a major concern to health 
providers. It is therefore, not surprising that a blanket ban on use o f  the drug was 
introduced recently (1997) and the drug, although showing a 67% efficacy, could 
not now be used in a place like Mwea.
Chloroquine replacement, SP, was also assessed in Mwea. Results show 
that 71% of cases examined responded adequately to the combination therapy. 
Interestingly both low level (Rl) [17%] and high level RI1 [4%], and RIII [8%] 
resistance were detected among the remaining 29% who failed therapy. This is
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very disturbing as this combination was recently introduced as first line therapy in 
place of CQ. As seen here in Mwea, the proportion of cases responding to each 
therapy is not significantly different, 67% CQ versus 71% SP. The encouraging 
observation is that failures to both therapies responded adequately to AQ 
treatment. The efficacy of AQ against CQ-resistant cases has been reported 
(Hawley et al., 1996) and it is once more demonstrated here even against SP 
failures. This would suggest that the drug is a potential “back-up” or “stand-by” 
and its use alone should be limited to failed treatment, at least in Mwea or central 
Kenya.
It has been postulated that resistance to SP rises rapidly upon its 
introduction, with a useful therapeutic life estimated to be about five years (for 
example Nzila et al., 2000). Results described here from different malaria 
endemicities (between 1997 and 1999) found different levels of SP failure. For 
example in the endemic sites of Mwea [1997] the number o f cases that failed 
therapy was 29% to SP. In Tiwi-1997 the number of cases that failed SP therapy 
was 66% and by 1998, resistance to SP decreased to 18%. The source of SP was 
authentic Fansidar® in both studies. Perhaps the improvement can be linked to 
lower use of the drug in the area or maybe due to other unknown factors. However, 
similar observations have been made from other studies. For example, a study 
reported by (Ndyomugyenyi and Magnussen, 2000), showed improved efficacy to 
CQ in 1998 (CQ resistance in site one, 23%; site two, 37%; site three, 38%) 
compared to 1995 (CQ resistance in site one, 30%; site two, 58%; site three, 58%). 
Large differences in drug response are found geographically such as the variations 
in e.g., cotrimoxazole response in different parts o f Uganda (Kilian et al.. 1998) 
and as observed in this study on SP sensitivity in different parts of Kenya. It is 
probable therefore that variations can occur in time too. It is also possible that the 
large reservoir o f untreated (asymptomatic) infections available to infect the vector 
in sites of intense malaria transmission may make the survival of drug-resistant 
mutants difficult in the absence of regular drug pressure (Fischhoff, 1996). For 
example, presence of mutations in dhfr that result in parasite resistance to 
pyrimethamine might result in decreased catalytic efficiency and therefore a
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competitive disadvantage (in the absence of pyrimethamine) compared with 
malaria parasites without the mutation, (Hastings, 1997).
In another site of western Kenya called Busia, where malaria transmission 
is holoendemic, resistance to SP was found to be 19%. Again in two sites in 
western Kenya and where malaria transmission is holoendemic, resistance to SP 
was found to be 13% in Oyugis and 19% in Kendu Bay. Other studies conducted in 
Kenya by the 1990s (van Dillen et al 1999), reported failure rates of 18.5% and 
9.5% to AQ and SP, respectively, in a hospital in northern Kenya, and rates of 
35.1% and 34.5% in another hospital in the west (van Dillen et al., 1999).
Interestingly resistance to SP in the epidemic foci was similar to the 
situation described for western Kenya. For example resistance to SP was 11% 
(Kisii) and 13% (Mt.Elgon). However, resistance to SP was high in Mosoriot at 
48%.
Clearly, there appears to be higher level o f  resistance to SP in urban than 
rural locations. In the endemic focus there was no statistical difference within the 
rural [P=0.541] and within the urban [P=0.147] locations. This allowed for pooling 
o f SP therapeutic data in both the locations. Higher degree o f in vivo failure to SP 
was reflected in urban towns of Mwea and Tiwi in contrast to the situation seen in 
rural areas namely Kendu Bay, Oyugis, and Busia [P= 0.05; OR = 2.35]. Similarly, 
evidence of high therapeutic failure to SP in the epidemic focus was noted in 
Mosoriot an urban town whilst high sensitivity to SP was reported in rural areas of 
Kisii and Mt. Elgon [P<0.001; OR = 6.62]. Again no significant difference [P=
0.966] was observed in the rural epidemic sites o f  Kisii and Mt. Elgon, allowing 
for results of sensitivity to be pooled together. Probable reasons for the higher level 
of SP resistance in urban areas compared to rural areas observed in these studies 
could be due to easy access and inadequate use o f  SP from informal sources in 
urban locations. Travel to and from urban locations is easier so transfer of resistant 
strains in travellers would be facilitated.
Where transmission is low, drug treatment will be widespread because of 
the high probability of an infection to evolve towards a clinical attack, i.e., most 
infections become symptomatic and this would select resistant strains that would 
spread rapidly because of the higher probability o f  self-fertilization. Together with
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easy access to standard antimalarial drugs close to towns, this probably explains 
the situation observed in Mosoriot where SP resistance is almost 3 times higher 
than in the rural Mt. Elgon or Kisii areas.
An epidemic of malaria in the highland area o f Chogoria (Omar et al„ 
2001b) led to hospitalization o f a group o f patients. The outbreak followed heavy 
rainfall. During the outbreak, patients were treated with standard antimalari.il drugs 
CQ, SP or AQ. However, upon failure o f initial therapy, patients were re-treated 
with the next line drug of either SP [if treated with CQ] or AQ [if treated with SP 
and vice versa]. Twenty four patients who failed to respond to subsequent therapy 
and were developing signs o f severe malaria were admitted and ultimately treated 
with intravenous QN. The Chogoria study is the first to report failure to first-line 
and second-line antimalarial drugs in a non-immune population in Kenya. 
Economic trade between the highland area o f Chogoria and the mesoendemic area of 
Tharaka and other neighbouring endemic areas is very frequent. The possibility, 
therefore exists of the importation of resistant parasites in asymptomatic gametocyte 
carriers. The absence of acquired immunity in the local population and the failure of 
first-line drugs may have caused the severe form of malaria disease. Molecular 
characterisation of drug resistant determinants, also discussed in this thesis, revealed 
high degree of mutations in genes conferring resistance to SP and CQ from parasite 
isolates from the hospitalized patients.
Attention has recently switched to combination therapy as opposed to 
monotherapy for treatment of uncomplicated malaria. Combination of 
antimalarials that do not share the same resistance mechanisms have been 
postulated to reduce the chance of selection o f the resistant parasite populations 
(White, 1999) and consequently of delaying spread of drug resistance. The 
rationale for combination treatment highlights important issues of clinical 
effectiveness, and o f reducing individual drug pressure in order to prolong the 
useful lifespan of SP. In this chapter, different drug treatment regimens were 
employed and their therapeutic advantages assessed. Treatment with CQ and SP 
(CQSP) was compared with SP in the holo-endemic area o f Busia. Similarly, a 
treatment regimen using co-trimoxazole was compared with SP in two sites of 
Oyugis and Tiwi.
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In Busia, the effectiveness o f SP alone versus the combination of CQSP in 
the treatment o f uncomplicated malaria was assessed. The principle of using CQ 
together with SP is because, CQ, as well as its additional effect on the parasite, is 
known to have antipyretic activities and hence plays an important part against the 
pathogenesis o f malaria fever. Its mode of action as an anti-inflammatory agent is 
not certain but it may interfere with production of tumour necrosis factor (TNF) by 
mononuclear cells stimulated with endotoxin (Kwiatkowski et al., 1995), and 
modulation o f cytokine production. Therefore, a treatment regimen, combining a 
4-aminoquinoline with the parasiticidal activity o f SP seems logical as it takes 
advantage o f the antipyretic and anti-inflammatory effects of the 4- 
aminoquinoline.
A significant outcome to treatment with CQSP compared with SP was 
observed in fever clearance times in the initial 24 hours (P=0.022). Since all 
patients treated with SP were treated with paracetamol, we observed no added 
effect on the outcome o f fever in this treatment group compared to the CQSP 
group as described above. And since paracetamol has been shown to have no anti­
inflammatory effect (Adam and Stankov, 1994), unlike drugs such as aspirin
W / | i  O ¿7
(acetylsalicylic acid),¿could therefore partly explain the above interpretation. The 
overall degree o f anaemia (Hb) was 11.6 (CQSP) and 11.7 (SP) by end of study 
period. Patients with high parasitaemia had a large fall in haematocrit in the first 3 
to 7 days following treatment in both groups. Similar observation has been been 
found in another study (ter Kuile et al., 1995) and has been related to the 
destruction o f parasitised and non-parasitised erythrocytes which is followed by 
haematological recovery on treatment successes.
Overall, the results of this study, in relation to previous investigation 
conducted in the Gambia, (Bojang et al., 1998) confirm that CQSP versus SP 
alone, has an advantage through antipyresis. Perhaps resistance to CQ (MOH, 1997 
Report) could explain the absence in the Kenyan context of the added advantage o f  
CQ to the CQSP combination on parasitological response. However, the advantage 
on fever clearance times offered by CQ to CQSP combination supports the 
antipyretic role o f CQ (Kwiatkowski et al., 1995) and its importance in alleviating 
initial malaria disease. The evidence so far suggests that combination therapy with
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CQ plus SP might achieve the aims o f first-line treatment for uncomplicated 
malaria, in terms of faster relief o f symptoms and sustained clearance of 
parasitaemia, better than either drug alone. However, the combination of CQ+SP 
may not be relevant in areas o f multidrug resistance and perhaps in these areas 
efforts or research should consider trials based on agents that are effective locally. 
There is no evidence of serious side effects associated with the combination in 
treating uncomplicated malaria and in order to fully assess the risks for treatment, 
surveillance for evidence o f  treatment-associated toxicity must be maintained.
Efficacy of co-trimoxazole, as described here, was found to be comparable 
to that o f SP. The studies were conducted in Tiwi (hyperendemic), situated in the 
coast and Oyugis (holoendemic), situated in western Kenya. The effectiveness of 
6mg trimethoprim and 30mg sulphamethoxazole/kg/24hours (co-trimoxazole) over 
5 days for the treatment of uncomplicated malaria showed no significant difference 
from that of SP with regard to treatment outcome. The combined incidence of 
parasitological failure rate for the two sites for co-trimoxazole was 14/123 (11%) 
and for SP 23/145 (16%) (RR 0.72, 95% confidence interval [Cl] 0.31-1.46, 
P=0.289). The 14 day clinical failure rate for the combined sites for co-trimoxazole 
was 4/123 (3%), and for SP 8/145 (6%), [RR 1.69, 95% Cl 0.91 to 3.15, P=0.129],
The results of this study represent the first report of a high level of clinical 
as well as parasitological effective response of co-trimoxazole to P. falciparum in 
Kenya, (Omar et al., 2001c). Similarly earlier reports from in vivo studies carried 
out in Mozambique (Wolfensberger, 1970), Nigeria (Fasan, 1971) and South 
Africa (Hansford and Hoyland, 1982) had shown a high efficacy of various 
regimens of co-trimoxazle against uncomplicated malaria with parasitological cure 
rates above 95% after 7-14 days, although some authors observed recrudescence 
rates (after 28 days) of 10.7% (Wolfensberger, 1970). More recently Bloland and 
colleagues (1991) reported 100% parasitological cure (44 out o f 44 children) after 
14 day follow-up in Malawi using a 5 day regimen o f co-trimoxazole and in The 
Gambia parasitological cure rate was found to be 96.7% and 92.3% after 6 and 21 
days respectively (Daramola et al., 1991). As Daramola and colleagues pointed 
out, the widespread use and availability of co-trimoxazole as an antibiotic may
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lead to considerable drug pressure and the development of resistant parasites has to 
be anticipated.
The recent finding (from Tanzania) of 22% of 61 children being 
parasitaemic 14 days after a 5 day regimen of co-trimoxazole (Mutabingwa et al., 
1996), i.e., parasitological cure rate of 78%, may be interpreted as a first sign of 
resistance. However, clinical (Clyde et al., 1971) as well as in-vitro studies 
(Petersen, 1987) suggest that such a cross-resistance may be limited.
Aggravation of clinical conditions requiring an alternative treatment is 
based on presence of parasitaemia (parasitological response) and or fever (clinical 
response). The revised WHO (1996) protocol that defines ETF as presence of 
parasitaemia on day 3 greater than on day 0, with fever sometimes leads to a wrong 
classification of patients. When left untreated, some patients with fever and 
positive thick film on day 3 (“treatment failure” according to the WHO 
classification) cleared the parasites and became afebrile on day 4 and remained so 
and aparasitaemic until day 14 (ACR). Such a scenario was observed in 2 cases in 
the epidemic area of Mt.Elgon. The 2 cases remained untreated and refused to 
complete the study but were followed up for assessment due to ethical 
considerations. These cases illustrate the limits of the in vivo test of resistance. 
However, this method is the valid measure of drug resistance that may be used to 
guide national antimalarial drug policy.
Analysis of Hb in patients responding or failing treatment to antimalarials 
examined in this study, show significant improvement in mean Hb levels o f  those 
who failed treatment in 3 endemic sites (Busia, Tiwi, Oyugis) and one epidemic 
site Mosoriot (Table 2.3.2.2 a to c). However, in the epidemic site of Mt. Elgon 
improvement was not significant in those failing or successfully treated. Similar 
observations were made in the meso-endemic Mwea and holo-endemic Kendu 
Bay, (Table 2.3.2.2 a and c). In another epidemic site, Kisii, improved Hb level 
was observed only in successfully treated patients, (Table 2.3.2.2.a). However, by 
the end of the study period there was an overall improvement in the Hb levels in all 
the sites irrespective o f the treatment regimen.
Examination of the mean parasite density [MPD] in all patients per site 
shows a match between parasite clearance and haematological improvement e.g„
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in Busia, Tiwi [1997,1998], Oyugis and Mosoriot. Perhaps, the extensive reduction 
in MPD in the treatment failures, for example in Tiwi 1997, MPDday0 = 15,530 and 
MPDday i4  = 2,925, could have prevented further destruction o f infected red blood 
cells which would have resulted in low level Hb. Results presented here show that 
treatment of malaria does lead to haematological improvement, o f  malaria 
associated anaemia. This Lnds further support to observations made elsewhere that 
effective treatment of malaria infection could improve haemoglobin status, 
(Bloland el al., 1993). It appears from these observations that analysis o f the Hb 
levels was important clinically and indicates a marked improvement on treatment, 
but the results do not necessarily correlate with its success or failure.
In vitro assays on 4 antimalarial drugs (CQ, SP, M Q, QN) and in 4 sites 
(Tiwi, Mwea, Busia, Oyugis) were carried out. The present study confirmed high 
level of CQ resistance (MOH, 1997; Shretta et al., 2000). Isolates maturing into 
schizonts at 8pmol/well (1.6pmol/litre blood) are considered to be resistant to CQ. 
All isolates showed maturation at the relevant cut-off of 8pmol/well (1.6pmol/litre 
blood) indicative of resistance.
Resistance to CQ in Kenya is “stabilised” with in vivo resistance o f 
between 61-80% (MOH, 1997). An inherent biological advantage of CQ-resistant 
parasites has been suggested as one explanation for the rapid spread of CQ 
resistance (Payne, 1987). However, the continued use of C Q  selects for resistant 
parasites, encouraging their survival and propagation, and this is likely to 
contribute to a rapid expansion of the reservoir of resistant strains.
Sensitivity to MQ was evidenced from the 4 studied sites. Mefloquine is 
not used as a standard regimen in Kenya. The absence of M Q drug pressure could 
perhaps account for the observed parasite susceptibility to MQ in vitro. 
Interestingly all CQR isolates examined were sensitive to MQ. It is unclear why 
CQR isolates are MQS (Cowman, et al., 1994). However molecular investigations 
have shown the role of a mutant pfmdrl at codon 86 (asparagine to tyrosine) in P. 
falciparum isolates, associated with CQR and MQS in Gambian isolates 
(Duraisingh et al., 2000). The obvious advantage to this observation would be the 
use o f MQ against CQR infection. This offers an attractive control option for use
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of MQ or a related drug, perhaps in combination, in areas where CQ resistance has 
stabilised.
Similarly all isolates tested were sensitive to QN. These findings are in 
agreement with those o f Haruki, et al., (1998) also conducted in Kenya. In another 
study, Pasvol, el al., (1991) found no isolate that was resistant to QN. They 
reported QN sensitivity at IC9 9  and IC5 0  of 2.72 and 0.364uM, respectively. All the 
isolates tested were also CQR. In situations of CQ and SP failure, therefore, QN 
will be a suitable alternative antimalarial to amodiaquine for treating multi-drug 
resistant cases, at least in the Kenyan situation. Perhaps quinine’s restricted use in 
hospitals for the management of severe and complicated falciparum malaria and 
treatment failure, and its short half-life, could explain absence of QN resistance 
over the years. Full sensitivity in vivo and in vitro to QN has previously been 
reported from Nigeria both in CQS and CQR isolates (Salako et al., 1988). 
However, there are reports of QN resistance in Africa (Jelinek, 1995; Brasseur et 
al., 1988; Brandicourt et al., 1986) but it is still uncommon and the drug still 
remains a reliable treatment. With no manifest resistance to MQ and QN, and in 
the absence of widespread MQ and QN drug pressure, sensitivity to the 2 drugs in 
vitro is expected.
Some isolates tested were highly resistant to SP in the in vitro system, and 
perhaps this could act as a “warning signal” of reduced efficacy to SP. Out o f a 
total of 36 isolates, 25 (69%) were SP resistant and 11/36 (31%) were SP sensitive. 
Overall SP failure rate observed clinically in this study was a mean of 27% in 
endemic and epidemc sites suggesting the importance o f close monitoring and 
surveillance of SP use and hence of its efficacy in different malaria areas of Kenya. 
Such a study is part of an ongoing and joint effort with the National Malaria 
Control Programme, (NMCP). In summary the in vitro assessments indicate the 
presence o f  resistance to CQ (100%), of 69% resistance to SP and of very high 
sensitivity to MQ and QN in the 4 malaria endemic sites in Kenya between 1997 
and 1998.
Both in vitro and in vivo tests of resistance have their limitations and the 
results described here show that the in vitro test of resistance is a complementary 
tool and may act as a “signal” of emerging resistance. The use of in vitro tests is
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limited to research purposes to provide baseline data on drug response and to 
monitor cross-resistance patterns and is unlikely to replace the in vivo test for 
therapeutic efficacy.
As a consequence of this work the importance of designating priority areas 
for surveillance and for continual monitoring of parasite resistance to antimalarial 
drugs in different malaria ecologies, is emphasized. The resulting information must 
be utilized at peripheral levels in order to optimize case detection and improve case 
management to achieve appropriate and effective preventive and therapeutic 
measures.
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The use o f formal health facilities as the first step for malaria treatment in 
Africa has been shown to be very low, (Dabis et al., 1989; Deming et al., 1989; 
Ruebush et al., 1995), while a high proportion o f  malaria episodes are treated at 
home unmonitored. Home diagnosis and appropriate treatment using antimalarials 
is potentially beneficial. This is due to the fact that malaria treatment initiated 
promptly at home may minimize the incidence of severe episodes, (Pagnoni, et al., 
1997).
In Kenya, a major obstacle to the effective implementation o f  malaria 
control strategy is the fact that antimalarials are usually given inappropriately 
either due to non-compliance or in inadequate doses. Ultimately, this leads to the 
parent or guardian seeking medical assistance from the hospital or health centres as 
a result of persistence of sickness at a time when, perhaps, the infection has 
progressed to a threatening level.
One of the major symptoms that prompt carers to initiate treatment at home 
is the sign of fever. In a malaria endemic area, fever or locally termed “homa” is 
usually the initial feature used to indicate a possible malaria infection although the 
underlying cause o f the fever may be different. The use of fever alone to diagnose 
malaria can result in unnecessary use of antimalarials creating drug pressure for 
resistance selection (Olivar et al., 1991). In one such study in Western Kenya, 
where malaria is holoendemic, Ruebush et al., (1995), self-treatment was 
extremely common among the residents of the rural community. They reported 
that, o f 138 episodes of febrile illness, 60% were treated at home with herbal 
remedies or medicines purchased at local shops, and only 18% received treatment 
at a health centre o f hospital. No treatment was sought by the remainder (22%). In 
another study in coastal Kenya, Mwenesi et al., (1995), found that of 118 mothers 
who had diagnosed their children as having malaria, 26% had given antimalarials, 
27% had given antipyretics or other medications, 23% said they had taken the child 
to a health centre, 6% had given a home remedy, and 18% had not given any 
treatment or done anything about the illness.
In highly endemic areas, two factors: self-medication and inaccurate drug 
histories, due to various social and cultural reasons (Nwanyanwu et al., 1996),
3.1 In tro d u ctio n
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represent serious constraints in performing and interpreting the in vivo tests. This 
could be true when some antimalarial drugs like CQ and SP have long elimination 
half-life; a mean of 4-8 weeks for CQ; [5 weeks (Frisk-Holmberg et al., 1984)] but 
up to 2 months have been reported (Ette et al., 1989)]. Similarly, half-life reported 
for SP is between 4-10 days (' Dollery 1991). The available urine
tests only detect antimalarials up to 14 days post drug intake, and the use of high 
performance liquid chromatography (HPLC) in the field is impractical. It is 
assumed that a negative urine test means no therapeutically effective level of 
antimalarial remains. The assumption is probably mistaken.
To give some indication o f the home treatment on parasite burden and the 
reliability of using fever as an index o f malaria infection, analysis of urine samples 
o f patients reporting febrile illness or malaise was carried out. Parasite density of 
microscopically positive cases was determined in home pre-treated patients and 
those that had not received treatment prior to presentation. Parasite density was 
taken as an estimate o f  parasite burden.
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3.2 Materials and Methods
3.2.1 Patients
Patient weight, age and home address were recorded on presentation at the 
outpatient departments of Mwea, Tiwi and Busia district hospitals. History of drug 
intake was taken and type or amount of drug ingested was recorded. Fever (locally 
known as homa) was taken to be body temperature o f > 37.5°C. The axilla or 
buccal temperature was taken and recorded for each child. Thermometers were 
swabbed clean with 70% ethanol between each use. History o f other signs and 
symptoms (headache, vomiting, coughing, headache, malaise, diarrhoea) was 
taken. A score of three pluses (+++) was assigned to highest recorded symptom, 
that is > 50% of patients with such symptom. Two pluses (++) for the next 
common symptom and one + (plus) for the least recorded symptom.
3.2.2 Urine test
Urine (approximately 5ml), was collected into sterile universal bottles. The 
Saker-Solomons’ urine test (Mount et al., 1989), for the determination of 
chloroquine was adopted, while a modification o f the Bratton-Marshall 
sulfonamide test (De Almeida and De Souza, 1983) was performed on each sample 
(see Appendix F, G).
3.2.2.1 Saker-Solomon test
This was performed to detect presence of CQ and desethylchloroquine 
(Appendix F). One ml of phosphate buffer solution, pH 8.0, was transferred to a 
15ml screw cap sterile centrifuge tube and 0.2 ml of 0.05% 
Tetrabromophenolphthalein ethyl ester, (TBPEE)-in-chloroform reagent solution 
was added [see Appendix F on preparation]. This was followed by 2 ml of patient 
urine sample. The tube and its contents was shaken vigorously for about 15 
seconds and allowed to stand for 15 minutes. After phase separation, a yellow 
green colouration o f  the chloroform layer is indicative of a negative test while a 
red-purple colouration is indicative of a positive test.
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3.2.2.2 Bratton-Marshall BIM test (Lignin test)
A modified version of this test was performed to detect previous intake of 
sulfonamide or sulfonamide containing compounds (Appendix G). One ml of urine 
sample was placed in a sterile screw cap tube. Then a drop o f  the prepared sodium 
nitrate solution was added followed by 2 drops of concentrated HC1. The tube and 
its contents was shaken and allowed to stand for 1 min. Then 3 drops of Bratton- 
Marshall solution was added, tube shaken to mix the contents and then allowed to 
stand for 1 min. Persistent purple colouration of the solution is indicative of a 
positive test while absence o f purple colouration or purple to brownish colour 
change is indicative of a negative test.
3.2.3 Standard controls
For standards and positive controls, authentic drugs [Fansidar, (Roche®) 
1.25mg/kg pyrimethamine and 25 mg/kg sulfadoxine and chloroquine base, 
25mg/kg of CQ (Avloclor®, ZENECA)] were used. Varying levels of drug 
concentration were tested in order to ensure that broad spectrum of drug levels in 
the urine samples is detected.
3.2.4 Statistical analysis
Epi-lnfo version 6 was used in data analysis. The statistical significance 
and odds ratio [OR] at 95% confidence interval Cl, was calculated using 
STATCALC from the 2 X 2  tables for cases with or without fever or parasitaemia 
and which tested positive or negative for antimalarials.
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3.3  R e su lts
Table 3.3.1 presents a summary of baseline information at the time samples 
were collected. The superscript denotes the year study was conducted. However, 
only 3 sites: Tiwi, Mwea, and Busia were chosen for analysis. The chosen sites 
differ in malaria transmission intensities and endemicity. Tiwi is hyperendemic, 
Mwea is mesoendemic while Busia is holoendemic. Overall, 171 samples from 
these sites were examined with 37, 42 and 92 from each site respectively.
The relationship between previous antimalarial drug intake and its 
influence or impact on parasite density or burden was assessed. Fever as an index 
of malaria infection was evaluated.
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Table 3.3.1 Urine analysis in S endemic sites of Kenya.
Mwea97Tiwi97 Busia9*Tiwi9* Oyugis98Kendu B99
C Q P
S P p
8 9 6 13 12 9
C Q P
S P N
27 19 17 34 8 18
C Q n
S P p
9 6 69 9 16 5
*c q n
S P N
15 14 12 11 18 21
**roN'p/F
SPN*p/F
108 38 113 142 126 120
CQ positive and SP positive
CQ positive and SP negative
CQ negative and SP positive
Control group Ipositive or negative for 
parasitaemia or fever]
**(CQN‘F/F : CQ negative and SP negative 
SPN‘F/F) (positive fever and parasitaemiaj
Superscript: Year of study
3 .3 .2  P a tie n ts
Table 3.3.2 presents the overall number (per site) testing positive or 
negative for either or both CQ and SP. In Busia, only 13%, of the samples 
examined tested negative to both drugs. The corresponding values for Tiwi and 
Mwea are 37.8% and 35.7% respectively. Values for Tiwi and Mwea are similar 
and much higher than those of holoendemic Busia. Values testing positive for CQ 
in both Tiwi (40%) and Mwea (43%) are higher than that for Busia (12%), but 
interestingly the holoendemic Busia has higher values for samples testing positive 
for SP, (69%) than in the mesoendemic Mwea (2%) and hyper-endemic Tiwi 
(11%). Samples testing positive for both drugs were found in all 3 sites, but the 
number is not significantly different from site to site.
In Busia samples were collected from patients aged 9/12-13 years, mean 
age of 8 years. In Tiwi and Mwea, samples were collected from patients aged 1 to 
13 years and 6/12 to 9 years, respectively with mean ages of 5.6 years and 5.2 
years respectively.
Table 3.3.2 Number of samples testing positive or negative
CQ/SP Busia
(%)
n=92
Tiwi
(%)
n=37
Mwea
(%)
n=42
c q n s p n' 12(13) 14(38) 15(36)
CQP SPN 11(12) 15(40) 18(43)
CQn SPp 63(68) 4(11) 1(2)
CQP SPp 6(6) 4(11) 8(19)
n = number of patients testing positive or negative for CQ and or SP
3.3.3 Parasite burden
Table 3.3.3 presents mean parasite density of patients from whom urine 
samples were collected. Parasite burden [indicated as the mean parasite density 
MPD] in all three sites for CQNSPN group was high with MPD ranging from 4,380 
to 7,330 parasite/pL of blood. In Busia, MPD per treatment group falls within the
1 3 4
same range with no significant difference between the values, although the CQSP 
treated group had the lowest burden, (4,005 parasite/pL). In comparing the 
holoendemic Busia to mesoendemic Mwea, the corresponding values show a 
pattern with CQpSPp having the lowest parasite burden. Interestingly, in Mwea the 
CQ-negative and SP-positive group bears the highest parasite burden with a value 
about twice that of CQ-positive and SP-negative group and indeed higher than the 
untreated group. The parasite density or burden of the CQpSPN and CQNSPp treated 
groups in hyperendemic Tiwi is not significantly different from the untreated 
group. However, the SP-positive group had the highest parasite burden. 
Interestingly, the CQpSPp group had no detectable parasitaemia suggesting that this 
group carried no parasite burden.
The P-values [significance level] for combined sites were calculated 
relative to the control group. Results from the 3 sites and for the group that tested 
positive to CQ and SP, showed on presentation a lower proportion with parasite 
burden (parasitaemia) relative to the control group (P<0.0016 odds ratio [OR] = 
0.15 [0.04 to 0.16]). No significant difference was observed in the proportion with 
parasite burden and testing CQNSPp or CQpSPN relative to the control group, 
(P=0.9596 OR 1.03 [0.34 to 3.02; P=0.2839 OR 0.58 [0.19 to 1.76]), respectively.
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Table 3.3.3 Mean parasite density: indicator of parasite burden per group in 
study sites
Drugs c q ns p n CQpSPn CQNSPp CQpSPp
Busia |N=92) 12 11 63 6
Parasite density 
(parasite/pL)
• Range
• Mean
3,400-29,600
7,330
2,010-5,200
4,964
1,900-5,400
5,057
2,100-4,300
4,005
Tiwi |N=37] 14 15 4 4
Parasite density 
(parasite/pL)
• Range
• Mean
3,400-13,000
4,742
1,890-5,200 
4,107
2,300-6,200
5,460
0
0
Mwea |N=42| 15 18 1 8
Parasite density 
(parasite/pL)
• Range
• Mean
2,040-7,600
4,383
1,600-2,980
2,628
4,880 1,300-2,100
1,749
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3.3.4 Fever
Axillary temperature was recorded in most patients supplying urine sample, 
even in the control group (the control group was negative for antimalarial intake as 
urine test revealed). In Busia the proportion of those with fever ranged from 41.7% 
in the untreated group to 83.3% in the CQpSPp group (see Table 3.3.4). Similarly, 
it ranged from 0% in the CQNSPp group to 50% in CQpSPp in Mwea and Tiwi, 
respectively.
The P-values for combined sites were calculated relative to the control 
group. Results from the 3 sites and for the group CQNSPp and CQpSPp, showed 
lower temperature (P=0.0002 at 95% Cl, OR 5.4 [2.06 to 14.48]; P=0.0086 at 
95%CI 5.59 [1.45 to 22.49])), relative to the control group [CQN SPN], 
respectively. No difference in temperature was observed for CQpSPN relative to the 
control group, (P=0.15 at 95% Cl, OR 2.24 [0.78 to 6.52]). The chi square (x2) 
trend for fever in the holoendemic site o f Busia, followed by Mwea then Tiwi, is 
shown in Table 4.5.4, (P=0.015, 0.029, 0.539), respectively.
Table 3.3.4 Proportion of patients with fever per group
Busia
Num n(%)
Mwea
Num n(%)
Tiwi
Num n(%)
c q n s p " 12 5(41) 15 1(7) 14 3(21)
CQP SPN 11 3(27) 18 5(28) 15 9(60)
CQN SPp 63 41(65) 1 0 4 0
CQP SPp 6 5(83) 8 4(50) 4 2(50)
Total 92 54(59) 42 10(24) 37 14(38)
X2 Trend p=0.015 P=0.029 P=0.539
Fever = Axillary temperature > 37.5°C
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3.3.5 Malaria indices most frequently reported by carers
See Table 3.3.5 for symptoms considered as indicative of malaria infection 
by carers. Fever ranked highest at 52% followed by cough, with diarrhoea ranking 
lowest.
Table 3.3.5 Malaria symptoms
SvmDtom Proportion Grade
N=171[%]
Fever 89[52] +++
Coughing 46[27] ++
Headache 19[ 11]
Malaise 9[5] +
Vomiting 5[3] +
Diarrhoea 3[2] +
138
3.4 Discussion
This study investigated the recognition of malaria by carers in the home 
setting. Assessment of anti-malarial drug use, in 5 study sites endemic for malaria 
in Kenya was determined. In addition the proportion o f urine positive for drugs 
amongst all age groups reporting at the health centres was assessed.
From the 3 sites o f Busia, Mwea and Tiwi, 44/171 (26%) of the patients 
were found to be positive for 4-aminoquinolines, 68/171 (40%) for sulfadoxine, 
and 18/171 (11%) for both of these drugs, Table 3.5.2.
The relationship between fever and the level of parasitaemia is at the core 
of recent attempts to find suitable case definitions of malaria attacks for use in 
epidemiologic studies (Smith et al., 1994; Greenwood et al., 1997). Both 
antimalarials and antipyretics may influence the relationship between fever and 
parasitaemia since carers treat fever by using antipyretics and / or antimalarials that 
may be taken before a visit to the clinic to reduce the fever, e.g. as observed in 
Ghana, (Ahorlu, et al., 1997).
Three areas of different malaria transmission intensities (mesoendemic, 
hyperendemic and holoendemic), were chosen in order to study the presence of 
drug in urine (positive for SP and or CQ) and its association with fever and 
parasitaemia prior to seeking formal treatment.
Overall, evidence of use of both CQ and SP (C Q 'SPp) was associated with 
lower parasitacmia on presentation, (P value o f <0.0016; OR 0.15 (95%CI 0.04- 
0.61) compared to CQ or SP administered singly. Similarly, when SP was taken 
alone (CQNSPp), there was a significantly lower temperature compared to the 
control group (this constituted the group without detectable drug in urine 
CQnSPn), (P=0.0002; OR 5.4 [2.06-14.48]). This was followed by a group that 
showed both CQ and SP (CQpSPp), (P=0.0086; OR 5.59 [1.45-22.49]) There was 
no significant temperature difference when CQ (CQpSPN) was detected alone 
(P=0.15; OR2.24 [0.78-6.52]). This supports the idea that C Q  is no longer effective 
in Kenya due to high in vivo failure rate, >70% (MOH, 1997). Significant 
proportion that had lower temperature and SP or CQSP in the urine, as explained 
above, were from Busia, ( x ,2 trend for Busia, Mwea and Tiwi was P=0.0116, 0,202 
and 0.551, respectively).
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Mean parasite density when sulphonamide or 4-aminoquinoline was 
detected in urine ranged between 1,749 and 7,330 parasites/fiL of blood. Certainly 
treatment initiated from home appears to be crucial in preventing the attainment of 
dangerous parasitaemic levels especially in the case of young children, in whom 
serious complications of malaria can arise quickly. The holoendemic Busia had the 
highest parasite burden. This is consistent with the endemicity as with Mwea and 
Tiwi. Again in Busia, no difference in parasite burden between groups whose urine 
showed CQpSPp or CQNSPp could be found (P>0.05). See also chapter 2, the in 
vivo studies for the effects o f CQ and SP in observed treatment trials.
Detection of parasitaemia, when drug can be confirmed in urine may mean 
under-dosage or the presence of resistance. Likely problems with malaria diagnosis 
and administration of antimalarials at home include (1) under-dosage which may 
contribute to drug resistance, (2) danger of over-dosage especially in children, 
although this has been found to be uncommon in areas with a high rate of self 
medication, (Deming et al., 1989).
As seen in this study, the decision to treat with antimalarials by carers was 
mostly based on fever [52% (89/171), compared to other symptoms], (Table 3.5.7). 
Results from this study indicate that highest proportion of subjects testing positive 
to CQ and or SP was observed in young children (<10 yrs), with a mean age of 
7.26 yrs (Busia); 5.6 yrs (Tiwi); 4.76 yrs (Mwea). This is not surprising since 
young and non-immune population are most susceptible to malarial disease in the 
endemic sites.
Coughing (presumed to indicate malaria by carers) was ranked second in 
the list of clinical symptoms. In malaria endemic countries clinical features of 
pneumonia are often confused with malaria due to overlapping symptoms 
(O'Dempsey et al., 1993). In Kenya, lower respiratory tract infections have been 
reported to be the second-most prevalent infection affecting mostly children, 
(MOH 1994). Perhaps this could explain the high rating (27%) by carers 
diagnosing “coughing" as indicative of malaria infection. Diarrhoea was 
considered the least characteristic (3%) symptom caused by malaria.
The urine tests used here are simple, sensitive and useful for field 
investigations on drug-use. Basically, i f  an individual has taken 25mg/kg CQ in
140
response to a febrile episode, the urine assay would test positive for approximately 
10 days, with lpg/ml detection limit (Mount et al., 1989). For patients who have 
been on a CQ 300mg weekly prophylactic regimen, the test has been found to 
remain positive for 5 days after the most recent dose (Steketee el al., 1988). This 
tool is therefore useful to monitor treatment compliance and evidence of recent 
drug use. It is however not clear, whether these tests could pick up local remedies 
used as a preventive measure. The modified Saker-Solomon test adopted here has 
been reported to cross-react with QN and proguanil (Mount et al., 1989). However, 
in in vivo and in vitro CQ sensitivity trials, the objective of the assay to exclude 
recent antimalarial drug use would still be fulfilled. On the other hand, the 
modified Bratton Marshall urine test for sulfonamides, has been reported to 
produce false positive results with nitrazepam, clonazepam, flunitrazepam and 
other drugs which carry an aromatic primary amino group or a drug which is 
metabolized to such compounds (D’Almeida and De Souza, 1983). So these drug 
tests are not highly specific, but experience here suggests they are relevant.
The findings o f the study have important clinical implications for a 
community-based care policy. Early and appropriate treatment of malaria detected 
in children by carers will prevent complications that arise as a result of persistence 
of symptoms and attainment of high parasitaemic levels leading to severe malaria 
or anaemia. The institution of home diagnosis and treatment as a tool for malaria 
control has long been advocated (Deming et al., 1989; Foster, 1995; Ruebush et 
al., 1995; Hamel et al., 2001). An important difference between home and health 
centre-diagnosed malaria, is that, in the case of the former, treatment is initiated 
using home- prepared herbs, analgesics and usually inadequate doses of 
antimalarials purchased at local drug shops. The final recourse, if the illness does 
not respond to home treatment, is the formal health sector (Dabis et al., 1989; 
Deming et al., 1989; Agyepong and Anderson, 1994; Ruebush et al., 1995; Ahorlu 
et al., 1997). Such cases may finally appear in the health centre/hospital with 
severe malaria. Therefore if home diagnosis and treatment strategy is to have a 
positive impact on malaria control and child survival, a strong and effective 
educational campaign will have to be instituted to address the problem of 
inadequate and inappropriate treatment especially for children. Increasing the
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carers’ awareness o f the symptoms and signs of simple and potentially life- 
threatening malaria and their appropriate management would have a  much needed 
impact in controlling malaria morbidity and mortality.
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CHAPTER 4
Molecular Characterisation of Drug-resistance determinants in 
Kenyan Epidemic and Endemic Malaria: I 
Fansidar® resistance
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4.1 Introduction
In Kenya, more than 30% o f parasite isolates from malaria cases are 
resistant in vivo to CQ (MOH, 1997, Rapouda et al., 1997; Shretta, et al., 2000) 
and up to 40% of the outpatient attendance in some areas is due to suspected cases 
of malaria (MOH, 1997). Guidelines on the treatment of malaria cases are still 
being worked out. Drug pressure (total drug use) is probably directly related to the 
development of drug resistance, as is the size of the parasite population exposed. 
Early detection of treatment failures and associated genetic changes will warn of 
the emergence o f drug resistance, and allow revision o f treatment 
recommendations for better control of the disease. This chapter examined the 
genetic determinants of drug resistance to SP. Varied genotypes o f dhfr and dhps 
have been found in different geographical areas where malaria is endemic. And in 
this chapter molecular characterization of SP drug resistant determinants in P. 
falciparum in endemic and epidemic regions of Kenya was investigated with the 
aim of assessing predictive value for PCR screening in treatment outcome.
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4.2 Materials and Methods
4.2.1 Dihydrofolate reductase |dhfr\ and dihydropteroate synthetase |dhps\ 
genes
4.2.1.1 Sample collection
Pre- and post-treatment parasite samples were collected from the patients as 
dry blood spots on glass fibre membrane [GFM] (Titertek) supported by 55mm 
diameter Whatman filter paper disc (BDH) (Warhurst el al., 1991). Samples were 
labelled and kept dry in resealable bags containing a desiccant. Bags were labeled 
to match samples. Bags were stored temporarily at room temperature, in the field 
before transportation to Malaria Unit, Centre for Biotechnology Research Institute, 
Kenya Medical Research Institute for genetic characterization where cold storage 
was maintained. Samples were later transported at ambient temperature to London 
School of Hygiene and Tropical Medicine (LSHTM) for further analysis and 
maintaining cold storage until needed.
Parasite DNA extraction procedure was as described by Warhurst et al., 
(1991). Blood spots were initially outlined with pencil to clearly mark the spot. 
Each GFM was supported on a fresh 2.5cm Whatman filter paper disc and placed 
on a sintered glass vacuum filter (Millipore). Blood was lysed by washing with 2-3 
mis sterile distilled water. Blood proteins and haemoglobin were removed by 
washing with 2.3mls of sterile normal saline. The prepared GFM was dried at 
room temperature for 1 to 2 hours and then stored in fresh labelled self-seal bags at 
4°C with desiccant to maintain dryness.
4.2.1.2 Polymerase Chain Reaction
Parasites were examined for antifolate-resistance associated point 
mutations in the dhfr (chromosome 4) and dhps (chromosome 8) genes using a 
nested PCR/RFLP method described by Duraisingh et al, (1998), (see appendix H 
for primer sequence). The nested PCR approach was used to amplify regions of dhfr 
and dhps genes containing antifolate associated point mutations. The nest 1 reaction, 
5 Op I reaction volume, contained a sector of the prepared GFM, 0.25pM of each nest 
1 primer, standard PCR buffer [1.5mM MgCh, 50mM KC1, lOmM Tris HC1 (pH 
8.3), 0.5% DMSO], 200pM of each of the dNTPs, 1U of Taq polymerase (BioLine).
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The reaction was allowed to proceed for 1 cycle at 94°C for 3mins, then 40 cycles at 
94°C for 1 min, 50°C for 2mins, 72°C for 2mins and finally at 72°C for 1 Omins.
The nest 11 reaction components, 0.25pM of each nest II primer, standard 
PCR buffer [1.5mM MgCl2, 50mM KC1, lOmM Tris (pH 8.3), 0.1% Triton X-100 
[Bioline]), 200pM o f  each of the dNTPs, 1U o f Taq polymerase, and 3 pi of nest I 
PCR products as template. Mineral oil overlay was added to avoid evaporation and 
aerosol formation. Tubes were briefly microfuged and placed in thermal cycler, 
(Teddington, Mdx, UK (Hybaid Cycler, UK). The reaction was cycled 35 times at 
94°C for 1 min, 45°C for 1 min, 72°C for 2 mins. An initial denaturation step of 94°C 
for 2 mins and a final extension step of 72°C for 10 mins was included.
4.2.1.3 Restriction Fragment Length Polymorphisms
4.2.1.2.1 Dihydrofolate reductase, dhfr
The method of Duraisingh was adopted (Duraisingh et al., 1998), see 
appendix I for restriction sites and pattern o f restriction digests. Restriction 
digestion o f the 522bp M3-F/ fragment with the enzyme NlaM  discriminates 
between the “wild type” allele Ala (GCA) and the “mutated” allele Val (GTA) at 
codon 16. The M3-F/ product contains an additional NIalll site that produced a 
376bp and a 146bp fragment serving as an internal control site for digestion. 
Presence o f Ala at dhfr codon 16 permits digestion of the 146bp fragment by 
NIalll yielding two fragments o f 93bp and 53bp. Standard laboratory lines of P. 
falciparum were used as controls for “wild-type” (negative control) and “mutant- 
type” (positive control) for each polymorphic sites on dhfr gene. The Thai strain 
K1 and the Gambian FCR3 strains were used as “wild-type” and “mutant-type” 
controls, respectively for dhfr codon 16.
Amplification containing codon 51 was digested with Tsp5091. The 
enzyme discriminates between the “wild type” allele Asn (AAT) and the “mutated” 
allele lie (ATT) at codon 51. If the enzyme cuts the M3-F/ fragment, a 154bp and 
64bp pattern, indicative of wild type sequence is obtained. W2 and K1 strains of P. 
falciparum were used as the positive control [mutant sequence] and negative 
control [wild type], respectively.
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XmnI restriction enzyme was used to distinguish between mutant and wild 
type codon 59. The presence of a restriction site, allows digestion giving 163bp, 
137bp and 26bp fragments indicative of mutant (Arg-59; CGT-59). A 189b and 
137b pattern, was indicative of wild type (Cys-59; TGT-59). P. falciparum strains 
K1 and T9/96 served as mutant and wild type controls.
Similarly, for codon 108, the PCR products from M3-F and M4-F 
amplification primers, were used to detect polymorphisms. Alul restriction enzyme 
was used to distinguish between wild type (Ser-108; AGC-108); BsrI can 
distinguish mutant (Asn-108; AAC-108) and BstNI distinguished mutant (Thr-108; 
ACC-108). Alul was used on fragment M4-F while M3-F was for BsrI and BstNI. 
P. falciparum strains K1 and T9/96served as mutant and wild type controls for 
Seri 08 and Asnl08, respectively. Whereas strain FCR3 was used for Thrl08 
positive control.
A Dral mismatch engineered in the F/ primer permitted the distinction of 
the wild type (Ile-164; ATA-164) from the mutant (Leu-164; TTA) at codon 164 
and using an M3-F/ amplified fragment. Two additional Dral sites are contained in 
the amplified fragment (control sites). Vl/S and K1 strains of 
P. falciparum were used as mutant and wild type controls, respectively.
4.2.1.3.2 Dihydropteroate synthetase, dhps
Codon 436 is contained in the K-K/ PCR product. Presence of wild type 
Ser-436 (TCT-436) was identified by Mnll digestion of the product giving 278bp, 
121 bp and 39bp fragments. The mutant (Ala-436; GCT-436) was identified by a 
pattern of 317bp and 121 bp. For mutant and wild-type controls, T9/96 and K1 
digest pattern were used, respectively. Determination for the presence of the amino 
acid sequence of Phe residue at codon 436, was not conducted as all the isolates 
examined harboured Ser or Ala residue or both.
Polymorphism at codon 437 was detected using Mwol restriction enzyme 
which detected presence of wild type (Ala-437; GCT-437) while Avail identified 
the mutant (Gly-437; GGT-437) contained in the K-K/ PCR fragment. Mutant and 
wild type controls were KI and FCR3, respectively.
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Codon 540 wild (Lys-540; AAA-540) to mutant (Glu-540; GAA-540) 
change was detected by FokI digestion of K-K/ PCR fragment. A digest 
comprising 320bp, 85bp and 33bp is indicative o f Glu-540 while 405bp and 33bp 
is indicative of Lys-540. For mutant and wild type control, TN-1 and K.1 were used 
respectively.
For codon 581, a change from wild type (Ala-581) to mutant type (Gly- 
581) was identified by the digestion of the L-L/ PCR product using the BstUl and 
BslI, respectively. T9/96 and K1 were used as wild type and mutant controls, 
respectively.
Codon 613 wild type (Ala-613; GCC-613), wild type sequence contained in 
L-L/ PCR fragment was identified by digesting the fragment with Mwol. The 
mutant sequence Ser or Thr-613, was identified by restricting the product with 
BsaWl (Ser-613) or Agel (Thr-613) restriction enzymes, respectively. K1 and W2 
were used as positive and negative controls for Ser-613, respectively; VL/S and W2 
were used as negative and positive controls for Thr-613, respectively.
4.2.1.4 Electrophoresis
PCR products or restriction digests were electrophoresed in 1.5%-2% gel 
(3:1 Ultrapure agarose (Gibco): Nusieve GTG (FlowGen, UK). A lOObp ladder 
marker was used for size estimation. Undigested PCR product and a negative 
control (without DNA material) were electrophoresed along with the digests. 
Electrophoresis was at 100V for 1.5-2 hours. Gels were stained in lOpg/ml 
ethidium bromide and visualized and photographed on an ultra-violet 
transilluminator (312nm) or documented using “GRABIT” gel documentation 
system.
4.2.1.5 Statistical Analysis
Statistical analysis o f  association between allele prevalence and drug 
failure was carried out using the STATCALC programme of Epi Info version 6, 
calculating chi square on 2x2 tables using Fisher’s exact test (or Yate’s correction, 
where indicated) in a two-tailed comparison. Significant association is assumed if 
P<0.05 or lower.
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Sensitivity SN: Percentage o f drug failures correctly predicted by the positive 
test result: (TP/TP+FN) x 100.
Specificity SF: Percentage o f successful treatments correctly predicted by the 
negative test (TN/TN+FP) x 100).
Positive predictive value PPV: Percentage of positive tests correctly 
predicting an unsuccessful treatment (TP/TP+FP) x 100).
Negative predictive value NPV: Percentage of negative tests correctly predicting a 
successful treatment (TN/TN+FN) x 100).
Key: TP = True Positives: FN = False Negatives: TN = True Negatives: FP = False 
Positives.
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4.2 Results
4.2.1 dhfr and dhps
All the samples examined for gene polymorphisms from the endemic and 
epidemic sites possessed "wild type" dhfr at codons 16 (A la-16) and 164 (lie-164). 
Similarly, they carried the "wild type" codons 581 (Ala-581) and 613 (Ala-613) o f 
the dhps gene. Mutations described in this thesis mean codon changes altering the 
amino acid coded for.
4.3.2 Prevalence of dhps and dhfr point mutations
4.3.2.1 Endemic
4.3.2.1.1 Tiwi (1997)
An overall prevalence of 33/38 (87%) mutant dhfr sequences with 24/38 
(63%) mutant dhps sequences was observed. There was a higher prevalence o f 
mutant dhfr sequences. Mixed alleles were detected in 9/38 (24%) for dhfr and 
11/38 (29%) for dhps. Twenty three out of 38 cases showed RI resistance to SP. 
There was one RII and one RIII case respectively. Table 4.3.2.1.1 displays the 
diverse genotypes of pre-treatment samples from this endemic region. The RII 
(T.8) was an infection in a 4-year old child. The isolate had a quintuple mutant 
genotype, 3 in dhfr at codons 51,59 and 108 and 2 in dhps at codons 437 and 540, 
(dhfr5' 59Ai,H dhps4'154°). Similarly, the RIII case was a 6.5-year old child and the 
isolate displayed Serl08Asn and Cys59Arg mutations of the dhfr gene. The mean 
age of treatment failures in Tiwi was significantly different from those successfully 
treated (3.6 ± 3.1 yrs and 8.08 ± 6.2 yrs): P=0.036. Thus, older patients in Tiwi 
were more likely to clear their infections.
4.3.2.2 Epidemic
4.3.2.2.1 Mosoriot (1997)
SP failures in Mosoriot were 10/21 (48%). Eight o f  these cases were RI 
type and one each of RII and RIII. Of the 21 isolates, 2 (10%) had mutant dhfr 
genotype and 8 (38%) had mutant dhps genotype. Mixed genotypes were not 
detected in this focus. Mutant genotypes for 8-RI failures were very diverse with 
mutant and or wild type sequence in both the dhfr and dhps gene, see Table
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4.3.2.2.I. The genotypes for RII case was dhfr: Serl08Asn and dhps: Ser436Ala, 
Lys540Glu. For the RIII case the dhfr was Serl08Asn and dhps Ser436Ala. The 
mean age o f  failures did not differ significantly from those that were successfully 
treated (13.0 ±10.3 and 15.9 ±21.6 yrs): P=0.696. Therefore age had no detectable 
influence on outcome of treatment in the epidemic site.
Prevalence of mutant dhfr and dhps genotypes in endemic Tiwi and 
epidemic Mosoriot is shown in Table 4.3.2.
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Table 4.3.2 Prevalence of mutant/ wild type genotypes of dhfr/ dhps genes in 
malaria endemic (Tiwi) and epidemic (IMosoriot) region of Kenya.
Tiwi 1997 
N = 38
w in mx
Mosoriot 1997 
N = 21
w m mx
Gene
dhfr
dhps
Codons
51 30 6 2 20 1 0
59 18 20 0 18 3 0
108 6 23 9 9 12 0
436 32 4 2 16 3 2
437 25 10 3 17 3 1
540 23 6 9 18 3 0
Key:
w: wild type 
m: mutant type 
mx: mixed
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T a b le  4 .3 .2 .1 .1 . P r e v a le n c e  o f  a n t i f o la t e  a s s o c ia te d  p o in t m u ta t io n s  in  K en y a n
Plasm odium  fa lciparum , T iw i 1 9 9 7
Study
No.
Age
(yrs.)
Dhfr dhps
51 59 108 436 437 540 R/S
T.1 2 N R N S G K/E Rl
T .2 2.7 N R S/N S G K/E Rl
T .3 4 N R N S A E Rl
T.4 1.5 N R N S A K Rl
T.5 0.5 I R N S G E Rl
T.6 3 I C N S A K/E Rl
T.7 1.5 N C N S A E Rl
T.8 4 I R S/N S G E Rll
T .9 3 N C S S A K Rl
T .10 5 I R N S A/G K/E Rl
T .1 1 2.8 N R N S G E Rl
T .1 2 13 N R S/N s A K/E Rl
T .1 3 2.5 N R N s A K Rl
T .14 5 N R N A A K Rl
T. 15 2 N R N S A K Rl
T. 16 12 I R N S A K Rl
T .1 7 5 N R N A A K Rl
T .1 8 6.5 N R N S A K RIII
T. 19 4.9 N R N S A K Rl
T .20 0.9 N R N S/A A K Rl
T.21 2 N R S/N S G E Rl
T .22 1 N R N S A/G K Rl
T .23 0.92 I C N S/A A K Rl
T .24 0.8 N/l C S/N S A K Rl
T .25 7 N C N S A K S
T.26 4 N C N A A K S
T.27 8 N C N S ~ A K S
T .28 6 N C S s A K S
T.29 15 N C S/N s G K/E s-
T .30 2.25 N C S s A K S
T.31 4 N/l R N s A/G K/E Rl
T .32 2.25 N C S/N s A K/E S
T .33 2.67 N C S/N s A K S
T.34 21 N C S s G K/E S
T .35 2.5 N C N s G K S
T.36 16 N C S/N s G K S
T.37 3.7 N C S A A K S
T.38 11 N C S S A K S
Key: white: wild type; grey: mutant type; R [RI, RII, RIII] = resistant; S = 
sensitive; N108=Asnl08 [mutant type]; S108=Serl08 [wild type]; C59=Cys59 
[wildtype]; R59=Arg59 [mutant type];K540=Lys540 [wild type]; E540 = Glu540 
[mutant type];S436=Ser436 [wildtype]; A436=Alanine[mutant type]; 
A437=Alanine437[wildtype]; G437=Gly437 [mutant type].
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T a b le  4 .3 .2 .2 .1  P r e v a le n c e  o f  a n t ifo la te  a ss o c ia te d  p o in t  m u ta t io n s  in K en y a n
Plasm odium falciparum , M o so r io t  1 9 9 7
Study
No.
Age
(yrs).
d hfr D h p s
51 59 108 436 437 540 R/S
M.1 34 N C N A A E Rl
M .2 19 N C N S A K Rl
M .3 26 N C N S G E Rl
M .4 11 N C N A A K Rill
M .5 12 N C N S/A A/G K Rl
M .6 9 I R N S A K Rll
M .7 2.9 N R N S G K Rl
M .8 8 N R N S G K Rl
M .9 4 N C N S/A A K Rl
M .10 13 N C N S A K S
M .1 1 6 N C N S A K S
M .12 71 N C N A A E S
M .13 5 N C S S A K S
M .14 12 N C S S A K S
M .15 6 N C S S A K S
M .16 4 N C S S A K S
M .17 0.7 N C S S A K S
M .18 3.9 N C S S A K R1
M .19 9 N C S S A K S
M .20 5 N C S S A K S
M.21 43 N C S S A K S
Key:
white: wild type; grey: mutant type; R [RI, RII, RIII] = resistant; S = sensitive; 
N108=Asnl08 [mutant type]; S108=Serl()8 [wild type]; C59=Cys59 [wildtype]; 
R59=Arg59 [mutant type]; K540=Lys540 [wild type]; E540 = Glu540 [mutant 
type];S436=Ser436 [wildtype]; A436=Alanine[mutant type]; 
A437=Alanine437[wildtype]; G437=Gly437 [mutant type].
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4.3.2.3 Predictive value of dhfr and dhps point mutations in Tiwi and Mosoriot 
(1997)
Wild type dhfr Ser-108 was seen in only one of the treatment failures from 
each location. Pre-treatment samples from all successful drug treatments from Tiwi 
and Mosoriot carried the wild type codons Asn-51 and Cys-59 while mutant Asn- 
108 was seen in some cases responding to SP in both areas (in Tiwi: T.25, T.26, 
T.27, T.31, T.35; in Mosoriot: M10, Ml 1, M l2).
Failure was associated with presence of mutated dhfr in Tiwi (P=0.003) and 
Mosoriot (P=0.008), (Tables 4.3.2.2.2a and b) and the same relationship was seen 
when Asn-108 was analysed alone. In Tiwi the presence of 2 or more mutations in 
dhfr was very highly associated with SP failure (PO.OOl). Here, the combination 
o f 2 or more dhfr mutations and any mutation in dhps was also highly associated 
with (P=0.0006). Only 3 doubly mutated examples of dhfr were seen in the 
Mosoriot group, but those were among the 10 drug failures. Drug failure here was 
associated with presence of mutated dhps (P=0.008) but the association was not 
significant in Tiwi. Failure was associated with the combined presence o f a 
mutation in dhps and in dhfr only in Mosoriot (P=0.008) and there was an 
association of failure here with the presence o f dhps Gly-437 (P=0.035).
For Mosoriot, the positive predictive value of dhps Gly-437 for drug failure 
was 100% (a measure of the utility of the test: Table 4.3.3.3a), and this was also 
the case when dhps Gly-437 occurred together with dhfr Asn-108. Positive 
predictive value was retained at 88% when any dhfr mutations were considered 
with any dhps mutations.
In Tiwi, (Table 4.3.2.2.2.b) the lowest positive predictive value is 69% 
(dhps\ Gly-437) and the highest is 100% for 2 or more dhfr mutations. The 
combination o f 2 or more dhfr mutations and mutated dhps also has a 100% 
positive predictive value.
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T a b le  4 .3 .2 .2 .2 a : A sso c ia t io n  b e tw e e n  a lle le s , a lo n e  a n d  in
c o m b in a t io n , w ith  S P  fa ilu r e  in  T iw i
Association 2 x 2
Table
M t M t-
P
value
SN
%
SF
%
PP
V
%
NPV
%
Dhfr mutation vs Res 25 0 0.003 100 39 76 100
Resistance Sen 8 5
Dhfr 108N vs resistance 24 1 0.003 100 39 76 100
8 5
2 or more dhfr m utations 23 2 0.001 92 100 100 87
0 13
2 or more dhfr m utations + 16 9 0.001 64 100 100 59
mutated dhps 0 13
Dhps mutation vs resistance 17 8 NS 68 46 71 43
7 6
Dhps 437G vs resistance 9 16 NS 36 69 69 36
4 9
Dhfr 108N + dhps 437G vs 9 16 NS 36 77 75 39
resistance 3 10
Mutated dhfr and dhps vs 17 8 NS 68 62 77 50
resistance 5 8
Dhfr vs. dhps m utation 6 2 NS
9 10
Combined TIW l/M OSORiOT 12 2 0.01
Dhfr vs. dhps mutation 13 19
Key: Sensitivity SN: Percentage of drug failures correctly predicted by the positive 
test result: (TP/TP+FN) xlOO; Specificity SF: Percentage of successful treatments correctly 
predicted by the negative test (TN/TN+FP) xlOO); Positive predictive value PPV: 
Percentage of positive tests correctly predicting an unsuccessful treatment (TP/TP+FP) 
xlOO); Negative predictive value NPV: Percentage of negative tests correctly predicting a 
successful treatment (TN/TN+FN) xlOO); TP = True Positives: FN = False Negatives: TN 
= True Negatives: FP = False Positives. Mt = mutation present; Mt - = mutation not 
present; Res = resistant; Sen = sensitive.
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2 X 2  Table showing an example of presence or absence of dhfr mutation in 
resistant and sensitive field samples .
Statistical analysis of association between allele prevalence and drug failure was 
carried out using the STATCALC programme of Epi Info version 6, calculating 
chi square on 2x2 tables using Fisher’s exact test (or Yate’s correction, where 
indicated) in a two-tailed comparison. Significant association is assumed if P<0.05 
or lower.
Outcome
resistant
sensitive
Genotype
mutant mutant
[+] [-]
25 0
8 5
When applied on an Epilnfo Version 6:
♦1 25 | 0 1 25
I
-1 8 | 5 11 13
Exp 33 S 38
Analysis of Single Table ; Odds ratio = Undefined; Exact limits preferred.Relative 
risk = 1.63 (1.06 <RR< 2.50); Taylor Series 95% limits for RR. Fishers’ exact test 
recommended since one table value is zero.
Chi-Sauares P-values
Uncorrected: 11.07 0.0008763
Mantel-Haenszel: 10.78 0.0010255
Yates corrected: 7.96 0.0047767
Fisher exact: 1-tailed P-value: 0.0025640 
2-tailed P-value: 0.0025640
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T able 4.3.2.2.2.b: A sso c ia t io n  b e tw e en  a l le le s ,  a lo n e  a n d  in c o m b in a t io n ,
w ith  S P  fa ilu r e  in M o so r io t
Association 2x2
Table
Mt Mt -
P
value
S
N
%
SF
%
PPV
%
NPV
%
dhfr mutation vs Res 9 1 0.008 9 73 75 89
resistance Sen 3 8 0
dhfr Asn-108 vs resistance 9 1 0.008 9 73 75 89
3 8 0
2 or more dhfr mutations 3 7 N.S. 3 10 100 61
vs resistance 0 11 0 0
%
dhps mutation vs resistance 7 3 0.008 7 91 88 77
1 10 0
dhps 43 7G vs resistance 4 6 0.035 4 10 100 65
0 11 0 0
dhfr 108N + dhps 437G vs 4 6 0.035 4 10 100 65
resistance 0 11 0 0
Mutated dhfr and dhps vs 7 3 0.008 7 91 88 77
resistance 1 10 0
dhfr vs. dhps mutation 6 0 0.01
4 9
Key: Sensitivity SN: Percentage of drug failures correctly predicted by the positive 
test result: (TP/TP+FN) xlOO; Specificity SF: Percentage of successful treatments correctly 
predicted by the negative test (TN/TN+FP) xlOO); Positive predictive value PPV: 
Percentage of positive tests correctly predicting an unsuccessful treatment (TP/TP+FP) 
xlOO); Negative predictive value NPV: Percentage of negative tests correctly predicting a 
successful treatment (TN/TN+FN) xlOO); TP = True Positives: FN = False Negatives: TN 
= True Negatives: FP = False Positives. Mt = mutation present; Mt - = mutation not 
present; Res = resistant; Sen = sensitive.
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4.3.3 Pre-treatment prevalence of dhps and dhfr point mutations
4.3.3.1 Endemic
4.3.3.1.1 Busia (1998)
Out of the 12 cases that failed SP treatment, 5 were RI, 4 were RI1 and 3 
were the R1II type o f parasitological response. O f the 5 RI cases, 2 had triple dhfr 
mutations (dhfr5' 59''0*), and 3 possessed quadruple mutations (dhfr5'’59''m dhps457). 
Pre-treatment analysis of the 4 RII cases, 2 were triply mutated (dh/r5' 59'0*), 1 had 
4 mutations (dhfr5 ' 5 9 ,1 0 8  dhps417), and 1 possessed 5 mutations (quintuple 
dhfr5 ' - 5 9 ,1 0 8  dhps457'540). All the 3 RIII infections had quintuple mutations 
(dhfr5'-59-'m dhps437-540).
Pre-treatment assessment on the 53 sensitive cases revealed 19 isolates with 
mutations; of these 6  had quintuple mutations (dhfr5' 59''0*dhps457540), and 4 with 
quadruple mutations (dhfr5' 59''°*dhps457), and 9 were triple mutated, (dhfr5''59''0*). 
All the remaining 39 sensitive cases harboured the wild type sequence of the 
residues examined.
4.3.3.1.2 Tiwi (1998)
Similarly, in Tiwi, there were 14 treatment failures to SP, 6  were of RI, and 
8  were of RIII type parasitological response. Of the 6  RI cases, 5 had triple 
mutations (dhfr''59’10*), and 1 had quadruple mutations (dhfr5' 59 lm dhps477). Of the 
8  RIII cases, 2 possessed triple mutations, (if/i/r51,59,108), 2 had quadruple mutations, 
(1 with dhfr5' 59''0*dhps45b\ 1 with dhfr5''59''0* dhps457) and 4 had quintuple 
mutations (3 with 5 1 -5 9 -1 0 8 dhps437’540; 1 with dhfr5''59''0*dhps45b54°).
Of the 62 cases responding to treatment, 6  had quintuple mutations 
(5''59'")Hdhps457 540), 8  possessed quadruple mutations ( 1  with dhfr5' 59'"Mdhps4ib\ 1 
with dhfr5' S9'"'*'dhps457) and 7 had triple mutations (dhfr5' 59 '0*). Two isolates 
were mixed clones of wild and mutant types at codon 108 and 51. The remaining 
39 samples were of wild type.
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4.3.3.1.3 Oyugis (1998)
Of the 9 SP failures, 4 were Rl, 1 was Rll and 4 were RIII. Pre-treatment 
analysis of these samples revealed that o f the Rl response samples 1 was with 
triple mutations (dhfr51 -5 9 ,1 0 8 ), and 3 were quadruple mutants (dhfr5' 59'w dhps4}1). 
The only Rll case had quadruple mutations (dhfr5' 59,m'dhps4il). Out of the 4 RIII 
type, all had quintuple mutations (dhfr?i 59'l0S'dhpsAil'S4°).
Pre-treatment analysis of the 60 sensitive infections showed the following 
mutant genotypes; 5 quintuple (dhfr5' 59''0Hdhps451 540), 7 quadruple, 2 with 
(dhfr5',59'1 °*'dhps45b), 5 with (dhfr5''59'°*dhps43b), 12 triple (dhfr5''59'um). Three P. 
falciparum infections were mixed (wild and mutant types) at codons 108, 59 and 
51. All the remaining 33 sensitive infections were wild type in both dhfr and dhps 
genes.
4.3.3.1.4 Kendu Bay (1999)
There was a total of 23 failures in Kendu Bay with 14 cases Rl, 8  were RII 
and 1 was RIII. Pre-treatment analysis on the 14 Rl type revealed, 3 had triple 
mutations (dhfr3' 59'10*)-, 7 had quadruple mutations, 4 with (dhfr5 1 5 9 , 1 °*dhps45b), 3 
with (dhfr5' '59’'°*dhps451) and 4 had quintuple mutation (5 l'5 9 ,l0 8 'i//ips4,7'54°). O f the 
8  RII cases, 6  had quadruple mutations: 1 with (dhfr5' 59'm dhps45b)', 5 with 
(dhfr5' 59''w dhps451), 2 had quintuple mutants (5''59'm 'dhps451'540). The only RIII 
case had quintuple mutations.
Out of the 97 sensitive cases, the following had polymorphisms on dhfr and 
dhps, 9 quintuple (dhfr5' 59'm 'dhps451 540), 4 quadruple (dhfr5' 59,'w dhps451) and 19 
triple (dhfr5' 59 '0H). Four isolates were mixed infections at codon-108 with wild 
(Ser-108) and (Asn-108). The remaining 61 sensitive isolates were wild type.
4.3.3.2 Epidemic
4.3.3.2.1 Kisii (1999)
Of the 54 SP-treated patients, 6  failed to respond. Out of these 6  SP- 
resistant cases, 1 was Rl and 5 were RIII. Pre-treatment analysis revealed that the 1 
Rl case had triple mutation dhfr5''59''0*. O f the 5 RIII cases, 1 had double 
mutations: dhfr'9,'m and 4 had triple mutations: dhfr5' 59''0*.
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Pre-treatment analysis o f the 48 sensitive infections showed that 8  had 
mutations on the dhfr and dhps genes, 2- triple dhft5' 59’w*, 1-double dhfi5 1 ,1 0 8  and 5 
single dhftl08. Forty isolates were wild type.
4.3.3.2.2. Mt.Elgon (1999)
Eight cases out of 61 failed treatment to SP, and o f these, 3 were of RI, 2 
were o f Rll type and 3 were o f RIII type of response. Pre-treatment analysis 
revealed that of the 3 Rl type, 2 had triple mutations (dhft5' 59'w*) and 1 had double 
mutations (dhft*9' l08). Of the 2 Rll, 1 had triple mutations (dhft5' 59''°8) and 1 had 
double mutations (dhft5'' l08). O f the 3 RIII cases, all had triple mutations 
(i/A/r51-59-108).
Pre-treatment analysis o f the 53 sensitive infections showed 2 with double 
mutations (dhft59 l08) and 2 with single 108 dhfr mutations. Two isolates were 
mixed (wild and mutant) infections at codons 108 and 51. The remaining 47 were 
wild type in both dhfr and dhps genes.
4.3.3.3 Association between dhfr and dhps genotypes and outcome
Taking the results from the endemic sites together, (Busia, Tiwi, Oyugis 
and Kendu Bay) there was a correlation between treatment failures and presence of 
four point mutations- 3 dhfr (dhfr5'' 59, l08) and 1 dhps (dhps4}1). The association 
between the quadruple mutations and treatment failure is significant (P < 0.001 and 
X2 = 55.01). There was also an association with quintuple mutations dhfr (dhfr5'' 
59, 108 and dhps4515*") and treatment failure. The association of the quintuple 
mutations and SP treatment failure was also significant (P < 0.001; f 2 = 14.76) (see 
Table 4.3.3.3e).
Similarly, analysis for association between treatment failure and dhfr and 
dhps gene polymorphisms in the epidemic foci of Mt.Elgon and Kisii was carried 
out and the association was significant when there were triple or double mutations 
in dhfr (dhft59' 108 or dhft5' ' l08), (P < 0.001; x 2 50.85 [triple]; P = 0 .0075 ;x2 8.02 
[double]) (see Table 4.3.3.3e).
Sensitivity, specificity and predictive values are also shown in table 
4.3.3.3e.
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T a b le  4 .3 .3 .3 a : Sulfadoxine/ pyrimethamine sensitivity profile of 
epidemic and endemic malaria in Kenya.
Endemicity Site N Sensitive
RI
Resistant 
RII Rill Total
Endemic
Busia 65 53 5 4 3 1 2
Tiwi 76 62 6 0 8 14
Oyugis 69 60 4 1 4 9
Rendu
Bay 1 2 0 97 14 8 1 23
330 272 (82%) 29 13 16 58(18%)
Epidemic
Risii 54 48 1 0 5 6
Mt.
Elgon 61 53 3 2 3 8
115 1 0 1  (8 8 %) 4 2 8 14(12%)
Key: N = number o f patients; R = Parasitological failure (grade RI.RII, Rill).
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T a b le  4 .3 .3 .3 b :  P r e v a le n c e  o f  p r e -tr e a tm e n t dhfr  a n d  dhps  p o ly m o r p h is m s  in
S P -r e s is ta n t  c a s e s  o f  e p id e m ic  a n d  e n d e m ic  m a la r ia .
Site
N
Quintuple 
dhfr S I , S 9 , 108  
dhps 436<or437,' 54°
Quadruple
dhfr 51, 1 0 8  
dhps 436*or437)
Triple* 
dhfr 5 I ' 5 9 , 108
Rn
Endemic
Busia 1 2 4 4 4 1 2
Tiwi 14 4 3 7 14
Oyugis 9 4 4 1 9
Kendu
Bay 23 7 13 3 23
Total 58 19 24 15 58
Epidemic
Triple
dhfr 5 I - 5 9 - 108
Double
dhfr 5 9 <or5 ').i° 8
Single 
dhfr 108
Kisii 6 5 1 0 6
Mt.
Elgon 8 6 2 0 8
Total 14 11 3 0 U
Key: * = Infections with Triple dhfr genotypes were the same infections with double 
(dhfr5, l°8) genotypes
N = Total resistant cases per site. RN Total resistant cases with multiple mutations
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T a b le  4 .3 .3 .3 c : P r e v a le n c e  o f  p r e - tr e a tm e n t  dhfr  a n d  dhps
p o ly m o r p h is m s  in  S P -s e n s it iv e  c a se s  o f  e p id e m ic  and
e n d e m ic  m a la r ia
Site S Quintuple 
dhfr 51,39' 108 
dhps 436<or437)-540
Quadruple
dhfr5'* 9-'0* 
dhps 436<or437)
Triple*
dhfr5'-59-'0*
Ns
Endemic
Busia S3 6 4 9 19
Tiwi 62 6 8 7 2 1
Oyugis 60 5 7 1 2 24
Rendu 
Bay 97 9 4 19 32
Total 272 26 23 47 96
(35%)
Epidemic
Triple
dhfr 5I'59' 108
Double
dhfr59' °r5„..08Single dhfr l01'
Kisii 48 2 1 5 8
Mt.
Elgon 53 3 2 1 6
Total 101 5 3 6 14
(14%)
Key: S = T ota l sensitive cases  per site. N s T o ta l sensitive cases w ith m u tations in dhfr and 
dhps genes.
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T a b le  4 .3 .3 .3 d : P r o p o r tio n  o f  p r e - tr e a tm e n t  dh fr  a n d  dhps  g en e
m u ta t io n s  in S P -r e s is ta n t  c a s e s  o f  e p id e m ic  a n d  e n d e m ic
m a la r ia
Endemic
Quintuple Quadruple Triple
RI (29) 4 14 1 1
Rll (13) 3 8 2
Rill (16) 1 2 2 2
19 24 15
Epidemic
Triple Double Single
RI (4) 3 1 0
RII (2) 1 1 0
Rill (8 ) 7 1 0
11 3 0
Key:
Single = dhfr 108
Double = dhfr W-SI MO«
Triple = dhfr 5 1 , 5 9 , 108
Quadruple = dhfr 51,59' 108dhps
Quintuple = dhfr 5 1 , 5 9 , 1 0 8 dhps
436 (or 437) 
436(or 437), 540
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T a b le  4 .3 .3 .3 e :
and epidemic malaria in Kenya
In d ic e s  o f  p r e - tr e a tm e n t  a s s o c ia t io n  o f  dhfr
a n d  dhps g e n e  p o ly m o r p h is m  w ith  r e s is ta n c e  in e n d e m ic
Genotype P t 1 fYates) SN SF PPV NPV
Endemic
Quintuple <0.001 19.92 33 90 42 8 6
Quadruple <0.001 39.77 41 92 51 8 8
Triple 0.182 1.78 26 83 24 84
Epidemic
Triple <0.001 49.66 79 95 69 97
Double 0.023 5.15 2 1 97 50 89
Key:
SN = sensitivity 
SF = specificity
PPV = positive predictive value 
NPV = negative predictive value
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4.3.4 Prevalence of dhfr and dhps mutations in severe malaria cases, 
Chogoria-Kenya
As explained earlier, association between genotypes conferring resistance 
to SP and treatment outcome could not be examined here since all the hospitalised 
patients progressed to severe malarial disease and were ultimately treated with QN. 
This section therefore, examined only the prevalence of genotypes of dhfr and 
dhps on admission in severe malaria patients. All isolates carried the wild type 
codons 16, 164 (dhfr) and 436, 581, 613 (dhps). Only one isolate (C l9) [see Table 
4.3.4] had the wild-type codons 51, 59, and 108 (dhfr) and 437 and 540 (dhps)\ the 
remaining 23 isolates had the mutant codons 51 and 108 of dhfr gene and codons 
437 and 540 of dhps gene; one isolate (C24) had mixed genotype (mutant and wild 
type) of codon 108. Isolate CIO carried the wild type codon 59 of dhfr gene and 
wild type codons 437 and 540 of the dhps gene.
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T a b le  4 .3 .4  P r e v a le n c e  o f  d h fr  a n d  dhps  p o ly m o r p h is m  in  s e v e r e  m a la r ia
patients, Chogoria (1997).
S/N dh f r  gene Dhps gene Therapy
51 59 108 437 540
Cl wwww wwww wwww wwww wwww 7
C2 wwww wwww wwww wwww wwww 7
C3 wwww wwww wwww wwww wwww 7
C4 wwww wwww wwww wwww wwww ?
C5 wwww wwww wwww wwww wwww 7
C6 wwww wwww wwww wwww wwww CQ>PSD
C7 wwww wwww wwww wwww wwww A q > p s d
C8 wwww wwww wwww wwww wwww PSD>AQ
C9 wwww wwww wwww wwww wwww ?
CIO wwww wwww CQ>PSD
C ll wwww wwww wwww wwww wwww PSD>AQ
C12 wwww wwww wwww wwww wwww ?
C13 wwww wwww wwww wwww wwww 7
C14 wwww wwww wwww wwww wwww CQ>PSD
CIS wwww wwww wwww wwww wwww 7
C16 wwww wwww wwww wwww wwww A q > p sd
C17 wwww wwww wwww wwww wwww CQ>AQ
C18 wwww wwww wwww wwww wwww PSD>AQ
C19 PSD>AQ
C20 wwww wwww wwww wwww wwww PSD>AQ
C21 wwww wwww wwww wwww wwww CQ>PSD
C22 wwww wwww wwww www\ wwww 7
C23 wwww wwww wwww wwww wwww 7
C24 wwww wwww III III wwww wwww 7
Key: ND =  NOT DETERM INBD; CQ -  CHLOROQUINE; AQ =  AMODIAQUINE; PSD =  FANSIDAR®; ? =  NO 
RECORD OF DRUG TREATM ENT;
\\\\ =  M U TA N T; BLANK =  WILD TYPE; = =  = MIXED WILD TYPE AND M UTANT GENOTYPES
> = a change from first to second treatment regimen.
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F ig u r e  4 a -b  dhfr  g e n e  p o ly m o r p h is m s
Figure 4a dhfr (Ser 108Asn)
P. falciparum  field isolates
1 2 3 4 5 6  7 8  9 10 11 12 13 14 15 16 17 M
Figure 4b dhfr (AsnS 1lle)
P. falciparum  field isolates
A representative number o f  P. falciparum field isolates is shown in Figures 4a-b (is shown). The 
labels signified as M = 100 bp ladder marker; ~ , w , = indicates uncut (UC) PCR product; 
approximates the band size (in base pair). Laboratory clones used as controls are shown for each 
figure. A band profile similar to the control K1 isolate indicates presence o f mutant Asn-108 
whereas a band profile similar to T996 control isolate indicates wild type Ser-108, see Figure 4a. 
Also as show n in Figure 4b, a band profile similar to W2 control isolate indicates presence of 
mutant Ile -5 1 whereas a band profile similar to K 1 isolate is indicative o f  wild type Asn-S 1.
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F ig u r e  4 c -d  dhps  g e n e  p o ly m o r h p is m s
Figure 4c dhps (Lr,540Glu)
P falciparum  field isolates
M 2 3 4 5 6  7 8  9 10 11 12 13 14 15
Figure 4d dhps (Ser436Ala)
P. falciparum  field isolates
M 2 3 4 5 6  7 8  9 10 11 12 13 14 15 16 17 18 19 M
A representative number o f P  fa lc iparum  field isolates is shown in Figures 4c-d . The labels 
signified as M -  100 bp ladder marker; , v  “  indicates uncut ( U C )  PCR product; -*  
approximates the band size (in  base pair). Laboratory clones used as controls are shown for each 
figure. As shown in Figure 4c, a band profile similar to the control TN/1 isolate indicates presence 
of mutant G lu -3 4 0  whereas a band profile similar to K l  control isolate indicates wild type L ys - 
$40. Sim ilarly in Figure 4d, a band profile similar to K l  control isolate indicates presence of wild 
type Ser-436 whereas a band profile sim ilar to T996 control isolate is indicative of mutant type 
Ala-436.
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In analysing pre-treatment samples for dhfr and dhps genotypes, it was 
found that samples from all successful treatment cases from Tiwi and Mosoriot 
(1997) carried the wild type codons 51 and 59 of the dhfr gene while mutant codon 
108 was seen in some cases responding to SP in both epidemic and endemic areas. 
This indicates, as expected, that Asn-108 was often not sufficient alone to 
determine resistance to the SP combination.
Resistance was associated with presence o f mutated dhfr in Tiwi (P=0.003) 
and Mosoriot (P=0.008), (Tables 4.3.3.3a and b) and the same relationship was 
seen when Asn-108 was analyzed alone. In Tiwi the presence of 2 or more 
mutations in dhfr was very highly predictive of resistance (P<0.001). Here, the 
combination o f 2  or more dhfr mutations and any mutation in dhps was also highly 
predictive o f resistance (P<0.001). Only 3 doubly mutated examples of dhfr were 
seen in the Mosoriot group, but those were among the 10 drug failures. Resistance 
here was associated with presence of mutated dhps (P=0.008) but this association 
was not significant in Tiwi. Resistance was associated with the combined presence 
of a mutation in dhps and in dhfr only in Mosoriot (P=0.008) and there was an 
association here with the presence of dhps Gly-437 (P=0.035). Perhaps dhps 
mutation may be more crucial when fewer dhfr mutations are present.
For Mosoriot, the positive predictive value (a measure o f the utility of the 
test) was 100% for mutations in dhps and this was the case also when dhps Gly- 
437 occurred together with dhfr Asn-108. This was retained at 8 8 % when any dhfr 
mutations were considered with any dhps mutations.
In the Tiwi sample the lowest positive predictive value is 69% (dhps: Gly- 
437) and the highest is 100% for 2 or more dhfr mutations. The combination of 2 
or more dhfr mutations and mutated dhps also has a 1 0 0 % positive predictive 
value. Together with the value of 77% for any mutation in dhfr and dhps, this also 
supports the results from Mosoriot suggesting that changes in dhps substantially 
influence the therapeutic response to SP, and this agrees with laboratory in vitro 
data (Triglia et al., 1997). The association seen between dhps and dhfr (effectively 
linkage disequilibrium) support the suggestion that drug selection is acting on the 
enzyme products of both genes.
4 .4  D isc u ss io n
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Acquired immunity in endemic areas may override the effect of mutations, 
which should determine drug failure. Since the younger age group in Tiwi was 
more likely to show drug failure, and the association o f drug failure to “resistant” 
mutations, at least in dhps, was less strong in this location. It is possible that a 
proportion of infections in this location that responded to SP treatment did so in 
spite o f parasites which were drug-refractory.
However, studies on presence of mutations in recrudescent infections 
revealed correlation between mutations in dhfr and dhps (Brooks et al., 1994) and 
SP treatment failure (Jelinek et al., 1999).
Results from the endemic (Busia, Tiwi (1998), Oyugis and Kendu Bay) and 
epidemic sites (Mt. Elgon and Kisii) showed that mutations in pre-treatment cases 
in both dhfr and dhps genes are associated with SP treatment failures, indicating 
the predictive value of these mutations [see Table 4.3.3.3d]. The sensitivity and 
specificity of the quintuple mutations in predicting treatment outcome, for the 
combined endemic sites, was calculated to be 33% and 90% respectively. 
However, the positive predictive value (that is the proportion o f subjects who 
failed to respond to SP and had quintuple mutations in pre-treatment), for the 
combined endemic sites, was 42%. Similarly, the negative predictive value NPV 
was 8 6 % in the combined endemic sites. The low (42%) PPV and low sensitivity 
(33%) could indicate patients’ acquired immunity contributing to parasite 
clearance in spite o f those parasites carrying mutated genes. It appears therefore, 
that use of these molecular markers in predicting treatment failure in endemic areas 
suffers this limitation. In the epidemic foci, where the immune effect is almost 
zero, the sensitivity was very high at 79% with a matching high specificity o f 95%. 
The PPV was equally high at 69%. Interestingly, the NPV (the proportion of 
subjects that responded to SP and did not have the quintuple mutations) stands at 
97%. Therefore, these molecular markers, to a very large extent, could be used as 
predictors of treatment failure in epidemic sites as evident from this work. 
Negative predictive value results indicate that prediction of treatment success 
would be reliable even in endemic areas.
Overall, the association of resistance phenotype and dhfr/dhps before 
treatment mutations seen in this study is significant both in the endemic [P<0.001,
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X 2 = 77.84] and epidemic foci [P<0.001, x 2 =  50.85], suggesting usefulness of 
these mutant genotypes in predicting treatment outcome to SP. This was higher for 
quintuple and quadruple mutations (PO.OOl, y? = 13.57) than triple mutations 
(P=0.07, x 2 = 3.24) [Table 4.3.3.3e] in endemic sites. The findings reported here, 
would suggest that multiple mutation in dhfr and dhps genes determines high level 
resistance to Fansidar® even though some sensitive isolates had mutations on 
dhfr/dhps genes [see Table 4.3.3.3c]. See Figures 4a, 4b, 4c, and 4d for a 
representation o f  field isolates showing mutant and wild type dhfr and dhps gene 
polymorphism.
In the epidemic sites, association was observed between isolates with 
double (P=0.023) or triple mutations (P=0.05) in dhfr gene and SP failure. This 
suggests that the presence o f infections with either double or triple mutations on 
dhfr is sufficient to predict SP failure.
The patient samples in Chogoria were different compared to other epidemic 
sites. Patients from this site had failed treatment to CQ, SP and AQ and progressed 
to severe malaria and were admitted. Examination of polymorphisms on dhfr and 
dhps on admission revealed that 22/24 (92%) Kenyan parasites from Chogoria 
epidemic, carried triple point mutations in codons 51 (Asn to lie), 59 (Cys to Arg) 
and 108 (Ser to Asn) of the dhfr gene; and also carried double point mutations in 
codons 437 (Ala to Gly) and 540 (Lys to Glu) o f  the dhps gene. Overall the high 
prevalence o f mutant genotypes and the probable absence o f acquired immunity to 
malaria could have resulted in failure of standard antimalarial therapy in this 
locality.
Mutations in the dhps enzyme of P. falciparum  are clearly of major 
importance in the mechanism of resistance to sulfa drugs (Triglia et al., 1997; 
Wang et al., 1997b), but a second component has been identified that appears to 
allow the parasite to more efficiently use folate to assist in bypassing the 
antimalarial effect of these drugs (Wang et al., 1997b). It is not clear what the 
factor is, but it may be a more efficient folate uptake system or alterations in 
enzymes that enable increased use of folate. It is not clear how important the folate 
factor is in resistance to sulfa antimalarial drugs in the field. Current data suggest
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that in the presence o f pyrimethamine, the folate effect that compromises 
susceptibility to sulfadoxine is much reduced, compared to its level when parasites 
are challenged with sulfadoxine alone (Wang et al., 1997b). The dhfr/dhps point 
mutations observed here most likely underly SP resistance in the study area. SP 
was only recently recommended as a replacement for chloroquine as first line drug 
in Kenya (MOH Report 1999). This would suggest that sentinel areas of the 
country should be closely monitored for SP resistance-associated point mutations 
in P. falciparum.
Overall, these findings call for a critical review of the policy adopting SP as 
first line drug in Kenya. There is obviously an urgent need to search for 
alternatives. Perhaps in trying SP/CQ, SP/ artesunate, amodiaquine/ artesunate and 
other new combinations it is hoped that success may follow these approaches. 
Outlets and use of such drugs should be closely monitored by the government if 
full scale resistance to any o f  the drugs is to be delayed or avoided.
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CHAPTER 4 II
Molecular Characterisation of Drug-Resistance Determinants in 
Kenyan Epidemic and Endemic Malaria: II 
Chloroquine resistance
175
Efforts made in the understanding of the genetic basis of CQ resistance led 
to the identification of pfmdrl (chromosome 5) and cg2 (chromosome 7) genes. 
Codon changes in these genes were linked to the CQ resistance phenotype. 
However, the association of these changes with resistance was found not to be 
absolute, either those of pfmdrl or cg2, was not absolute, suggesting another 
essential genetic difference. The mechanism o f CQ resistance was earlier 
suggested to be multigenic (Foote et al., 1990b). In 1990, an American group had 
reported association of CQ resistance with changes in chromosome 7 in a 
laboratory cross (Wellems et al., 1990). In 1997 (Su et al., 1997), the group 
identified a candidate gene (cg2) on chromosome 7. While changes in cg2, as 
confirmed by other workers (Basco and Ringwald, 1999; Durand et al., 1999; 
Adagu and Warhurst 1999b; McCutcheon et al., 2000), were linked to CQ 
resistance in vitro, the association was not complete. Transfection studies (Fidock 
et al., 2000a) ruled out cg2 as the determinant of CQR. Recently, Fidock et al., 
(2000b) identified another gene (pfcrt) on chromosome 7 coding for the 
Plasmodium falciparum chloroquine resistance transporter as the main genetic 
determinant o f in vitro resistance. Pfcrt encodes a 10 transmembrane-domain 
protein in the lysosomal membrane, but its precise function remains unclear. A 
change in codon 76 of the pfcrt gene, Lys-76-Thr (AAA to ACA) appears to be 
strongly linked to the CQ resistance phenotype with other changes within the gene 
probably playing a complementary role.
In this section pfcrt changes were examined in Kenyan isolates obtained 
from malaria patients in Mwea (1997: endemic), central Kenya. A parallel 
assessment of the pfmdrl codon 8 6  and 1246 status o f  the isolates was carried out 
and a comparison was drawn as to the degree of involvement of each gene in CQ 
resistance. Analysis was carried out revealing the extent of the match between 
pfmdrl and pfcrt with CQ resistance. Samples from recrudescence were also 
analysed for evidence of selection.
In addition, samples from severe malaria patients in Chogoria in 1997 
(epidemic) were examined for drug-resistant determinants in cg2, pfmdrl. Pfcrt 
polymorphisms were not examined in the Chogoria samples as Chogoria study was
4 .7  In trod u ction
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already completed by the time the pfcrt gene was identified. The molecular 
analysis of isolates from Mwea was carried out in collaboration with the University 
of Maryland (see Appendix J for personnel involved) while the in vivo work was 
conducted in Kenya.
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4.8 Materials and methods
4.8.1 Endemic
4.8.1.1 Mwea
4.8.1.1.1 Analysis of pfcrt and pfmdrl
Reagents for PCR were purchased from Gibco-BRL (Gaithersburg, MD) 
and restriction endonucleases from New England Biolabs (Beverly, MA), see 
appendix J. All genotypic analysis of the isolates was performed by PCR 
amplification of parasite DNA, allele-specific restriction analysis (ASRA) at 
codons of interest. PCR primers and reaction conditions for the ASRA of 
polymorphic codons o f pfcrt (76, 220, 271, 325, 356 and 371) were as described 
(Djimde et al., 2001). Pfmdrl was also analyzed at codons 8 6 , 1034, 1042 and 
1246 as described (Djimde el al., 2001), but with some modifications and 
additions. For analysis of codon 1246, a nested PCR was performed, utilizing a 
primary PCR with primers mdrl246-l (5'-
GGGGATGACAAATTTTCAAGATTA-3') and mdrl 246-2 (5’-
GGGGACTAACACGTTTAACATCTT-3'), and a secondary PCR with primers 
mdrl246-Dl (5'-AATGTAAATGAATTTTCAAACC-3') and mdrl246-D2 (5’- 
CATCTTCTCTTCCAAATTTGATA-3'). The secondary product was analyzed by 
digestion with Bgl II as described (Djimde et al., 2001). For size discrimination 
the secondary product was determined in 2% NuSieve agarose (FMC, Rockland, 
MD). Programs for the above PCR were as follows. Primary PCR: initial 
denaturation at 95°C for 5 mins, followed by 45 cycles o f denaturing at 92°C for 30 
seconds [sec], annealing at 45°C for 30 sec, and extension at 65°C for 45 sec; with 
a final extension at 72°C for 15 mins. Secondary PCR programs were as above but 
for 15-20 cycles, and with the extension time decreased to 30 sec.
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4.8.2.1 Parasite samples
Chogoria Mission Hospital is situated on the eastern slope o f Mt. Kenya at 
altitude of 1,585 meters. The hospital has a large catchment area ranging from 
Tharaka division to southern and central Meru districts (see chapter 2 for detailed 
description of study sites).
Diagnostic parasite samples were obtained from febrile patients (aged 15 to 
70 years) admitted to the Hospital in May 1997, during a malaria epidemic. Many 
of the cases had failed first and second line drug treatment (CQ, followed by AQ or 
SP). A blood sample obtained from each of the patients was blotted on glass fibre 
membrane and allowed to dry and then stored dry at 4°C until needed for analysis. 
The dry blood samples were prepared as described by Warhurst et a l., (1991), see 
4.2.1.1.
4.8.2.2 Pfmdrl gene
4.8.2.2.1 Semi-nested PCR for codon 184 and 1034
The novel allele specific, one tube, semi-nested PCR was used to amplify 
regions of the pfmdrl gene containing CQ resistance associated point mutations (see 
Appendix H) (Grobusch el al., 1998). Each reaction contained 3 oligonucleotide 
primers (outer forward, inner forward [mutant, or wild type specific] and reverse).
Although allele specific PCR method o f Grobusch et al., (1998) was used in 
analysing codon 8 6 , 184, 1034, 1042 and 1246 there was a limitation in getting 
amplified products from some of the samples. Therefore, a PCR-RFLP was also 
employed utilizing primer P3 and the outer primer 184R used by Adagu and 
Warhurst (1999a). These primers flanked pfmdrl codons 8 6  and 184. Primers 1034F 
and P2 were used to amplify a fragment containing codons 1034, 1042 and 1246.
P3/184R PCR product was digested with AfllH to detect changes in codon 
8 6 . The 1034F/P2 product was digested with either Vspl or EcoR V to detect changes 
in codon 1042 and 1246.
4 .8 .2  E p id e m ic
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4.8.2.2.2. Restriction Fragment Length Polymorphism for codons 
86 and 1246
The enzyme reactions were performed following the conditions described 
by manufacturers. For codon 8 6 , 1042, and 1246 the following restriction enzymes 
were used, A f i l l  I, VspI, and EcoRV. The enzyme digestions were calculated for a 
final volume of 20pl using 5pl o f the nested PCR product, 1U of the enzyme, with 
buffer and temperature conditions as described by the manufacturers (New 
England Biolabs, Hitchen, UK). The samples were left to digest overnight 
(approximately 1 2  hours) after which digestion was stopped by the addition of 2 pl 
loading buffer (50mM Tris [pH 8.0], EDTA [pH 8.0], 0.5% SDS, 40% sucrose, 
0.25% orange G (Sigma)). See Appendix G for details on the restriction pattern for 
each enzyme.
4.8.2.3 Cg2 gene polymorphisms
The method described by Adagu and Warhurst, (1999b) was used to screen 
the 24 samples for cg2 polymorphisms (chromosome 7) associated with chloroquine 
resistance. Primers Hubland Hub2 were selected to flank k repeat region and the 
three point polymorphisms upstream of the 5’ end o f the repeat. Similarly, Luql and 
Luq2 primers span the y repeat and a point polymorphism at the 3’ end of the repeat.
Primer name______________________ Primer sequence
k repeat region
Hubl 5’..TAT GAA TTT GGG TAA ATC G..3’
Hub2 5’..ATA TAT CAC TAA GTT GTA GCT..3’
y repeat region
Luql 5’..GTG GAA AGG TTC CTT TAC T..3’
Luq2 5’..ATA ATC TGG AGA CAC AAC T..3’
Each of these two primers was used at a final concen'ration of 0.8 pM in a 
reaction mixture o f 50pl, containing 150pM of each of the four dNTP, 1.25 U of 
Taq polymerase (Bioline, Springfield, NJ) and standard PCR buffer (1.5mM 
MgCl2, 50mM KC1, lOmM Tris-HCl [pH 8.3], 0.01% (w/v) gelatin). Forty rounds 
of amplification were performed.
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4.8 .2 .3.1 R e str ic t io n  F r a g m e n t  L e n g th  P o ly m o r p h is m s
Digestion of the Hubl/Hub2 PCR products with Tse\ (New England 
Biolabs, Beverly, MA) (0.75U at 65°C (see Adagu and Warhurst, 1999b) produced 
restriction patterns indicative o f either the Dd2 or HB3 type of the cg2 gene. A 
lOpl digest mixture (containing 4pl Luql/Luq2 PCR product, lp l reaction buffer) 
incubated with Rca\ (Boehringer Mannheim, Mannheim, Germany) (1U at 37°C) 
produced patterns indicative of the 7G8 or HB3 types of this gene. Dd2 (South­
east Asian) or 7G8 (South American) served as the CQ-resistant/mutant controls, 
and HB3 as the CQ-sensitive/wild-type control. The Hubl/Hub2 PCR products 
contain Tse\ restriction site - 2 sites in the Dd2 type cg2 gene and 1 site in the HB3 
type gene. Enzymatic digestion o f the PCR products produced restriction patterns 
indicative of either Dd2 or HB3 type cg2 gene (see Adagu and Warhurst, 1999b).
Luql/Luq2 PCR products, 7G8 type, contain one Real site while the HB3 
type PCR products contain two Rca\ sites. Enzymatic digestion o f  the products 
produced patterns indicative of 7G8 or HB3 type cg2 gene. Digestion was carried out 
at 37°C utilizing 1U of Rca\. Dd2 (South East Asian) or 7G8 (South American) were 
used as CQ resistant or mutant positive controls while HB3 served as CQ sensitive or 
wild type positive control. Primers were obtained from Life Technologies. A Rca\ 
digest pattern of 194bp and 97bp is indicative of 7G8 type while a 119bp, 106bp and 
45bp is indicative of HB3 type. Note that the 119bp and 106bp products co-migrate as 
one band.
Undigested PCR products’ size polymorphisms of 291bp and 270bp are 
respectively indicative o f 7G8 and HB3 y repeat, whereas the size o f  the cg2 gene k 
repeat, using Hubl and Hub2 primers, is 716 bp (Dd2) and 700 bp (HB3). The size of 
the k  repetetive unit is 16 bases.
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4.9  R e su lts
4.9.1 Endemic
4.9.1.1 Mwea (1997)
The /?/cr/-Lys76Thr polymorphism was carried by all the 60 pretreatment 
isolates. Similarly, Ala220Ser (57/57), Gln271Glu (57/57), and Arg371Ile (60/60) 
(secondarily associated with Lys76Thr) were harboured by these isolates. Changes 
in codons 326 (Asn326Ser) and 356 (Ile356Thr), which were imperfectly linked to 
the CQ resistance phenotype (Fidock et al 2000b, Djimde et al., 2001), were 
detected respectively in 56 of 59 (95%) and in 1 of 57 (2%) isolates tested. Two 
samples presented mixed (wild and mutant) alleles at 326. Heterogeneity at the 
326 and 356, contrasting the tight linkage o f 76, 220, 271 and 371, was also 
observed in Mali samples (Djimde et al., 2001), as well as in isolates from Malawi 
(Kublin et al., unpublished). As pfcrt mutations were present in all the pre­
treatment samples, the post-treatment samples were not examined. However, the 
post-treatment samples were examined for pfm drl mutation even though 93% 
initially showed the 8 6 Tyr mutation (see Table 4.9.1.1).
The Asn8 6 Tyr pfmdrl mutation previously implicated in CQ resistance 
was detected in 92% of CQS cases and 91% o f the resistant cases at DO. Two of 
these exhibited a mixture of Asn8 6  and 8 6 Tyr. Interestingly, samples taken at D14 
recurrent cases, all (100%) carried the mutant sequence o f codon 8 6 . Only the 
wild-type alleles were observed at codons 1034 (Seri 034, 52/52) and 1042 
(Asnl042, 52/52) in the D14 recurrent infections. In contrast, there was marked 
heterogeneity at codon 1246 in the pre-treatment [DO] isolates, 41 of 58 (71%) 
samples had the Aspl246Tyr mutation, four o f which exhibited a mixture of the 
two alleles and the remaining isolates exhibited wild type sequence. All (100%) 
the D14 recurrent infection had the Aspl246Tyr mutation.
To analyze the pfmdrl polymorphisms o f the pre-treatment [DO] isolates 
with respect to subsequent parasitological outcome, we first segregated the isolates 
based on the WHO parasitological grading criteria. Those in the sensitive grade 
(S), comprised 40 of the 60 (67%) isolates, and 20 (33%) were resistant at RI or 
Rill level.
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As Table 4.9.1.1 details, when examined individually, the DO and D14 
parasite isolates had mutations in the pfmdr1 codons 8 6  and 1246; [Tyr8 6 : DO 
93%, D14 100%; Tyrl246 DO 71%, D14 100%]. However, isolates that harboured 
both the Asn-8 6 -Tyr and Asp-1246-Tyr comprised 47% (17/36) of the sensitive 
infections and 75% (15/20) of the resistant infections (P=0.083). Of the 20 D7 
recurrent isolates, 90% harboured the Asn8 6 Tyr and 70% harboured the 
Aspl246Tyr in mono-allelic or mixed fashion, similar to the prevalence in the pre­
treatment infections. There was no clear selection o f combinations of the pfmdrl 
polymorphisms relative to the DO sensitive isolates; only a modest increase in the 
frequency o f  the paired 86Tyr/1246Tyr was observed (DO sensitive 47%; D7 post­
treatment 65%). However, all D14 recurrent cases, (8 /8 ; 100%), had Asn8 6 Tyr and 
Aspl246Tyr mutant genotypes on the pfmdrl suggesting 100% selection for both 
genotypes together (P <0.001 [for 8 6 Tyr] and P=0.76 [for 1246Tyr], (see Table 
4.9.1.1). P value (also 2-tailed) for combined 8 6 Tyr and 1246Tyr selection was 
significant [P=0.020].
Table 4.9.1.1 : Prevalence of pfm drl and pfcrt genotypes in CQ 
treatment failures from Mwea 1997.
Isolates N p f c r t  76T(%) P f m d r l  86Y(%) p fm d rA  1246Y(%) 86Y+1246Y(%)
Day 0 60 100 93 71 63
Day 0 S 40 100 92 65 47
Day 0 R 20 100 91 76 71
Rl 1 NA 100 83 83
RII 11 N A 100 100 100
Rill 8 NA 83 59 50
RI-RIII 20 NA 91 70 68
Day 7 20 NA 90 70 65
Day 14 8 NA 100 100 100
Key: NA = not done; S = Sensitive; R (1, II, III) = Resistant;
All the parasites harboured p/m76Thr. In contrast to pfcrt, presence of wild-type 
Asn8 6  and Aspl246 in treatment failures was 9% and 30%, respectively. 
However, none of the isolates carrying pfm drl8 6 Tyr or 1246Tyr had the wild-type 
pfcrt Lys76 as all tested isolates harboured 76Thr (mutant) genotype. It was 
therefore not possible to examine the two genes for linkage.
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4.9.2 Epidemic
4.9.2.1 Chogoria (1997)
Although records of drug treatment for half o f the samples were not 
available, Table 4.9.2.1 shows that 11/12 patients received, prior to parenteral QN, 
Fansidar® and chloroquine or AQ to which the infection was not sensitive. All the 
infections responded to parenteral QN therapy. Where available, records of drug 
treatment show that patients had received at least 2  antimalarial treatment regimens 
prior to parenteral quinine therapy.
4.9.2.2 Drug resistance associated polymorphisms
As presented in Table 4.9.2.1, the allele specific PCR (AS-PCR) results show 
that 22 of the 24 samples had the mutant codon 8 6  while the remaining 2 (Cl and C7) 
had the wild type sequence. All the 24 samples had mixed wild type and mutant 
codon 184 (not included in the Table). Twenty-two o f  the parasites carried the wild 
type sequence of codon 1034 and the remaining 2 (C l5 and C20) had mixed 
sequences o f mutant and wild type. Interestingly, while all the 24 parasites had the 
wild type sequence of codon 1042, 20 carried the mutant sequence o f codon 1246 and 
the remaining 4 which carried mutant codon 8 6 , had the 1246 wild type sequence 
though one, C20 (see above), had the mixed genotype of codon 1034. The 
PCR/RFLP results confirmed the AS-PCR results for codons 8 6 , 1042 and 1246.
The cg2 k repeat analysis, based on size variation and restriction fragment 
length polymorphism shows, in all, that 18 of the 2 1  samples examined (8 6 %) carried 
the Dd2 type while 3 (14%) had the HB3 type. For technical reasons, 3/24 samples 
were not determined. Similarly, 4/24 samples were not examined for cg2 y repeat. 
Size and RFLP analysis of the 20 samples examined showed that 18 (90%) of these 
carried the 7G8 type cg2. Presence of Dd2 or 7G8 cg2 genotype is reported to be 
associated with chloroquine-resistance while an HB3 cg2 genotype is associated with 
sensitivity.
PCR products of 291 bp and 270bp respectively indicate o f 7G8 and HB3 y
repeat.
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Table 4.9.2.1: Genetic profile and treatment regimens of 24 severe
malaria cases from Chogoria, 1997.
S/N Pfmdrl g e n e eg 2 g e n e Therapy
8 6 1034 1246 tc-size K-RFLP y - s iz e y-RFLP
Cl w w w w w w w w w w w w w w w w w w w w ?
C2 WWWW w w w w w w w w w w w w w w w w w w w w ?
C3 w w w w w w w w w w w w w w w w w w w w w w w w ?
C4 WWWW w w w w w w w w w w w w w w w w w w w w ?
C5 w w w w w w w w w w w w w w w w w w w w w w w w ?
C6 w w w w w w w w w w w w w w w w w w w w CQ >PSD
C7 w w w w w w w w w w w w w w w w w w w w Aq > psd
C8 w w w w w w w w w w w w w w w w w w w w w w w w PSD>AQ
C9 w w w w w w w w w w w w w w w w w w w w 9
CIO w w w w w w w w w w w w C Q >  PSD
C ll w w w w w w w w ND ND ND ND PSD>AQ
C12 w w w w w w w w w w w w w w w w w w w w 9
C13 w w w w w w w w w w w w ND w w w w 9
C14 w w w w w w w w w w w w w w w w w w w w ND CQ >PSD
C15 w w w w = = = = w w w w w w w w w w w w w w w w 9
C16 w w w w \w \w w ND w w w w ND w w w w Aq > psd
Cl 7 w w w w w w w w ND w w w w ND ND CQ>AQ
C18 w w w w w w w w w w w w ND w w w w w w w w PSD>AQ
C19 w w w w w w w w ND PSD>AQ
C20 w w w w = = = = = PSD>AQ
C21 w w w w w w w w w w w w w w w w ND w w w w CQ>PSD
C22 w w w w w w w w w w w w w w w w w w w w w w w w 9
C23 w w w w w w w w ND ND ND w w w w ?
C24 w w w w w w w w w w w w ND ND 9
K e y :
S/N =  SERIAL NUMBER; ND =  NOT DETERMINED; CQ =  CHLOROQUINE; AQ =  AMODIAQUINE; 
PSD =  FANSIDAR®; ?  = NO RECORD OF DRUG TREATMENT; \ \ \ \  =  MUTANT; BLANK =  
WILD TYPE; s s  =  MIXED (W ILD  TYPE AND M UTANT GENOTYPES).
> = a change from first to second treatment regimen.
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Figure 4e-fpfm drl gene polymorphisms
F igure 4e p fm d r l  ( AsP1246r>'r)
F igure Ai p fm d r l  (a»"86t>t)
P. falciparum  field isolates
M  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Polymorphism on pfm drl showing a representative number of P falciparum  field isolates. Th e  labels 
signified as M -  100 bp ladder marker; — -  approximates the band size (in base pair). Laboratory clones 
used as controls are shown for each figure.
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The surveillance of chloroquine-resistant malaria would be greatly 
facilitated by identification of reliable molecular markers of drug resistance that 
would be applicable in the field. Ideally presence of these markers or determinants 
could correlate with in vivo treatment outcome. The studies described here 
examined the roles played by putative drug-resistant determinants in CQ 
resistance.
In the Mwea study, the pfcrt mutation Lys76Thr was present in 100% of 
the CQR isolates but could not be definitively implicated in resistance here since 
76Thr was also present in all in vivo susceptible isolates. Evidence o f the ancillary 
role of pfmdrl to pfcrt (Warhurst, 2001b; Babiker et al., 2001) and linkage 
disequilibrium has been reported (Adagu and Warhurst 2001). However, lack o f 
wild type pfcrt in this site did not permit an evaluation of this suggestion.
As observed here while there were 40/60 CQ sensitive cases and in some 
other studies in East Africa (e.g., 18/23 CQ sensitive cases from Mozambique 
Mayor et al., 2001), the pfcrt codon 76 mutation indicative o f in vitro resistance is 
present in all isolates examined. Report of Dorsey et al., (2001) in Uganda 
indicated presence o f this mutation in all the 114 isolates tested, half o f which were 
responsive to CQ in vivo. It is possible that, in these areas, where CQ-resistance 
level is fairly high, the Thr-76 change may not be discriminative enough to allow 
its use as predictor o f drug failure. These observations are consistent with those of 
Pillai et al., (2001) in Laos and Durand el al., (2001) from samples collected from 
malaria endemic regions of sub-Saharan Africa, South East Asia and South 
America. However, in other areas like Mali, (Djimde et al., 2001), Sudan (Babiker 
et al., 2001) and Nigeria (Adagu and Warhurst, 2001), absence o fpfcrtlbThr was 
an excellent predictor of successful CQ treatment. In Mali for instance, for 
pfcrtlbThr, the PPV (percentage o f mutadon-positive isolates correctly predicting 
a treatment failure) was 30% and the NPV (percentage of negative tests correctly 
predicting a successful treatment) was 98%. A test result showing apparent 
absence of pfcrtlbThr was an excellent predictor of successful CQ treatment. 
When results of patient population under 10 years of age in Mali was examined the 
PPV improved appreciably. Where the prevalence of pfcrtlbThr before treatment
4 .1 0  D iscu ss io n
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was 41%, it rose to 1 0 0 % with no mixtures in samples taken after treatment failure 
(Djimde et al., 2001). It appears therefore that the mutant p fcrtl 6Thr is completely 
selected by CQ treatment, indicating crucial role in resistance, while incomplete 
selection of PfmdrI8 6 Ty occurs. Absence of pfcrtl 6Thr, predicts treatment 
success (Warhurst, 2001b).
As seen in Mwea and Chogoria, pfmdrl codon 1246 mutation, which is rare 
in Africa, but highly associated with South America isolates, (Foote et at., 1990b; 
Povoa et al., 1998; Zalis et al., 1998) is emerging in this part of Africa. Its arrival 
would suggest increasing level o f CQ resistance in Kenya. The mutation has also 
recently been detected in a few samples (13/50) from South Africa (McCutcheon et 
al., 1999). In Chogoria, isolates contain mixed wild and mutant genotypes of 
codon 184. Changes in this codon appear to have no correlation with CQ resistance 
(Foote et al., 1990b). Only 2 samples carried mixed mutant (Cysl034) and wild 
type (Seri034) genotypes. Interestingly, these samples had mutant sequence of 
codons 8 6  and 1246 of pfm drl gene shown in Table 4.8 .3.2.1 [see Figure 4e, and 
4f]. The low prevalence o f  1034 mutation in Africa is expected, since this and the 
1042 mutation are found mainly in S. America (Foote et al., 1990b, Povoa et al., 
1998; Zalis et al., 1998). The 4 Chogoria samples carrying wild type codon 1246 
had mutant codon 8 6  and 3 o f these had cg2 point polymorphisms. At least 18 
(75%) o f the samples had cg2 (see below) and pfmdrl CQ resistance related 
mutations. This study on hospitalized cases is the first time codon 1246 mutation 
has predominated in samples from East Africa. In Zaria, Nigeria (1993), codon 8 6  
(Asn to Tyr) mutation was the only pfm drl sequence variation detected in the area 
(Adagu et al., 1997) and it was associated with low level CQ resistance. Reed et 
al., (2000) found in transfection studies that pfmdrl Tyr-1246 significantly 
increased CQ-resistance o f an already slightly-resistant clone i.c., a clone with 
mutant pfcrt. The combined presence o f  these 2 mutations in pfmdrl could suggest 
that a higher degree o f CQR is developing in Kenya.
The Chogoria samples were also examined for changes in cg2 gene (Su et 
al. 1997). The k and y repeat regions of the gene were examined in this study. 
Eighteen (86%) of the 21 samples examined had the Dd2 type sequence o f k repeat 
while 90% of the 20 samples examined for y repeat had the 7G8 type cg2
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sequence. A match between pfmdrl 1246 mutation and eg 2 y repeat 
polymorphisms was obtained for sixteen (89%) o f  the 18 samples that were 
examined for sequences changes in both genes. This high level match between 2 
South American CQ resistance associated markers, on different chromosomes, 
would suggest that the mutations that were once rare in Africa are emerging in the 
continent particularly in East and perhaps South Africa. Overall, 18 (75%) of the 
24 samples tested had the cg2 and pfmdrl polymorphisms and this would strongly 
suggest CQ resistant status (Adagu and Warhurst, 1999b). It is not surprising 
therefore that many of the patients had failed initial treatment.
The allelic exchange experiments and drug profile study of transfectants 
(Fidock et at., 2000a) suggest that the cg2 polymorphisms do not primarily determine 
CQ resistance but the results are due to physical linkage of cg2 and pfert on the same 
chromosome (Adagu and Warhurst, 2001). Other findings (Adagu and Warhurst, 
1999b, Basco and Ringwald, 1999, Durand el al., 1999 and McCutcheon et al., 2000) 
found incomplete association of these polymorphisms with CQ resistance.
Presence o f  the pfert76Thr may be necessary for in vitro resistance but it is 
not sufficient to predict in vivo treatment outcome in areas where resistance 
prevalence is relatively high, >60% in Kenya. Mutations on pfmdrl may be 
important here in increasing resistance to CQ and perhaps additional 
polymorphisms on pfert may be involved in modulating CQ response as previously 
suggested (Fidock et al., 2000b). The need for complementary mutations in pfert 
and probably pfm drl may explain the slow development and spread o f  CQ 
resistance. Factors including drug absorption, pharmacokinetics of individual 
patients, parasite dynamics and patient immunity may indeed be additional factors 
that can influence treatment outcome.
There are obvious public health implications and it will be important to 
carry out more extensive surveys across Kenya as CQ therapy is reduced following 
the national ban on its use. Recent findings in Malawi suggest that mutant pfert is 
deleterious to the parasite and diminishes in prevalence when CQ pressure is 
reduced, with a consequent rise in CQ efficacy (Kublin el al., unpublished 
observations). Similar observations were made in Thailand where gradual increase 
in in vitro CQ sensitivity on samples collected between 1978 and 1986, coincided
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with the withdrawal o f CQ for treatment o f falciparum malaria, (Thaithong et al., 
1988). Perhaps, after proper and absolute withdrawal o f CQ, it may be possible to 
re-introduce CQ in Kenya, maybe this time in combination with another 
“appropriate” antimalarial.
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5.1 Introduction
Study of the population structure o f P. falciparum using genetic and 
molecular biology approaches has provided some of the most accurate information 
about parasite evolution and population genetics (Escalante et a/., 1998). In this 
chapter variations in 3 well characterized merozoite surface proteins, 1 and 2 
(coded by mspl and msp2 genes> and glutamate rich protein (glurp gene) were 
used as molecular markers to determine the diversity among P. falciparum in 
endemic and epidemic areas o f Kenya. The genes code for highly immunogenic 
antigens (Anders and Smythe, 1989) are very polymorphic in nature and are 
regarded as suitable for parasite typing. Variations in degree of genetic diversity in 
different areas (Creasey et al., 1990; Babiker and Walliker, 1997) have been 
suggested to be due to differences in transmission intensity (Creasey et al., 1990; 
Paul et al., 1995; Babiker and Walliker, 1997). A high level o f  diversity in P. 
falciparum has also been reported in hypo-endemic regions (Babiker et al., 1991; 
Paul et al., 1998). Studies on P. falciparum  diversity reported in Kilifi and Sokoke 
areas of Kenya which experience seasonal malaria with peaks o f  transmission 
during the rainy period, (Kyes et al., 1997), showed equal (50%) prevalence o f IC 
and FC alleles of the msp2 gene in clinical and asymptomatic malarial infections. 
Another study conducted in Kenya was in the western part o f the country (Qari et 
al., 1998). The group examined mspl alleles and identifiede amino acid 
substitution due to crossover recombinational events.
Malaria outbreaks in Kenya are becoming more frequent leading to high 
morbidity and mortality, (MOH, 1994-2001). It was proposed that epidemic 
infections, as seen in the highlands, are likely caused by one clone and 
polyclonality and extensive diversity as seen in endemic infections are not 
expected in epidemic outbreaks.
Genetic diversity studies based on 3 unlinked variants of the glutamate rich 
protein gene (glurp) and merozoite surface protein gene (mspl and msp2) were 
carried out using samples from severe malaria patients admitted in Chogoria 
Mission Hospital (an epidemic site). Studies on uncomplicated malaria cases from 
additional endemic and epidemic sites in Kenya used the msp2 marker. Studies in 
Kenya examining genetic diversity among isolates causing epidemic malaria have
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not previously been done. Each of the 3 genes contains a highly polymorphic 
region composed of repeated units: block 2 of mspl gene (Tanabe et al., 1987; 
Kimura et al, 1990), block 3 o f msp2 gene (Smythe et al., 1990) and region 2 of 
giurp protein gene (Borre et al., 1991; Triglia et al., 1992). In addition to size 
differences, the allelic variants of mspl and msp2 were classified into 3 (Kl, 
M AD20 and R033) families o f mspl and 2 msp2 (FC27 and 3D7/IC) as defined by 
the sequence o f the repeat units.
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5.2 Materials and methods
5.2.1 Study site and population
5.2.1.1 Endemic areas
Tiwi, Mwea and Kendu Bay areas were the chosen endemic sites (see 
Chapter 2 for details on sites and patients description). These sites differ in malaria 
transmission intensities and endemicity. Tiwi is hyperendemic, Mwea is 
mesoendemic and Kendu Bay is holoendemic.
5.2.1.2 Epidemic sites
The epidemic sites include Mosoriot, Mt. Elgon, Kisii and Chogoria where 
malaria outbreaks were experienced.
5.2.2 Sample collection and DNA preparation
Blood sample obtained from each patient was blotted onto 25mm diameter 
glass fibre membrane, GFM (Titertek), (Warhurst et al., 1991), see 5.2.1.1 for 
detailed protocol on sample/DNA preparation.
5.2.3 Polymerase chain reaction
The PCR was nested as described by Snounou el al., (1999). See Table
5.2.3 for primer sequences.
Nest I reaction
A single-tube reaction using each of the three sets o f  nest I primers, (Ml- 
OF/M1 -OR; M2-OF/M2-OR; G-OF/G-OR) and containing a sector of the prepared 
GFM was used in a 50pl reaction volume. The reaction mixture consisted o f standard 
PCR buffer [1.5mM MgCl2. 50mM KC1, lOmM Tris HC1 (pH 8.3), 0.1% Triton X- 
100 [Bioline]), 125nM of each primer, 125pM of each dNTP (Pharmacia Biotech), 
and 1U of Taq polymerase (Bioline). The reaction mixture was overlaid with mineral 
oil. The PCR was allowed to run as follows: an initial denaturation o f 5 minutes (min) 
at 95°C, followed by 25 cycles of annealing [58°C for 2 min for glurp-, 61°C for mspl, 
msp2]\ extension 72°C for 2 min, and denaturation 94HC for 1 min. A final extension 
cycle of 72°C for 5 min was included.
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Nest II reaction
To analyse for each individual polymorphic gene, 6 separate nest II reactions 
were performed. One pi of the nest I product was used as template in nest II 
reaction. The final volume of the reaction was 20pl. Reaction mixture contained 2pl 
standard PCR buffer (1.5 mM MgCl2.50 mM KC1, 10 mM Tris HC1 [pH8.3], 0.1% 
Triton X-100), 250nM of each primer, dNTPs 125pM each dNTP, and 1.0U 
AmpliTaq Polymerase (Perkin Elmer Cetus, USA). The PCR assays were carried 
out in thermal cycler (Perkin Elmer Cetus, USA, [in Kenya] and Hybaid, 
Teddington, Mdx, UK [whilst in London School], with the following conditions: 
PCR was allowed to run as follows: an initial denaturation of 5 minutes (min) at 
95°C, followed by 30 cycles of annealing [58°C for 2 min for glurp; 61°C for mspl, 
msp2]; extension 72°C for 2 min, and denaturation 94°C for 1 min. A final extension 
cycle of 72°C for 5 min.
Controls
Standard laboratory lines o f P. falciparum were used as positive controls in 
all the reactions. For the KI allelic family of mspl, the laboratory strains Kl, T9/96 
from Thailand and 3D7 (unknown origin) were used as positive controls. MAD20 
(New Guinean laboratory clone) and R033 originally isolated in Ghana, strains 
[courtesy Ali Alluoeche] were used as positive controls for MAD20 and R033 mspl- 
allelic family. Positive controls for msp2-¥C21 and IC allelic family employed use of 
Kl and T9/96 or 3D7 strains, respectively. For glurp reactions the Kl was used as the 
positive control although any laboratory strain could be used. Negative control 
involved PCR reactions with no template DNA.
5.2.4 Electrophoresis and analysis
M spl and glurp band sizes were resolved in gels containing 1.75% Ultra pure 
agarose (Gibco) and 0.75% NuSieve“" GTG agarose (FlowGen, UK) in TBE buffer 
(0.1M Tris base, 0.1M Boric acid, 50mM EDTA [pH 8.0]) or TAE (40mM Tris 
acetate, ImM EDTA). A 1.5% ultra pure agarose and 0.5% NuSieve® GTG agarose 
were used for separating products o f msp2 and glurp genes. Gels with mspl and msp2 
products were run for 1.5 hours while glurp products were run for 2 hours, at a
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constant voltage of 100V. A lOObp-ladder (Pharmacia Biotech) was used as the 
molecular size marker. Gels were stained with ethidium bromide in TAE buffer and 
results visualized and photographed on an ultra-violet UV transilluminator 
(312nm) using a gel documentation system, “GRAB1T”.
Table 5.2.3 Primer sequences for mspl, msp2 and glurp genes
Nest I
Gene
glurp
Primer sequence Sequence (S’—>3’)
G-OF(fwd) TGAATTTGAAGATGTTCACACTGAAC
G-OR(rev) GTGG AATTGCTTTTTCTTCAACACT AA
mspl Ml-OF(fwd) CTAGAAGCTTTAGAAGATGCAGTATTG
Ml-OR(rev) CTT AAAT AGT ATTCTAATTCAAGTGG ATCA
msp2 M2-OF(fwd) ATGAAGGTAATTAAAACATTGTCTATTATA
M2-OR(rev) CTTTGTT ACCATCGGT ACATTCTT
Allele
Nest II glurpll G-NF (fwd) TGTTCACACTG A ACAATT AG ATTT AGATCA
G-OR(rev) GTGGAATTGCTTTTTCTTCAACACT AA
mspl (Kl)
Ml-KF(fw) AAATGAAGAAGAAATTACTACAAAAGGTGC
MI-KR(rev) GCTTGCATCAGCTGGAGGGCTTGCACCAGA
mspl (MAD20)
Ml-MF(fwd) A AATG AAGG A ACA AGTGG AACAGCTGTT AC
Ml-MR(rev) ATCTG AAGG ATTTGT ACGTCTTG AATT ACC
m spl (R033)
Ml-RF(fwd) T AA AGG ATGG AGCAAAT ACTCAAGTTGTTG
Ml-RR(rev) CATCTGAAGGATTTGCAGCACCTGGAGATC
msp2 (IC/3D7)
M2-ICF(fwd AG AAGT ATGGCAG A A AGT A AKCCTY CT ACT
MI-ICR(rev) G ATTGT A ATTCGGGGG ATT AGTTTGTTG
msp2 (FC27)
M2-FCF(fwd) A AT ACT AAG AGTGT AAGGTGCARATGCTCCA
M2-FCR(rev) TTTT ATTTGGTG ATTGAGAATTG AA
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5.2.5 Statistical analysis
This was calculated for each typing reaction, msp-1, msp-2 and glurp 
(Chogoria) and msp2 (in other sites). Relative sizes of the amplified DNA from the 
test samples were determined from a regression equation relating logarithm of size 
of the markers to distance moved in millimetres. Overall frequencies were 
calculated as a ratio of samples found to harbour a particular variant over the total 
number of samples collected in any one survey. The multiplicity of infection 
(MOI) [probable minimum number of clones represented] was calculated as the 
number o f distinct fragments per PCR positive sample (Beck et al, 1997).
197
5.3 Results
The nest II primer sequences were designed to amplify and produce a 
single fragment per allele. The presence o f more than one band was therefore 
indicative o f multiple alleles. The 3 polymorphic markers were used on samples 
from Chogoria. However, only msp2 marker was used on samples from Tiwi, 
Mwea and Kendu Bay, Mosoriot, Mt. Elgon and Kish sites. The success rate for 
samples genotyped from each site is shown in Table 5.3.
5.3.1 Endemic
Tiwi (1997)
In the 37 Tiwi samples examined, there were 7 and 6 types of IC and FC 
alleles of msp2 respectively. Of 37 sampled infections 6 isolates were clonal 
infections with either IC or FC msp2 allele (MOI=l). For mixed infections 
(defined as infections containing more than one clone) the range o f MOI was 
between 2 and 4 (mean=2.35; standard deviation SD=0.797), observed in 31 
isolates.
Kendu Bay (1999)
Eleven types of IC and 6 types of FC were seen in 31 samples from Kendu 
Bay. Seven isolates out of these 31 samples were clonal infections (MOI=l) of IC 
or FC msp2 allele. The MOI in the remaining 24 mixed infections was between 3 
and 4 (mean=3.51; SD=0.510).
Mwea (1997)
Genotyping of 28 isolates from Mwea revealed 7 types of IC and 6 types of 
FC. Seven out o f 28 infections were clonal (MOI=l). The range of multiplicity in 
21 mixed infections was between 3 and 4 clones (mean=3.37; SD=0.497).
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5.3.2 Epidemic
Mosoriot
In the 20 Mosoriot samples examined, there were 3 and 5 types o f IC and 
FC alleles o f msp2 respectively. Similarly, 5 out of these 20 were assessed as 
clonal infections (MOI=l) and for the remaining 15 mixed isolates, the range of 
multiplicity was found to be between 2 and 3 clones (mean=2.53; SD=0.516).
Mt. Elgon
In the Mt. Elgon region, 30 samples were genotyped and of these, 4 and 3 
types were o f IC and FC msp2 allele respectively. Seven out of the 30 samples 
were clonal infections (MOI=l). MOI in the remaining 23 mixed infections was 
between 1 and 2 clones (mean=1.53; SD=0.510).
Kisii
A total of 36 isolates were examined for parasite diversity in the msp2 
locus. The results showed 8 and 5 types to be IC and FC msp2 allele respectively. 
Nine out o f 36 infections were clonal infections MOI=l. The MOI was calculated 
to be between 1 and 2 (mean=1.38; SD=0.492) in the remaining 27 mixed 
infections.
Overall, the frequencies of the different allelic families of msp2 were not 
seen to vary appreciably between 2 epidemic sites of Mosoriot [2-4 genotypes per 
infection] and Chogoria [3-4 genotypes per infection] (see section 5.3.3) and 3 
endemic sites of Kendu Bay, Mwea and Tiwi [2-4 genotypes per infection] 
(P=0.482, students /-test). However, there was significant difference between the 
endemic sites [2-4 genotypes per infection] and the 2 epidemic sites o f Kisii and 
Mt. Elgon [1-2 genotypes per infection] (P<0.001, /-test).
In summary, overall analysis o f  DNA from isolates tested from malaria 
endemic and epidemic sites indicates the presence of more than one clone in the 
majority of samples.
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5.3.3 Mspl, msp2 and glurp II  markers in Chogoria
The allelic families of the msp-l (Kl, MAD20, R033), nisp2 (IC, FC) and 
glurp fragments were substantially diverse, see Figure 5.3.3 (a to 0- The prevalence 
of each allelic family was estimated by calculating the percentage of fragments 
assigned to one family by PCR with family-specific primers within the overall 
number of fragments detected for that locus in the group considered.
All the distinguishable allelic variants for each marker were marked 
numerically starting with the largest in size; 7 for glurp (PCR product size range 
700bp-1300 bp), 12 for msp2 (comprising 4 FC27-type variants (PCR product size 
range 300 bp-400 bp) and 8 3D7-IC-type variants (PCR product size range 480 bp- 
690 bp), and finally 14 variants for mspl with 10 Kl-type variants (PCR product 
size range 200 bp-330 bp) and 3 MAD20-type variants (PCR product size range 
230 bp-210 bp) and only 1 RÜ33 allelic variants o f 160 bp, see Figure 5.3.3.
A minimum number of intra-allele size-variant antigens was detected. This 
was 14 in msp-l block 2, 12 in msp-2 block 3 and 7 in the glurp II fragment. For the 
multiplicity of infection per individual sample, the minimum and maximum number 
of clones detected was 3 and 4 respectively (mean=3.12). Furthermore, since most 
isolates contained multiple genotypes, it was impossible to determine in which 
specific combination these alleles occurred in individual parasites. See Figure 
5.3.4a-b for a representation of field isolates.
Frequency calculations (explained in materials and methods) for each 
variant of a particular marker family was done, see Figure 5.3.3. Of the mspl K l- 
allele, the most frequent fragment was 250bp (25%); MAD20 220bp (21%); R033 
160bp (50%). For msp2 FC allele, 320bp (17%) was most frequent and of the 
msp2-IC type a 500bp fragment (33%). In the case of glurpll fragments, the 900bp 
was most prevalent, (33%).
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Table 5.3. Comparisons of observed variation of msp2 among individuals living in 
areas with different levels of malaria endemicity.
Malaria Area n n![%| Mean
(MOI)
Multiple 
Infection (%)
Holoendemic Tiwi 38 38[ 100] 2.35 84*
Holoendemic Kendu
Bay 30 30[100] 3.51 76*
Mesoendemic Mwea 40 28[70] 3.37 69*
Mean 3.08
Epidemic Mosoriot 20 20[95] 2.53 55*
•• Mt. Elgon 30 30[ 100] 1.53 58*
“ Kish 36 32[89] 1.38 56*
Chogoria 24 24[100] 3.12 64**
Mean 2.91
Key:
* = % of multiple infection from uncomplicated malaria (harbouring 2 clones 
[in epidemic areas] and [3 clones in endemic areas])
** = severe [complicated] malaria [harbouring 3 clones in epidemic Chogoria]. 
! = Number of samples successfully genotyped 
MOI = Multiplicity o f infection
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Table 5.3.1.2 Variable sequence of msp-2 in Plasmodium falciparum field 
Isolates from malaria endemic and epidemic areas.
Site Number
of
isolates
Variable
sequence
Allele Intra-allele 
size variant*
Minimum 
number of 
variants*
Endemic
38 490-680 IC 7• Tiwi 300-390 FC 6 13
28 510-670 IC 7• Mwea 310-360 FC 6 13
31 470-700 IC 11
• Rendu Bay 290-410 FC 6 17
Epidemic
510-660 1C 3• Mosoriot 20 270-390 FC 5 8
490-680 IC 4
• Mt. Elgon 30 310-390 FC 3 7
520-670 IC 8
• Risii 36 320-380 FC 5 13
480-690 IC 8
• Chogoria 24 300-400 FC 4 12
Note: * = the total number of the IC/ FC sequence by size (bp) observed in total 
isolates examined per site.
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and msp2 alleles frequency of sample from epidemic 
C'hogoria.
Figure 5.3.3 A com parative graphical representation of plurp, m spl
a  glurp
F ragmant stza (bp)
e. m spl - Kl
Fragment aiza (bp)
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Table 5.4: Msp2 profile of P. falciparum  in endemic /epidemic malarious 
countries
Country Malaria* No. of isolates msp2 % Author
Endemicity investigated IC FC Multiple
Infections
Brazil Meso- 20 “ “ 30 Creasy et al., 
1990
Thailand Hypo- 56 51.8 48.2 70.4 Paul et al., 1998
Sudan Meso- 40 55 45 - Babiker et al., 
1995
PNG Hyper- 116-221 53 47 72 Paul et al., 1995
Senegal
Kenya:
Holo- 135 52** 41** 93 Konate et al.. 
1999
Kilifi Hyper- 42 50 50 71 Kyes et al., 1997
Sokoke “ 95 50 50 69 “
Mwea Meso- 28 54 46 69 This study
Tiwi Hyper- 38 54 46 84 This study
Kendu Bay Holo- 31 65 35 76 This study
Mosoriot Epi- 20 38 62 55 This study
Mt. Elgon Epi- 30 57 43 58 This study
Kisii Epi- 36 62 38 56 This study
Chogoria Epi 24 67 33 64 (This study; 
Omar et a! 
2001b)
* = Different malaria transmission intensities
** = 7% were IC/FC hybrids, [Konate el al.. 1999]
Hybrid = parasite carrying neither IC or FC allele but has a propotion of sequence from 
both alleles due to recombination
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F ig u r e  5 .3 .4  P a r a s ite  d iv e r s ity  in  Plasmodium fa lciparum
Figure 5.3.4a mspl-K.1
P. falciparum field isolates
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 C
Figure 5.3.4b msp2-FC
P. falciparum  field isolates
M 2 3 4 5 6 7 8  9 10 11 12 c
~350bp
The diversity of P. falciparum was demonstrated through amplification of the 
polymorphic regions of the 3 genetic markers glurp, mspl and msp2 (Snounou et 
al., 1999). The PCR primers used produce one single PCR fragment per allele, 
hence detection of more than one-sized band in the gel indicated the presence of 
more than one allele in that isolate. The detection of different sized bands 
indicated diverse strains of P. falciparum. A representative o f field isolates 
showing the nested-PCR products is shown in figure 5.3.4a (m spJ-K \) and figure 
5.3.4b (msp2-FC). The predominant pattern corresponds to 230bp/ K1 family for 
mspl [Figure 5.3.4a] whereas the predominant 350bp fragment of the FC family 
for msp2 [Figure 5.3.4b].
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Transmission intensity o f malaria depends, in addition to climatic factors, 
on the density and infectivity of the anopheline vector and on variation in parasite 
rate in the human host (Babiker et al., 1997). In highly endemic areas, stable 
parasite rates are usually seen all year round. This is observed despite seasonal 
fluctuations in mosquito densities and entomologic inoculation rates (EIR) (Smith 
et al., 1993). In contrast in areas o f low endemicity the prevalence o f  infection may 
be sensitive to changes in transmission intensity, for example due to rainfall 
variation that causes changes in mosquito density to occur (Babiker et al., 1997). 
Difference in transmission intensities between endemic regions has been 
implicated as one of the factors leading to geographical variation and parasite 
diversity (Creasy et al., 1990; Paul et al., 1995; Babiker and Walliker, 1997). A 
number of studies have suggested a positive correlation between the mean number 
of genotypes per infected person and transmission intensities (Babiker et al., 1997; 
Paul et al.. 1995; Babiker and Walliker, 1997). Multiple parasite genotypes have 
frequently been observed in individuals living in endemic areas, for example 
multiclonal infections were apparent in 83% of the samples analysed in a study 
carried out in Zimbabwe (Creasy et al., 1990). Similarly, 82% o f  samples from 
Senegal carried more than one clone (Ntoumi et al., 1995). Another study 
conducted by Babiker and Walliker, (1997) and carried out in Michenga village in 
Tanzania, (where malaria is holoendemic) and in Asar village in Sudan (where 
malaria is mesoendemic), indicated that the number of alleles of m spl and msp2 
genes was much greater in Michenga than in Asar. Furthermore, studies from 
hypo-endemic and seasonal malaria areas have shown higher than expected levels 
of P. falciparum  parasite diversity, (Babiker et al., 1991; Paul et al., 1998).
Results from Kenyan endemic and epidemic sites described in this chapter 
indicated presence o f multiple genotypes in 7 sites o f differing malaria 
transmission intensities, 4 epidemic and 3 endemic. Results from 2 epidemic sites, 
Mt. Elgon and Kisii show that the P. falciparum genotype number per infected 
host is an average between 1 and 2 clones, showing significant difference between 
these 2 epidemic sites and endemic sites of Mwea, Tiwi and Kendu Bay (P=0.03) 
where an average of 2 to 4 genotypes was observed. In contrast, an average of 2 to
5 .4  D isc u ss io n
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4, and 3 to 4 genotypes per infected human host, was observed in the epidemic 
sites of Mosoriot and Chogoria, respectively, with no significant difference (P=0.5) 
with the endemic sites.
The msp2 profile of the samples examined in this study resembled those of 
other African countries (Babiker et al., 1995; Konate et al., 1999) suggesting a 
similar pattern of diversity.
Polyclonality and extensive diversity as seen in endemic infections were 
not expected in epidemic outbreaks [see Table, 5.3.1.2]. Genetic diversity could be 
expected to correlate with transmission intensity [see Table 5.4], because human 
superinfection would result in superimposition of genotypes carried by different 
vector mosquitoes (Babiker et al., 1995). The reduced parasite diversity in 
Mt.Elgon and Kisii highlands is similar to the limited diversity in the Amazonian 
region of Venezuela (Laserson et al., 1999) and supports this contention. These 
observations contrast with epidemic outbreaks in Mosoriot and Chogoria 
(P<0.001), Table 5.4. The extensive diversity seen in the epidemic regions of 
Chogoria and Mosoriot may not be surprising in view of the fact that these areas 
are bordered by endemic lowlands. Here the outbreaks could be due to parasite 
transfer from the surrounding endemic areas. Population movement between 
epidemic and endemic areas is likely to be a major vehicle for the spread of diverse 
parasite strains. The transfer o f infective anopheline mosquitos could also be 
involved, carrying different parasite lines.
Linkage analysis of the parasite phenotype and allelic variants of markers 
(m spl, msp2, glurp) in the epidemic site o f Chogoria was not possible due to 
polyclonality. The analysis would have investigated the association of severe 
malarial infection and multi-drug resistance with genetic diversity o f the markers 
studied (see chapter 4 I-II).
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CHAPTER 6
Detection and Quantification of P. falciparum  in blood samples 
using nucleic acid sequence based amplification
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Widespread resistance of P. falciparum against standard antimalarial drugs 
such as chloroquine and Fansidar is leading to increased morbidity and mortality. 
As well as a need for better techniques to diagnose the infection, there is a need for 
reliable molecular methods to monitor drug therapy following treatment. Efforts 
currently focus on the detection of drug resistant determinants and of their 
association with treatment failure. This places great reliance on the accurate 
determination of treatment failure especially on the detection of persistent 
infections following drug therapy.
The availability of a fast, sensitive, reliable and quantitative method for the 
detection o f parasite survival during and after drug treatment will help clinicians to 
monitor and, if necessary, adjust the treatment regimen. The detection and 
identification of specific nucleic acids present at very low levels, have been greatly 
facilitated by the development of in vitro target amplification techniques that 
exploit the enzyme-mediated processes of DNA replication (Mullis and Faloona, 
1987), DNA ligation (Wu and Wallace, 1989; Barany, 1991). The main objective 
of this study was the evaluation and further development of a quantitative nucleic 
acid sequence based amplification (QT-NASBA) assay for the detection and 
quantification of P. falciparum RNA in blood samples from malaria patients for 
monitoring viable parasite persistence following treatment, (defined by 
recrudescing parasitaemia). In this chapter, the QT-NASBA was put into use and 
evaluated. The second phase involving antimalarial drug treatment efficacy studies 
is currently underway.
This work was performed in collaboration with Biomedical Research 
Centre o f the Royal Tropical Institute (The KIT), in Netherlands (Appendix K). 
The field component involving sample collection from patients was conducted in 
Kenya, (see chapter 2 on in vivo aspect of the study) and the NASBA study was 
performed at The KIT.
6.1 In tro d u ctio n
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6.1.1 Description of Nucleic acid sequence based amplification NASBA
The invention of polymerase chain reaction PCR has revolutionized the 
ability to amplify and manipulate nucleic acid sequence in vitro (Mullis, et a i, 
1986). The commercial rewards of PCR technology has driven the development of 
other nucleic acid amplification and detection methodologies and one of these 
technologies is nucleic acid sequence based amplification NASBA. The company 
Organon Teknika is the inventor of the NASBA technology.
NASBA technique amplifies a target nucleic acid sequence, amplifying 
RNA in the presence of homologous genomic DNA, under isothermal conditions. 
Detection and amplification of RNA target sequences means therefore, NASBA, 
almost invariably measures persistence o f  living organisms, because o f the 
unstable characteristics of RNA. It can also be applied to studies of gene 
expression where required. Smits et al. (1997) previously described the 
development of a qualitative and semi-quantitative NASBA assay for the detection 
and semi-quantification of P. falciparum and in this study further development of 
this qualitative NASBA into a quantitative NASBA is continued.
6.1.1.1 IN ASBA amplification process
NASBA operates under isothermal conditions (i.e., without temperature 
cycling) making it suitable for large scale manual screening. The amplification 
procedure employs reverse transcriptase (RT), RNAse H, and T7 RNA 
polymerase, in concert with two primers, to produce an isothermal amplification 
process, (Sooknanan and Malek, 1995) (see Figure 6.1.1.1). Initially a single 
stranded RNA (referred here as RNA analyte and denoted as RNA(+)) anneals to 
primer 1 (PI) which has a 5’ T7 promoter tail. This step is followed by extension 
of PI with RT to synthesize a single copy o f  cDNA. The RNA of the RNA-cDNA 
hybrid is then degraded by RNAse H to allow  primer 2 (P2) to anneal to the single- 
stranded cDNA [DNA (-)]. P2 is then extended with RT to form a double stranded 
DNA consisting o f a template for transcription and a T7 promoter. T7 RNA
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polymerase then initiates transcription and generates multiple copies of antisense 
RNA product [RNA (-)], which terminates at the 5’ end of P2.
In the subsequent stage each newly synthesized RNA(-) product then 
anneals to a P2 primer from which a DNA product is synthesized with RT. The 
RNA strand of the resulting RNA:DNA hybrid is degraded by RNAse H to allow 
PI to anneal to the 3’-end of the DNA product [DNA (+)]. The DNA product is 
extended with RT, using PI as the primer, to form a double-stranded DNA 
template with T7 promoter. The resulting DNA product directs the synthesis of 
many copies of RNA product [RNA (-)] by T7 RNA polymerase. Each newly 
transcribed RNA product [RNA (-)] can again be used as a template for synthesis 
of a DNA product [DNA (+)], which, in turn, can be used as a template to 
synthesize more of the RNA product [RNA (-)]. The continuous self-perpetuating, 
repetition of this process results in the exponential amplification of RNA and 
intermediate DNA products, which can be in excess of 1-trillionfold within 90 
minutes, (Sooknanan and Malek, 1995). In addition, DNA template can be used in 
the NASBA reaction following a pre-treatment step of primer annealing, extension 
and denaturation. For schematic representation, see Figure 6.1.1.1.
Quantitation of template RNA or DNA, is a useful procedure in many 
biological fields, including virology. Indeed, the availability o f reliable techniques 
for the absolute quantitation of DNA and RNA species may be the key to a better 
understanding of the pathogenic steps of most viral or parasitic diseases and for a 
more precise monitoring of patients treated with specific antiviral or antiparasitic 
compounds.
211
Figure 6.1.1.1 Schematic representation o f  Nucleic acid sequence based amplification 
NASBA (adapted from Sooknanan and Malek. 1995).
Key:
PI primer 1 incorporating T7 promoter
P2 primer 2
RT: Reverse Transcriptase
17 RNA pol: T7 RNA polymerase (requires 17 promoter sequence on I)NA) 
RNA-ase H breaks down SSRNA strand when bound to c-DNA product 
* start of reaction
double stranded DNA can be used in NASBA reaction following a
pre-treatment step.
212
6.2 Materials and methods
6.2.1 Sample collection and storage
Blood samples were collected from malaria patients visiting two health 
centers, Oyugis Bay (60) and Kendu Bay (60) in Kenya, located in an area where 
malaria is holoendemic. Fifty pi of EDTA blood was mixed with 950 pi o f 
guanidinium isothiocyanate (GuSCN) L6 lysis buffer and stored at -70°C until 
processed for RNA isolation. At the same time thick blood films were prepared 
from these blood samples for counting the parasites microscopically.
Lysis buffer (L6) was made by dissolving 120 g of GuSCN in 100 ml 0.1 
M Tris-HCl pH 6.4 after which 22 ml 0.2 M EDTA pH 8.0 and 2.6 g Triton X-100 
were added (Boom et al., 1990).
6.2.2 Microscopy
The microscopic examination of thick blood smears was used as ‘gold 
standard’ for comparison with the quantification of parasites in the QT-NASBA. 
Thick blood films were stained with Giemsa and microscopically examined. 
Parasites and white blood cells were counted to a total of 200 white blood cells. 
The number of parasites/ pi of blood was calculated assuming that there are 8,000 
white blood cells per pi blood.
6.2.3 Cloning and production of in vitro RNA for standards
Primers Plas-IF (5’ TC AG AT ACCGTCGT AATCTT A 3’) and Plas-2R (5’ 
AACTTTCTCG CTT GCGCGAA 3’) were used to amplify by PCR a 170 base 
pairs (bp) region of the P. falciparum asexual phase 18S rRNA gene. The amplified 
fragment was cloned into the plasmid pCR2.1-TOPO (Invitrogen, Carlsbad, CA) and 
large quantities of in vitro RNA were produced using the SP6/T7 transcription 
system (Boehringer, Mannheim, Germany).
6.2.4 Site-directed mutagenesis for quantitation standard
In order to quantify the number of parasites in the blood samples by QT- 
NASBA, an internal standard RNA was co-amplified as a competitor using the 
same amplification primers as the wild type RNA (WT-RNA). For this construct.
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20 bases in the centre of the WT target sequence were randomly rearranged using a 
specialized computer program. The resulting sequence was checked by computer 
analysis for the presence of secondary structures and possible homology with the 
original 170bp sequence. Next, the modified sequence was constructed using site 
directed mutagenesis (Ciceron et al., 1999) and cloned into plasmid pCR2.1- 
TOPO. In vitro RNA was transcribed as described above. This modified in vitro 
RNA is referred to as “quantification RNA” (Q-RNA). For the quantification of in 
vitro WT-RNA, 10h molecules o f in vitro Q-RNA were added to each 50pl sample; 
for the quantification of parasites in patient blood, 107 molecules o f  in vitro Q- 
RNA were added to each 50pl sample.
6.2.5 Nucleic acid isolation
To verify if the limit of parasite detection by the QT-NASBA is below 40 
parasites/pl of blood detected by microscopy, 108 parasites/ml (105 parasites/pl of 
blood) was diluted down to 101 parasites/pl of blood, using in vitro culture as 
parasite source. These were used as controls (standard). Each control was 
individually spiked with 10h molecules of in vitro Q-RNA as competitor (note that 
pilot studies indicated that 10h Q-RNA molecules are the optimal amount that 
could be quantitatively measured, hence this amount was used to spike the 
controls). Similarly, all samples to be examined were spiked with this amount of 
Q-RNA. Nucleic acid from both samples and controls was isolated using GuSCN- 
silica procedure described by Boom et al., (1990). Briefly each sample/control was 
mixed with L6 lysis buffer (see 6.2.1) and activated silica (30pl) was added to bind 
nucleic acid [activated silica was prepared as follows; 60g silica particles (SIGMA, 
S5631) was suspended in a total volume of 500 ml H2 O. The particles were left to 
sediment for 24 hours. After removal o f 430 ml of the supernatant, another 500 ml 
of double distilled water was added. Upon sedimentation 440 ml of the supernatant 
was removed. Finally, 600 ul 32% HC1 was added and the silica was suspended 
and dispensed in 4 ml portion and autoclaved to destroy contaminating nucleic 
acids].
The nucleic acid-silica complex was then washed twice with wash buffer 
(10 M GuSCN, 100 mM Tris-HCI, pH 6.4), and then once with 70% ethanol and
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finally washed once with 30pl of acetone. Then nucleic acid was eluted from the 
silica into lOOpl o f double distilled water. This thus contained both Q-RNA and 
parasite [WT] RNA.
6.2.6 QT-NASBA
Primers and probes were selected based upon published sequences of the 
18S rRNA genes of P. falciparum (McCutchan et at., 1988). For the NASBA, 
primers Plas-IF (5’ TCAGATACCGTCGTAATCTTA 3’) and Plas-2R T7 
(5 ’ AATTCT A AT ACG ACTC ACT ATAGGG AG AG A ACTTTCTCGCTTGCGC 
GAA 3’) were used. RNA from P. falciparum, P. malariae, P. vivax and P. ovale 
are all amplified in the NASBA using these primers.
6.2.7 Detection
The NASBA amplification products were hybridized to a biotinylated 
capture probe (5’ACCATAAACTATGCCGACTAGG 3’) which was bound to 
streptavidin-coated magnetic beads. The samples were then separately hybridized 
to ruthenium-labeled WT- (5’ CCTT ATG AG A A ATC A A AGTC 3’) and Q- (5* 
AATAACTGCACCAGTGTATA 3’) -detection probes followed by 
electrochemiluminescence (ECL) detection. The light emitted by ruthenium is 
detected by a photoelectric cell, thus offering a precise measurement for 
quantification.
6.2.8 Calculations and statistical analysis
The ECL provided for each sample a WT-RNA and a Q-RNA signal generated 
from hybridization to the WT- and Q-detection probes, respectively. The WT-RNA 
signal is proportional to the number of parasites present in the sample, whereas the 
Q-RNA signal is inversely proportional. The WT-RNA signal was divided by the 
Q-RNA signal for the calculation of the number o f in vitro WT-RNA molecules 
per sample. Using linear regression, the raw data were then compared to the graph 
drawn from the values for the calibration series of blood samples containing 
known numbers o f parasites. Below are the calculation steps used in determining 
the unknown parasite density (count).
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1. The ECL signal was obtained for WT and Q RNA.
2. Then log)0 [WT-RNA signal/ Q-RNA signal] was calculated.
Parasite count for each sample was then obtained from the standard curve [y = a(x) 
+ b; y  = is the log|0 number of parasites, a = slope, x  = logio [WT-RNA signal/ Q- 
RNA signal], and b = intercept on the y-axis (e.g Fig. 6.3a).
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6.3 Results
6.3.1 Quantitative ribonucleic acid Q-RNA
The detection limits of in vitro WT- and Q- RNA with their homologous, 
ruthenium-labelled detection probes were determined. After amplification in the 
NASBA followed by ECL detection amounts as low as 200 copies of in vitro RNA 
per 2pl sample could be detected for both RNAs. No cross hybridization between 
the two probes and target RNAs could be observed. This made the in vitro Q-RNA 
ideally suited for use as competitor RNA since Q-RNA and WT-RNA were 
amplified with equal efficiency and did not mutually interfere.
6.3.2 Detection limit
Figure 6.3.a shows the relationship between the number of parasites present 
in the sample and the amount of RNA or number of parasites as calculated from 
the QT-NASBA results. Using a simple mathematical formula a wide range o f 
both in vitro RNA molecules and parasite numbers can be accurately quantified. 
Two hundred up to 108 molecules of in vitro RNA can be detected in a 2pl o f 
sample. However, the control quantitation was carried out on parasitised cells in 
culture and thus does not entirely reflect conditions using actual patient samples, 
which usually have a restricted parasite stage representation with mainly small ring 
stages.
6.3.3 Reproducibility
RNA isolates from thirty different individual blood samples from cultures 
were tested in the QT-NASBA on 2 different days. Analysis o f these data shows a 
high reproducibility. No significant day-to-day variation could be observed. When 
duplicate blood samples from the same patient were tested, only 1 out of 15 
samples showed a more-than-tenfold (14-fold) difference between duplicate 
samples, whereas all other samples showed a less-than-tenfold difference.
6.3.4 Comparison with microscopy
Comparison of the microscopy count obtained by examination of thick 
blood smears with the results obtained with the QT-NASBA on 120 blood samples
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from patients with clinical malaria revealed in 112/120 cases (93%) a less-than- 
tenfold difference between the results obtained with both methods, see Figure 
6.3.b. The detection limit of infected patient blood by the QT-NASBA, was <10 
parasites/ pi of blood. The differences for the other 8 samples were a factor 1 l(2x), 
12 (3x), 34(lx), 100(lx) and 166(lx). Fifteen samples had a relatively low (less 
than 500 parasites/pl) parasitaemia. Four out o f seven samples with a higher-than- 
tenfold difference between microscopy and QT-NASBA belonged to this group of 
samples from patients with a low parasitaemia. Four blood samples that were 
negative by microscopy showed low parasite numbers (0.01, 0.2, 1.1 and 1.2 
parasites/ pi blood) when tested in the QT-NASBA.
Figure 6.3a Graphical representation showing log values of the ECL signal 
against standard (cultured) parasite count (antilog value gives 
true parasite count).
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Figure 6.3b Comparison between field (microscopy 
count) and QT-NASBA
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6.4 Discussion
Microscopic examination of Giemsa stained thick blood films is for many 
good reasons still the most widespread method for the diagnosis of malaria (Kain 
et al., 1994). The method is cheap, relatively fast and allows species identification 
as well as quantification of parasites. However, for non-immune individuals such 
as small children and for pregnant mothers a detection threshold which is as low as 
possible is desirable. Especially in the early stages o f malaria, when patients have a 
low parasite burden, the microscopic examination does not always fulfil this 
requirement. Early detection o f low viable parasite counts in treated persons would 
also be valuable for clinical evaluation o f drugs and, possibly, for following 
routine therapy.
Many alternative approaches for the diagnosis of malaria have been 
developed and applied, such as antigen detection tests, acridine orange (a 
fluorescent dye for staining parasite DNA/RNA) microscopy, PCR and serology, 
all with more or less success (Kain et al., 1994). The NASBA technique has 
proved to be a sensitive and specific assay in diagnostic microbiology. In addition, 
there is extensive evidence, especially from the field of virology, that NASBA can 
be used for the quantification o f infectious agents (Chan et al., 1999). Smits et al., 
(1997) previously described the development of a qualitative NASBA assay for the 
detection and semi-quantification of P. falciparum. The further development of 
this qualitative NASBA into a quantitative NASBA (QT-NASBA) makes use of 
modified Q-RNA which is added to each sample. The addition o f in vitro Q-RNA, 
which serves as a competitor, allows for the simple and reproducible quantification 
of parasites in a single tube assay.
The QT-NASBA, as observed in this study, allows for quantification of P. 
falciparum over a wide range o f parasitaemia (10 to 108 parasites per ml blood). 
The threshold of detection of 10 parasites per ml (0.01 parasites per pi) blood in 
cultured samples is at least 2,000 times more sensitive than routine microscopy, 
which has a detection limit of approximately 20 parasites per pi (Bruce Chwatt et 
al., 1984). The detection limit o f the QT-NASBA is < 1 Oparasites/ pi blood for 
patient blood. The results of routine microscopy and QT-NASBA gave an 
excellent correlation in 112/120 (93%) of the samples. However, parasite detection
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from patient samples of 40 parasites/ pi, (see figure 6.3.b) varied widely between 
10 to 103 parasites/pl blood when detection by QT-NASBA was employed. Only 8 
out of 120 blood samples from patients with clinical malaria showed a discrepancy 
between microscopy count and QT-NASBA of more than a factor 10. Four of these 
eight samples were from patients with low parasitaemias. It is well known that the 
microscopy count is not very exact especially with respect to low parasitaemias 
(Carballo et al., 1996; Kain et al., 1994). In addition, QT-NASBA was capable of 
detecting low parasitaemias in four blood samples which were originally scored as 
“negative” by routine microscopy. Since all samples were from patients with 
clinical signs of malaria, this suggests that the QT-NASBA indeed has a lower 
threshold of detection than routine microscopy.
The QT-NASBA will in all probability not replace routine microscopy at 
high parasitaemias, especially in highly endemic areas where most clinical malaria 
cases have parasitaemias ranging between 1000 to 20,000 parasites per pi. In 
addition the QT-NASBA test is expensive, relative labour-intensive and requires a 
high level of expertise and a well-equipped laboratory. However, QT-NASBA, in 
contrast to routine microscopy, is excellently suited for detecting and quantifying 
low parasitaemias, making it a valuable tool for both the diagnosis of malaria in 
those patients who have low parasitaemias and for the monitoring of the efficacy 
of drugs or vaccines in clinical trials. The usefulness of QT-NASBA in 
antimalarial efficacy studies may be in the detection or quantification of low level 
parasitaemia in patients failing therapy.
The use of nucleic acid amplification techniques within the medical 
microbiology laboratory is becoming more and more accepted. The ability of PCR 
and NASBA assays to target and to amplify RNA specifically has led to several 
clinical applications. Some of these are already available in the form of 
commercial kits. NASBA technology has been adapted for application in routine 
diagnostic setting with a wide range of application in diagnosis of pathogens. 
NASBA’s in vitro application has enabled the detection and quantitation of vimses 
such as Human Immunodeficiency virus (HIV) with a high degree of sensitivity, 
(van Gemen, et al., 1993; van Gemen et al., 1994). Quantification of vimses is 
useful in obtaining information about prognosis of patients and monitoring of
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antiviral therapy. Other applications that have been described are the development 
of an assay for the bacterial pathogen responsible for tuberculosis, and a genetic 
aberration leading to cancer, (Sooknanan et al., 1993). Clinical utility and 
relevance o f these assays has been reported, though in some studies these 
techniques are limited because of poor reproducibility, especially for low copy 
numbers and unequal amplification dynamics for different genotypes, (Bremer et 
al., 2000; Schmitt, 2001). Other studies have confirmed reproducible and sensitive 
performance of NASBA (Witt et al., 2000; Loeffler et al., 2001; Simpkins et al., 
2000).
Each of these areas of clinical application employing the use of self- 
sustained sequence replication reaction systems, ideally requires absolute rather 
than relative quantitation. To achieve these requirements critical challenges 
including determination of reaction conditions, control of potential carryover 
contamination, and simplification of the detection systems are important and 
require standardization in order to improve the reliability of quantitative assays.
2 2 3

Malaria treatment needs to be prompt, effective and affordable. The 
situation in Kenya demands critical evaluation of the standard antimalarial drugs in 
use.
Data presented in this thesis, from susceptibility studies indicated the 
presence of SP and CQ resistant P. falciparum  infections in vivo in 5 endemic 
sites. In Mwea, central Kenya, by 1997, parasitological failure rate was 37% to SP 
and 33% to CQ. Similarly, in Busia, western Kenya, parasitological failure rate to 
SP was 18% by 1998; whereas in Oyugis (1998) and Kendu Bay (1999) southwest, 
SP parasitological failure rate was 13% and 19%, respectively. In the coastal 
region of Tiwi, SP parasitological failure was 18% by 1998. Results from other 
malarious areas o f Kenya have shown similar failure rates for the antifolates. For 
instance van Dillen el al., (1999) reported parasitological failure rates of 9.5% and 
34.5% to SP by 1993, in northern and western Kenya, respectively.
SP resistance in epidemic sites in Kenya varied from 11% in Kisii to 48% 
in Mosoriot. Indeed in the recent past, morbidity and mortality is rising. Over 300 
fatal cases were recorded during the epidemic outbreak in Rift Valley in 1997 
(unpublished observations).
Antimalarial drugs play an exceedingly important role in preventing and 
interrupting transmission, (Garfield and Vermund, 1983). Antimalarial drug 
prophylaxis offered in populations residing in epidemic-prone areas of Kenya is 
important in curbing mortality and morbidity associated with the malarial disease 
but also raise concerns on emergence of drug resistance. This could perhaps partly 
explain the relatively high antimalarial drug resistance rates recently observed in 
the Kenyan Highlands, in this study [as observed in Chogoria, Kisii, Mt. Elgon, 
Mosoriot and elsewhere (Shanks et al., 2000)].
Influence of patient immunity clearly impacted on treatment outcome as 
seen from endemic and epidemic studies presented here. The influence o f host 
immunity in clearing resistant infections was found to be strongest in high 
transmission settings. Any immune response of the host, which in one way or 
another inhibits parasite growth or suppresses the development of clinical 
symptoms, will supplement the effects of the drug even if the parasite population is 
partially resistant. Semi-immunity develops with age within the first 5-15 years of
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life in areas with stable and intensive malaria transmission, (Gilles and Warrell, 
1993) thence the increased ability to clear resistant parasites will be a function of 
age. Findings from Tiwi (endemic) and Mosoriot (epidemic site), for instance 
emphasized that age o f  patient was an important and independent predictor of 
treatment failure and that resistance in endemic areas will affect drug efficacy in 
young children and less-immune patient before it affects older patients.
Data in in vitro results presented here clearly show that the P. falciparum 
isolates tested from Kenya are resistant to CQ and also in many cases to SP; The 
observation that strains were sensitive to MQ and QN supports the use of QN in 
treatment of refractory cases. Sensitivity to MQ and QN would suggest that either 
of these drugs can be used in treating cases resistant to CQ, SP or AQ. At present, 
QN is reserved as third-line drug used particularly in the treatment o f severe 
malaria infection. MQ which is also effective against Kenyan P. falciparum is 
costly and may not be affordable by that proportion of Kenyans who need it most. 
Sensitivity studies on the current second line drug AQ were not performed in this 
work but reports from national surveys show high sensitivity o f more than 90% in 
Kenyan sentinel sites (Rapouda et al., 1997). This finding must be tempered by the 
reflection that the tests would have been better carried out using 
desethylamodiaquine, which is the active species present in the blood (Churchill et 
al.. 1986). However, in vivo studies done in 1993 by van Dillen et al., (1999) 
reported parasitological failure rates to AQ of 18.5% and 35.1% in northern and 
western Kenya, respectively.
It will be useful for Kenyan government, in the light of findings reported in 
this thesis, to speedily look for alternatives, possibly a combination or 
combinations of antimalarials. Such drug combinations should be assessed for 
efficacy against Kenyan isolates, and if effective should be reserved as “back-up” 
treatment regimen. Effective drug policy should be in place and antimalarial drug 
use, handling and outlets should be well controlled and monitored to avoid drug 
pressure and mis-use o f the drugs. Surveillance or drug efficacy monitoring, as has 
been practised in Kenya should continue, perhaps sentinel sites should be carefully 
chosen for greater representation and should include epidemic or highland areas.
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The resistance profile seen here is mirrored by the presence of resistance- 
associated mutations. Antifolate combinations of which Fansidar® (S/P) is the new 
first-line drug, are failing as observed in the study areas examined. This is 
consistent with other reports (Nzila et al., 2000). Characterisation of the isolates 
for dhfr/dhps mutations revealed a prevalence paralleling the observed in vivo/ in 
vitro resistance. This is a warning signal that this first-line drug may not last very 
long, stressing the urgent need to look for alternatives. Triple mutations in dhfr 
gene (dhfr51,59, l08) or quintuple mutations in dhfr/dhps (dhfr5,159,108dhps437/54°) are 
highly associated with Fansidar® resistance. This finding would suggest that 
Fansidar® resistance in Kenya is probably a function of both pyrimethamine and 
sulfadoxine resistance (Omar et al., 2001a). Further studies will confirm this 
observation. The antifolate combination co-trimoxazole was as effective in this 
study as Fansidar*. We are bound to suspect that resistance to both antifolate 
combinations has similar determinants. Although it is less easy to give co- 
trimoxazole treatment because its half-life is short, this feature means that 
"prophylactic" selection for resistance in new infections will not be as common as 
in Fansidar* (Mberu et al., 2000). Control of co-trimoxazole use is as important as 
control of the use o f Fansidar, but may be more difficult since the former drug 
combination is widely used in prophylaxis for opportunistic infections in AIDS. It 
would be ideal to control the use o f all drugs and attempt to avoid resistance 
development but this must be balanced by the need for ready access for life-saving 
purposes..
Results presented here on CQSP versus SP showed no significant 
difference in relation to haematocrit and parasite clearance between the two drugs, 
perhaps explained by the high (>60%) parasitological failure to CQ (MOH, 1997; 
Shretta et al., 2000). However, a clear improvement was observed in fever 
clearance times in CQPS treatment group suggesting an advantage over alternative 
antipyresis. Chloroquine in combination with SP, therefore, has obvious benefits 
but may not be a good option for routine therapy.
Fear of future development o f resistance to newly introduced antimalarial 
drugs should allow for caution when dictating drug policies and use patterns. Drug 
pressure is probably the leading factor in development of resistance, as soon as a
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drug becomes widely used, the parasite is placed under increasing selective 
pressure. Fear of resistance to potential alternative drugs leading to an endless 
cycle o f policy changes, each requiring the use o f  more expensive drugs, has 
produced an inertia or passivity, which has allowed, at least in part, continued use 
of ineffective treatment. Findings in this thesis may perhaps lead to reforms in 
strategies for the management of drug resistance. It may be advisable to 
discontinue the use o f drug early, when resistance is encountered in a parasite 
population, deviating from the current practice o f continuing to use the first line 
drug for as long as possible. A strategy of switching to alternative drugs earlier 
would almost certainly reduce the morbidity due to protracted infections during the 
development of drug resistance. More importantly, it might even improve the 
chances of being able to return to the use o f the first line drug at a later date 
(Thaithong et al., 1988), if  drug pressure is promptly withdrawn and the expansion 
of the resistant reservoir is arrested. In the Kenyan situation where CQ is no longer 
utilized as the first-line drug, monitoring the frequency of CQ drug resistant 
determinants on pfmdrl, and pfcrt will be important. Recent findings in Malawi 
suggest that mutant pfcrt is deleterious to the parasite, ie renders it unfit and the 
mutant diminishes in prevalence when CQ pressure is reduced, with a consequent 
rise in CQ efficacy (Kublin et al., unpublished observations) as also shown in 
Thailand (Thaithong et al., 1988). Perhaps, after proper and absolute withdrawal of 
CQ, it may be possible to re-introduce CQ in Kenya, maybe this time in 
combination with an “appropriate” antimalarial.
Measures have to be put in place to prolong the useful life of the new first 
and second line dmgs and postpone development o f  drug resistance in Kenya. This 
is particularly important in view of the fact that currently no new effective and 
cheap antimalarial drug is in the market for immediate use as a first line treatment. 
Such protection can be achieved by improving compliance with drug regimens, 
increasing malaria diagnostic capacities of health facilities and implementing strict 
guidelines for laboratory confirmation of suspected treatment failures wherever 
possible before a second line drug is given. The latter will be as important for the 
government health services as for the private sector. As seen in this study, home 
treatment by carers is a common practice as the urine study indicated. Certainly
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treatment initiated from home appears to be crucial in preventing the attainment of 
dangerous parasitaemic levels especially in the under 5 years who are mostly at 
risk o f severe complications. Home treatment is also encouraged due to the relative 
inaccessibility o f health care facilites. There are, however, potential problems with 
the diagnosis and administration of antimalarials at home. These include (1) 
under-dosage which may contribute to drug resistance, (2) danger of over-dosage 
especially in children, although this has been found to be uncommon in areas with 
a high rate o f self medication, (Deming et al., 1989). Early and appropriate 
treatment of malaria detected in children by carers (Hamel et al., 2001) will 
prevent complications that arise as a result of persistence of symptoms and 
attainment of high parasitaemic levels leading to severe malaria or anaemia. A 
strong and effective educational campaign will have to be instituted to address the 
problem of inadequate and inappropriate treatment especially for children. 
Increasing the carers' awareness of the signs and symptoms of simple and 
potentially life-threatening malaria and their appropriate management (Hamel, et 
al., 2001) might have the much needed impact in controlling malaria morbidity and 
mortality.
‘Parasite diversity was determined by use of molecular markers including 
m spl, 2 and glurpll genes. Allele of msp2 seen would suggest highly diverse 
isolates in both malaria endemic and epidemic regions. The diversity observed in 
the epidemic sites may be due to importation o f different parasite strains from the 
surrounding malaria endemic areas. These highland areas have fertile land and 
there is intensive agricultural activity that attract migrant workers. Therefore, 
parasite transfer from the surrounding malaria endemic areas is a possibility. Visits 
between lowland and highland areas could be a contributing factor. The high 
prevalence of the “mutated” dhfr, dhps, cg2, and pfm drlgenes, may be partly due 
to importation of diverse resistant strains to epidemic areas. Use of mosquito nets 
(treated/ untreated with insecticides) among highland dwellers should be 
encouraged to limit transmission o f malaria infection.
In this thesis a quantitative nucleic acid sequence-based amplification (QT- 
NASBA) assay for the detection and quantification o f viable P. falciparum in 
blood samples was developed and evaluated. The detection limit o f the parasites in
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patient blood was demonstrated to be between 0.1 parasites/pl and 10 parasites/pl 
blood. Wide variations that exist between the QT-NASBA and microscopy, in 
particular at low level parasitaemia, should be investigated and this is currently the 
focus of future studies. Application of QT-NASBA will be useful when monitoring 
parasite clearance following treatment and perhaps for monitoring vaccine 
efficacy.
It is hoped that the findings o f this thesis have enhanced knowledge o f 
antimalarial drug efficacy and the role of point mutations (in genes believed to 
code for drug targets) in determining drug resistance. The understanding of this 
subject is important in view of the need to facilitate monitoring for drug resistance 
and to search for clinically useful antimalarials. While this thesis has contributed to 
general knowledge it is obvious that similar studies are required. The QT-NASBA 
is a useful diagnostic protocol, however additional evaluation is necessary in view 
of improving the sensitity and cost-effectiveness in order to make it user friendly. 
By this, QT-NASBA will become a useful tool in the epidemiological monitoring 
o f antimalarial drug efficacy of infected malaria patients.
Additional studies in the Kenyan highlands including epidemic sites should 
be conducted even in the absence of malaria outbreak: monitoring infections in 
symptomatic and asymptomatic patients; and observations on treatment efficacy 
will provide essential parasitological and clinical information on parasite strains. 
These will be useful in view of selecting appropriate regimens for prompt 
treatment and prophylaxis. Studies addressing population dynamics in endemic and 
epidemic or, between endemic and epidemic areas of Kenya should be carried out. 
This will provide further information on the frequency and distribution o f 
resistance-associated gene polymorphisms. The results will provide an early 
warning signal of “emerging” drug resistance prompting appropriate measures.
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A P P E N D I C E S
APPENDIX A
Site Year Drug studied Endemicity Location
Tiwi 1997 SP Hyper-endemic Southeast
Tiwi 1998 Co-tri, SP “
Mwea 1997 CQ, SP Meso-endemic Central
Busia 1997 CQSP, SP Holo-endemic Northwest
Oyugis 1998 Co-tri, SP Holo-endemic Southwest
Kendu
Bay
1999 SP Holo-endemic Southwest
Mosoriot 1997 SP Epidemic Western Highlands
Chogoria 1997 SP, CQ, AQ, QN Central (Mt. Kenya)
Kisii 1999 SP “ Western Highlands
Mt. Elgon 1999 SP W est( Kenya-U ganda 
border)
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A P P E N D I X  B
Participation information: You have been asked to participate in a medical research 
study. It is very important that you understand the following general principles 
which apply to all participants in our studies.
(1) Your participation is entirely voluntary
(2) You may withdraw from participation in this study any time.
(3) Please feel free to ask any questions that will allow you to understand clearly 
the nature o f  the study.
Summary of the project:
Malaria is a major public health problem in many developing countries. 
Estimates o f malaria mortality range from 1.5 to 2.7 million deaths worldwide per 
year (WHO, 1994), and approximately 1 million of these deaths occur among 
children under five years of age (WHO, 1993). In tropical Africa alone, 2 million 
children die from malaria annually.
The emergence and spread of chloroquine resistant Plasmodium faliparum 
in many endemic areas has complicated further the control of malaria. 
P.falciparum resistance to CQ/SP is intense and widespread and maybe 
responsible for the resurgence of the disease with an inreased death rate. In Kenya, 
high level resistance to CQ requires the application of second line drugs such as SP 
(for CQ resistance) and AQ (for SP resistance) for the treatment of uncomplicated 
malaria. When used inappropriately, resistance to these drugs may rapidly emerge 
and spread. Accurate assessment of the effectiveness of antimalarial drugs and 
treatment regimens and o f the prevalence and spread of drug-resistant strains is 
essential to allow public health authorities to develop and evaluate adequate 
treatment strategies as stated in the strategy for “Global Malaria Control” 
formulated by the World Health Organization. This study will concentrate on 
resistance to CQ, SP, CQSP or co-trimoxazole.
Medical care:
You will be entitled to medical care for malaria (non-severe or severe). You 
will be treated at no cost to you. All recruits with an Hb less than 5.0g/dL will be 
given iron (ferrous sulphate) tablets lOmg/kg per day single dose for 1 month. 
Recruits with a temperature >37.5°C will be given paracetamol 6 hourly and the 
carers/ mothers encouraged to keep the patient cool and drinking plenty. Other 
conditions which require treatment or admission will be dealt with on individual 
basis. Care must be taken not to prescribe any other drug with antimalarial 
properties (eg tetracycline, co-trimoxazole, trimethoprim, proguanil) unless the 
clinical conditions necessitates such treatment in which case the recruit will be 
withdrawn from the trial.
I agree to participate in the study whereby fingerstick blood will be obtained.
Name ____________________________________________
Signature/ Thumb print______________________________
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Contact (home) address
CASE RECORD FORM
| Record Number I Study site 1 Full Name I Guardian's Name
j Age Weight I Hb/Ht I Hb/Ht | Drug name Total drug dose
Jfmonths^^ (kg) J DayO 1 Day 14 J m ^ b a s e ^
|| Previous antimalarials 
I (Y/N/Unknown^
Drug Dosage Urine Test (drug) (concentration)
DAYO DAY1 DAY2 DAY3 DAY4 DAY5 DAY6 DAY7 DAY 8 DAY9 DAY10 DAY 11 DAY12 DAY13 DAY14
Date
Danger signs
History of fever 
(last 24 hrs)
Previous
medication
Axillary
temperature
Parasite
count
T reatment 
(no.tabs)
| Concomitant 
| treatment
Reasons for 
exclusion or 
loss to f/up
Observations
Overall assessment ETF LTF ACR Exclude
'• '' ' '' ''
Loss to f/up
APPENDIX C
FIELD PERSONNEL
Name
SabahA.Omar
Designation
Research Officer (RO)
Station
KEMRI
Duty
Team Leader 
PhD student
Sites
All
Recording
Sabah A Omar RO KEMRI All 1997-9
Frederick Kiarie Technicians " All 1997-9
David Maina Technician Oyugis 1998
Kipruto arap Too Technician 
Binti Omar Nurse Tiwi
Kendu
Oyugis
Tiwi
1999
1998
1997-9
Grace Ochieng Nurse Rendu Bay Kendu 1999
Microscopy
Sabah A Omar RO KEMRI All 1997-9
Stephen Kniaru Technician KEMRI All 1997-9
Ayala Ouma “ “ All ••
Gachare George Ministry 
of Health 
DVBD
Tiwi 1997
“ “ •• Busia 1998
Kimani Maina Ministry 
Of Health 
DVBD
Mwea 1997
Urine tests
Sabah A Omar RO KEMRIA1I 1997-9
Daniel Kariuki Technician KEMRIAU 1997-9
Year
1997-9
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Treatment
Name Designation Station Sites Year
Patrick Gichuki Clinical OfficersMwea Mwea 1997
Bakari A Saumu " Tiwi Tiwi 1997-8
Morris Wekesa 
John Namale
“ Busia Busia 1998
Owiti Awour 
Mark Ouma ••
Oyugis Oyugis 1998
John Oduor “ Rendu Bay Rendu 1999
Prof. Dieter Gump Dr. Chogoria Chogoria 1997
Mission Hospital
Peter Ndaru Technician“ “ “ 1997
Gachihi Goerge KEMRI Mosoriot Mosoriot 1997
“ “ Mt. Elgon Mt.Elgon 1999
“ Risii Risii 1999
GFM, NASBA, Hb
Sabah A Omar RO REMRI All 1997-9
Joseph Mwangi Assistant research
Officer (ARO) Tiwi 1998
Oyugis 1998
Rendu
Bay 1999
Fatma Shamte ARO REMR1 Busia 1998
Tiwi 1998
Oyugis 1998
Rendu
Bay 1999
Peter Ndaru Nurse Chogoria
Mission
Hospital
Chogoria 1997
Name Designation Station Sites Year
In vitro test 
Sabah A Omar RO KEMRI Mwea, Tiwi,
Daniel Kariuki Technician
Busia, Oyugis 1997-8 
“ “ 1997-8
Maourice Adoyo “ Oyugis 1998
Patient Follow-up
Mary Waithera Demographers Mwea Mwea 1997
Ramadhani Kazumbe Tiwi Tiwi 1997-8
Mary Nafula Wanyama Busia Busia 1998
Vivian Akoth Oyugis Oyugis 1998
Serinah Anyango Kendu Bay Kendu 1999
Wycliffe Simuyu Mosoriot Mosoriot 1997
Stephen Migwi Mt. Elgon Mt.Elgon 1999
Mercy Ogola Kisii Kisii 1999
Incentive organizer |Lunch and return fare (transport)!
Lydia Chip Technician KEMRIA11 1997-9
Drivers
Arap Too Drivers KEMRIA11 1997-9
Wangunyu 
Michael Wainaina
277
APPENDIX D
Calculation of wash media fo r WHO in vitro M ark II drug test (WHO, 1990)
For each isolate 958pL of the RPMI1640/Hepes solution and 42pL is required. This 
volume adds to lOOOpL (ml of wash media). Only 900pL is needed per isolate and into 
this 100p.L of patient blood is added. Fifty microlitres of the washmedia/patient blood is 
then added into each WHO pre-dosed well. From row A to H requires a total volume of 
50p.L X 8 = 400pL for a single column, in duplicate, the volume will be 400pL X 2 = 
800pL.
To calculate for 50 isolates therefore the wash media required will be:
To perform in vitro analysis in duplicate and per sample:
1640 RPMI/ Hepes: 958pL X 50 = 47,900pL (47.90mls)
Sodium Bicarbonate: 42pL X 50 = 2,100pL (2.10mls)
Volume o f wash media 50,000/jL (50mls)
Volume per drug test:
900p.L (wash media) + 100pL (patient blood) = lOOOpL (1ml),
Aliquot 50pL into column A and B (in duplicate)
APPENDIX E
Concentration of drug tests, WHO M ark II (1990a) 
Wells Drug concentration (pmolAvell)
CQ MQ QN SP
A 0 0 0 0
B 1 2 4 10 f  Sensitive
C 2 4 8 30
D 4 8 16 100 J
E 8 16 32 300 1
F Tó 32 64 1000 L Resistance
G 32 64 128 3000
H 64 128 256 10000 J
Bold and underlined = cut-off point for resistance; For SP threshold o f schizont growth 
was taken to be 8 nuclei or more normal nuclei. Concentration o f SP is at a ratio of 
80:1. Dose shown for SDX [sulfadoxine].
2 7 8
A P P E N D I X  F
S a k e r  S o lo m o n  T e s t
This tests describes an adaptation of a method developed by E.G.Saker and E.T.Solomons 
for assay of drugs of abuse in urine which permits facile qualitative or quantitative 
determination of CQ and metabolites in the field. The CQ is partitioned from buffered 
urine (pH8.0) into a chloroform solution of tetrabromophenolphthalein ethyl ester 
(TBPEE) to give a purple colour, the intensity of which is proportional to the sum of the 
concentrations of CQ and its metabolites.
R e a g e n ts
1) Chloroform
2) Tetrabromophenolphthalein ethyl ester (TBPEE)
3) K2HP04.3H20
4) KH2P04
The pH8.0 buffer contained 324g of K2HP04.3H20  and lOg of KH2P04in 1 litre of water. 
The solution of 50mg TBPEE dissolved in 100ml of chloroform was shaken with 10ml of 
2mol/l aqueous HC1. After the phase separation, the aqueous phase was aspirated by 
Pasteur pipette, leaving 0.05% TBPEE-in-chloroform reagent solution. Solution was kept 
in the dark and and refrigerated. Fresh solution was made during every field trip.
A P P E N D IX  G
B ra tto n - .Y Ia rsh a ll  (B M ) T est
The technique employed in this thesis is a simple modification of the BM test, described
and adopted from De Almeida and De Souza, (1983).
R e a g e n ts
Reagent 1: sodium nitrite solution, 0.03mmol/l or 0.2mg/100ml or 0.2(w/v) in
distilled water.
Reagent 2: hydrochloric acid (concentrated)
Reagent 3: Bratton Marshall solution (BM); dissolve 20mg N-( 1-napthyl)-ethylene
diamine dihydrochloride in 20ml distilled water, adding 3 drops of 
concentrated HCI acid.
Reagents 1 and 2 are stable at room temperature. Reagent 3 is stable for at least 2 months
and was kept 5-10°C in a brown bottle (as described).
A P P E N D I X  H
Oligonucleotide primers:
dhfr and dhps polymorphisms
NESTII primer sequences
dhfr 
M3 
F/
F
M4
5TTTATGATGGAACAAGTCTGCGACGTT3'
5 ' A A ATTCTTG AT A A AC A ACGG A ACCTttT A3 ’
5'G A AATGT A ATTCCCT AGATATGgAAT ATT3’ 
5TTA ATTTCCCAAGT AAA ACT ATT AGAgCTTC3'
dhps
K
YJ
J
L
U
5TGCT AGTGTT AT AG AT AT AGGatG AGc ATC3 '
5'CT AT AACG AGGT ATTgC ATTT AAT gC AAG AA3' 
5TGCT AGTGTT AT AGAT AT AGGTGGAGAAagC3’ 
5'AT AGG AT ACT ATTTG AT ATTGG Ace AGG ATT cG3' 
5TATTACAACATTTTGATCATTCgcGCAAccGG3'
NESTI primer sequences 
dhfr
Ml
M5
dhps
R2
R/
5TTTATGATGGAACAAGTCTGC3' 
5'AGT AT AT ACATCGCT AAC AG A3'
5 ' A ACCT A A ACGTGCTGTTC A A3' 
5'AATTGTGTGATTTGTCCACAA3'
pfmdrl polymorphisms
Codon Primer sequence (5'-3')
184 Pfmdrl -184F: ATG AT AATAATCCTGG ATCT 
Pfmdrl-184M: AGITCTTTTTAGGTTTACT 
Pfmdr-184R: AGTTCTT ATTCCC ATT A A AG 
Pfmdr-184 W : AGTTCCTITTTAGGTTTACA
1034 Pfmdr-1034W: AGCTTT ATGGGG AT ACA 
Pfmdr 1 -1034F: CAT ACTGTT ATT A ATT ATGG 
Pfmdr 1 -1034M : AGCTTT ATGGGG ATTGT 
Pfmdrl-1034R: TC A A ATG AT AATTTTGCAT
1042 Pfmdr 1 -1034F: CAT ACTGTT ATT AATT ATGG 
Pfmdrl-1034R: TC A A ATG AT AATTTTGC AT 
Pfmdrl-1042M: AGCGCTC AATT ATTT AT AG 
Pfmdr 1 -1042W : GCGCTC A ATT ATTT ATG A
1246 Pfmdrl -1246F: GG A A A ATC A ACTTTT ATG A 
Pfmdrl-1246R: AGGTTCTCTTAATAATGC 
Pfmdr 1 -1246M : TGTG ATT AT A ACTT A AGCT 
Pfmdrl-1246W: TGTG ATT AT A ACTT A AGCG 
P3/184 fragment
P3 ATGGGT AAAGAGCAG A A AG AG 
1034F/ P2 fragment
P2 TT AGGTTCTCTT A ATA ATGCT 
A P P E N D I X  I
Restriction Incubation Point Restriction Restrction
enzyme tem perature
r c )
mutation site
i
pattern (bp)
N lalll 37 OCA J ()*’ ' A
3’
5’..... CATG...3’
...... GTAC..5’
t
i
376,146
Tsp5091 65 AAT^  | ATT 5’....... AATT....3*
3’....... TTAA....3’
t
i
154, 120
XmnI 37 TGT^ çCGT
3’..,
5...GAANNNNTTC.
CTTNNNNAAG..5’
t
i
,3’163, 137
Alui 37 AUC |  QgAAC 5’..AGCT...3’
3’..TCGA..5’
t
i
326, 196
BsrI 65 AUC' | Qg AAC 5’...ACTGGN...3’
3’...TGACCN...5’
T
4 a
180, 146
BstNI 60 A(K 108ACt 5\..CC GG..3’ 
T 
T
3\.GG CC..5’ 
A Î
4
181, 145
Dral 37 att164,ta 5’....TTTAAA..3’ 245, 143, 1(
3’...AAATTT..5’
Î
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A P P E N D I X  I
Restriction Incubation Point Restriction Restriction
enzyme temperature
(°C)
mutation site pattern (bp)
i
Mnll 37 t c t 4 3 6 c k t 5’...CCTC (N)7..... 3’ 317, 121
3’...GGAG (N)6.... 5’
t
A i  G
MspAlI 37 tct436<xt 5\..C  GC G...3’ 406 
C T 
T C
3’..... G CG C...5’
G T a
4-
Mwol 60 y t i l i A 5’..GCNNNNNNNGC...3’ 387 
3’..CGNNNNNNNCG...5’
t
28 2
A P P E N D I X  I
Restriction
enzyme
Incubation
temperature
(°C)
Point
mutation
Avail 37 GC yGG  A
FokI 37 aag540gag
BstUI 60 g c g 5 8 j GGC
BslI 55 G C C ^ g jG G C
Mwol 60
BsaWI 60
Agel 25 occ613acc
Restriction Restriction
site pattern (bp)
u
5’....... GG CC....3’ 404
T
T
3\.C C  GG..... 5’
A t
4
5 ’....... GGATG(N)q...3’ 320, 85
3’.........CCTAC (N),3...5’
t
4
5’..... CGCG...3’ 105
3’..... GCGC...5’
t
4
5’....CCNNNNNNNGG..3’ 128
3\..GGNNNNNNNCC..3’
T
4
5’...... GCNNNNNNNGC..3’ 128
3’.... CGNNNNNNNCG..5’
Î
A4 A
5’.... CCGG ....3’ 131
T T
T T
3... GGCC....5’
A ÎA
4
5\..ACCGGT..3’ 128
3’...TGGCCA..5’
t
2 8 3
A P P E N D I X
Restriction Incubation Point
enzyme temperature mutation
(°C)
AflIII 37 aat86tat
267
VspI 37 aat1042oat
300,
Restriction Restrction
site pattern (bp)
i
5\..ACPu Py GT...3’ 503,
3’...TGPyPuCA.... 5’
t
i
5’...ATTA AT..3’ 130,
3V.TAATTA...5’ 410,
t
EcoRV 37 gat1246tat 5’.
i
..GATATC...3
290 3’...CTATAG...5
t
810,
2 8 4
A P P E N D I X  J
Mwea Study 1997: Molecular characterization of pfcrt gene 
Institute: University of Maryland
Personnel
Joseph Cortese 
Christopher Plowe 
Jean-Claude Akpa
APPENDIX K
Quantitative Nucleic acid Sequence-based amplification, QT-NASBA: Development 
and application
Institute: The Royal Tropical Institute
Personnel
Dr. Henk Schallig 
Dr. Linda Oskam 
Gerard Schoone 
Nel Kroone
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